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Abstract 
Adherent CD34+ cells are a stem cell enriched population with a high frequency of primitive 
stem cells that are genetically primed to differentiate into tissue-specific lineages.  These cells 
make up the adherent CD34+ cells in peripheral blood which are the focus of this study.  The first 
aim of this study was to transcriptionally characterize adherent CD34+ cells relative to non-
adherent CD34+ cells using a whole human genome Affymetrix U133 plus 2 array.  The 
subsequent analysis demonstrated transcriptional differences in genes which are involved in 
quiescence, cell cycle, homing and adhesion, which are likely to be relevant to the suitability of 
adherent CD34+ cells for clinical application.  To verify the microarray analysis, a selection of 
representative transcripts was chosen and their relative expression was compared using real-time 
qPCR.  To analyze further the stem cell characteristics of adherent CD34+ cells, the DNA 
replication timing kinetics of pluripotency-associated genes in bone marrow-derived adherent 
CD34+ cells, non-adherent CD34+ cells, and foetal mesenchymal stem cells were conducted and 
compared to those of embryonic stem (ES) cells.  This showed that pluripotency-associated 
genes Oct4 and Nanog replicate early in the cell cycle similar to ES cells.  The second aim of this 
study was to examine the potential use of adherent CD34+ cells in neural injury.  As adherent 
CD34+ cells are primitive stem cells, it was reasonable to hypothesize that these cells would 
differentiate into neural cells in vitro, but these experiments revealed that these cells are not 
neurogenic and, in our hands, do not differentiate into neural cells.  The experiments revealed 
that adherent CD34+ cells differentiate efficiently and reproducibly into microglia-like cells 
(CD34MG cells).  CD34MG cells upregulated microglia-associated antigens and demonstrated 
functional characteristics of microglia cells including TNFα and IL-6 release in response to 
lipopolysaccharide.  CD34MG also stimulate responders in a mixed lymphocyte reaction, 
suggesting antigen presenting capabilities.  To determine if these cells might be exploited for use 
in brain tumour therapy, it was shown that CD34MG migrate and invade in response to brain 
tumour glioma cells.  Results also suggest that these cells are capable of presenting glioma 
specific antigen to immune cells in an autologous lymphocyte reaction in vitro.  The combined 
results suggest that CD34MG cells might be exploited for therapeutic purposes in brain tumours.  
Stem cells are currently being explored for their therapeutic potential.  This study demonstrates 
that adherent CD34+ cells and CD34MG cells may be useful for clinical use.   
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Chapter 1 Introduction 
 
1.1 Stem cells 
Stem cells are undifferentiated cells defined by their capacities to self-renew indefinitely and to 
produce lineage defined progeny which can either be transamplifying progenitor cells or 
terminally differentiated effector cells.  Stem cells are categorized by their developmental 
potential.  Totipotent stem cells are able to give rise to all embryonic and extra-embryonic cells.  
Pluripotent stem cells are isolated from the inner cell mass of the blastocyst and are able to give 
rise to all cell types of the embryo proper.  Multipotent cell types are able to give rise to a subset 
of cell lineages within the same germ layer.  Oligopotent stem cells are able to give rise to a 
more restricted subset of cell lineages than multipotent cells.  Unipotent cells are able to give rise 
to only a single mature cell type.  In adults, stem cells were previously thought to be more 
lineage restricted, able to give rise to progeny cells of the corresponding tissue.  Tissue-specific 
stem cells have been identified in the body and have been described in most tissues including the 
brain, intestine, heart, bone marrow, and blood1-4.  The prospective identification of highly 
purified stem cell populations from adult tissues and the  development of clonogenic assays for 
their function is essential for both understanding the capacity of these cells to regenerate tissues 
and for definitively  measuring their plasticity.  
 
Yamanaka and colleagues166 (2006) were the first to demonstrate that somatic cells can be 
genetically reprogrammed into induced pluripotent stem (iPS) cells by transducing cells with 
four genes associated with pluripotent embryonic stem (ES) cells, Oct3/4, Sox2, Klf4, and c-
Myc166-168.  The same group has more recently reported that reprogramming does not require c-
Myc, and that only Oct3/4, Sox2, and Klf4 are required to generate inducible pluripotent stem 
(iPS) cells in both mouse and human fibroblasts169,170.  These iPS cells have identical properties 
to ES cells and give rise to chimeric mice169,170.  Induced pluripotent stem cells are not tumor 
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forming and the absence of c-Myc increased the safety of these cells for potential clinical use.  
Inducing pluripotency of fibroblasts in humans for subsequent differentiation provides 
therapeutic potential of iPS for autologous cell therapy.   
 
1.2 Stem cell division 
In order for stem cells to simultaneously renew and give rise to lineage specific progeny, they 
must undergo asymmetric division.  Asymmetric cell division is defined as any division that 
gives rise to daughter cells with different cell fates5-8.  Asymmetric division ensures the balance 
between self-renewal and differentiation, and is required to maintain homeostasis, while 
symmetric division is required for population recovery after depletion5-7.   
 
Studies of Drosophila stem cell division have suggested two mechanisms of asymmetric stem 
cell division5.  When division is governed by intrinsic mechanisms, regulators of self-renewal are 
localized asymmetrically during mitosis so they are inherited by only one daughter cell5.  Cells 
orient themselves relative to surrounding tissue and use apical-basal or planar polarity of the 
surrounding tissue to set up an axis of polarity5.  During mitosis, the axis is used to polarize the 
distribution of cell fate determinants and the mitotic spindle is oriented such that cell fate 
determinants are inherited by only one of the daughter cells5.  Uneven distribution of these 
determinants leads to establishment of different cell fates.   
 
If asymmetric division is governed by extrinsic niche mechanisms, the stem cell remains in close 
contact with the stem cell niche and depends on contact for maintaining self-renewal potential5,9.  
The cell orients its mitotic spindle parallel to the niche surface, thus only one daughter cell can 
maintain contact with the niche and retains self-renewal capability5.  If the stem cell plane of 
division is perpendicular to the niche surface, two stem cells are generated5.   
13 
 
 
An example of asymmetric stem cell division has been intensively studied in Drosophila neural 
tissue, and is becoming more defined in the adult human brain5,7.  Studies have demonstrated that 
the orientation of the mitotic spindle influences post-natal human neural stem cell fate and the 
fate of daughter cells.  Neural stem cells (NSC) remain in contact with the supporting ependymal 
layer on the lateral wall of the lateral ventricle1,5 (Figure 1).  These ‘type B’ cells are slowly 
proliferating stem cells which asymmetrically divide, both self-renewing and giving rise to 
rapidly dividing progeny ‘type C’ cells1.  Type C cells in turn generate differentiated neuroblasts, 
‘type A’ cells, which migrate and terminally differentiate into neurons1 (Figure 1).  Neuroblasts 
migrate as chains of cells along tunnels of glial cells formed by type B cells.  Rapidly dividing 
precursor type C cells form focal clusters scattered along the network of glial tunnels1.   
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Figure 1. Asymmetric neural stem cell division.  This model of neural stem cell division is an example of 
asymmetric division within the mammalian system.  The neural stem cell niche is within the subventricular 
zone of the brain, which lies adjacent to the lateral wall of the lateral ventricle.  Multiciliated ependymal 
cells line the wall of the ventricle.  Neural stem cells, type B cells, slowly divide giving rise to rapidly 
dividing precursor type C cells which subsequently give rise to neuroblasts which are considered type A 
cells.   
B 
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Blood vessel 
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1.3 Stem cell multiplicity 
Traditionally, there have been two broadly categorized stem cell types which reside in the bone 
marrow, hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC)10,11.  Recently, 
different research groups have identified heterogeneous populations of stem cells in the bone 
marrow.  These populations may or may not be overlapping, but have been assigned different 
names including multipotent adult progenitor cells12 (MAPC), marrow-isolated adult 
multilineage inducible cells13 (MIAMI), very small embryonic like cells14-16 (VSEL), as well as 
precursor germ cells17,18.  These cells have been demonstrated in vitro to be capable of 
upregulating phenotypic characteristics of various tissue specific lineages10-14,16-18.  The 
differentiation of tissue-specific stem cells into effector cells of a different germ layer is highly 
controversial.  Previous studies of stem cell differentiation remain under scrutiny as some results 
are found to be irreproducible and inconsistent.  The irreproducibility of stem cell differentiation 
is inexplicable, but may be due to donor variability, detection strategies, cell purification 
techniques, or any number of reasons.  Inconsistent results lead to alternative explanations for the 
observed differentiation of tissue-specific stem cells to unrelated cell types.   
 
There are currently several theories to explain the multiplicity observed in stem cells from 
various adult tissues (Figure 2).  First, direct stem cell transdifferentiation was proposed as the 
mechanism by which stem cells potentially contributed to cell types of different lineages19. 
Publications first suggested contributions of bone marrow and circulating stem cells to non-
haematopoietic tissue as well as the differentiation of NSC into blood lineages20,21.  These 
observations were thought to result from the transdifferentiation of developmentally plastic HSC 
and NSC to alternate lineage fates20,21.  According to the second theory, lineage conversion was 
proposed to occur by the dedifferentiation of lineage defined stem cell to a more primitive 
multipotent cell, followed by redifferentiation along an alternative lineage.   
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Figure 2. Stem cell multiplicity.  Proposed mechanisms that may underlie observations of apparent adult 
stem cell plasticity including transdifferentiation of developmentally plastic stem cells, de-differentiation of 
a tissue-specific cell to a more primitive cell, presence of multiple lineage specific stem cell types within 
the isolated stem cell population, cell fusion or the presence of pluripotent stem cells.   
 
The third explanation is that multiple types of tissue defined stem cells exist within a sample 
population.  Many demonstrations of plasticity were inferred after in vitro differentiation and in 
vivo transplantation of unpurified heterogeneous cell populations such as unfractionated bone 
marrow (BM) derived cells.  It is possible that unfractionated populations of BM cells contain 
multiple stem and progenitor cell populations, suggesting that distinct stem cells are instead 
accounting for observed transdifferentiation.  Unfractionated BM contains multiple progenitor 
cell types including MSC, HSC, endothelial precursor cells and muscle progenitor cells22.  
Appropriate progenitor cells could contribute to differentiation of cells consistent with their 
intrinsic germ lineage, leading to observations suggestive of transdifferentiation.  The fourth 
explanation of plasticity describes the highly controversial cell-cell fusion whereby the donor 
cell contributes to tissue regeneration by fusing with damaged cells from the host.  Cell fusion 
has been implicated in contributions of transplanted BM cells to hepatocytes, cardiomyocytes, 
and Purkinje neurons.  This was originally suggested after demonstrating the capability of 
embryonic stem (ES) cells to fuse to cultured neural cells or BM cells23,24.  Although it has been 
proposed that heterokaryotic cell fusion in adults might exist as a physiological repair 
mechanism, the events are extremely rare in transplanted animal models.   
Direct 
transdifferentiation 
De-differentiation Multiple stem cell 
types 
Pluripotent  
stem cell 
Cell fusion 
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Finally, contributions across multiple tissue types could arise from rare pluripotent stem cells 
found postnatally.  Two groups have identified rare primitive stem cell populations in peripheral 
blood and bone marrow which express markers typically associated with pluripotent ES cells.  
Ratajczak and colleagues hypothesized that during development, a pool of VSEL cells are 
deposited in the bone marrow to maintain postnatal homeostasis and tissue regeneration of 
haematopoietic and nonhaematopoietic tissues16,25.  Identified in the bone marrow and umbilical 
cord blood, VSEL cells express CXCR4+ and are enriched for mRNA for early muscle, heart, 
neural, liver, intestinal epithelium, epidermal, and pancreatic markers, similar to pluripotent ES 
cells25.  Exposure of these cells to permissive environments leads to differentiation to 
neuroectoderm, cardiomyocytes, and pancreatic cells.  A second stem cell enriched population 
was identified by Gordon and colleagues which are adherent CD34+ small lymphocyte like cells 
found in peripheral blood11,26,27.  They are isolated from the bulk of CD34+ cells by their ability 
to adhere to tissue culture treated plastic, and are morphologically and transcriptionally distinct 
from non-adherent CD34+ cells26.  Adherent CD34+ cells are quiescent, metabolically inert stem 
cells and express genetic messages which encode for liver, heart, epithelial, and pancreatic 
cells26.  Adherent CD34+ cells are considered to be a population of primitive stem cells with 
high frequencies of stem cells which are genetically primed to differentiate into tissue-specific 
lineages26.  These collective cells make up the adherent fraction of CD34+ cells in peripheral 
blood and are the main population of focus in this study.   
 
1.4 Bone marrow stem cell niche 
The stem cell niche can be defined as a spatial structure in which stem cells are housed and 
maintained in an undifferentiated state10,28-30.  The haematopoietic stem cell niche is located in 
the sinusoidal endothelium in the trabecular bone of the bone marrow10,11.  The balance between 
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self-renewal and lineage differentiation is governed by molecular cross-talk between the stem 
cells and the osteoblasts lining the sinusoidal endothelium10,28.   
 
1.4.1 Developmental migration 
One interpretation of the multilineage capabilities of stem cells in the marrow is that bone 
marrow is a general stem cell repository for cells that can be mobilized for various purposes 
during adulthood.  Signals within the microenvironment induce the mobilization of stem cells 
from the bone marrow into circulation.  Ratajczak et al31,32 hypothesized that during 
development, pluripotent stem cells are deposited in the bone marrow for future use,  a 
phenomenon that has been termed ‘developmental migration’. They hypothesized further that 
during ontogeny, stem cells are chemoattracted to the bone marrow which provides a 
microenvironment appropriate for a stem cell niche14,25,33.  Chemokine, CXC motif, receptor 4 
(CXCR4)-expressing stem cells migrate in response to stromal cell-derived factor-1 (SDF1), 
while c-Met+ stem cells migrate in response to hepatocyte growth factor (HGF)33.  Studies have 
shown that both hematopoietic and non-hematopoietic stem cell migration into the bone marrow 
are CXCR4/SDF1 and c-Met/HGF dependent34,35.  These cells remain in the bone marrow and 
are mobilized into the circulation during injury to aid in tissue repair and regeneration14,35.  This 
theory is based on the detection of VSEL cells in adults which express ES cell-associated 
markers Oct4, Nanog, Rex1, and stage-specific embryonic antigen (SSEA)14,16,25,33.  Adherent 
CD34+ cells and VSEL cells express a similar panel of markers. 
 
1.4.2 Haematopoietic inductive microenvironment 
Stem cell self-renewal and differentiation is determined by the inductive microenvironment 
within the stem cell niche.  The haematopoietic inductive microenvironment was first described 
in a study by Wolf and colleagues36,37 of the growth and differentiation of spleen colonies in 
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mice, arising from transplanted bone marrow.  This study revealed that the differentiation of 
multipotent stem cells is influenced by their physical location in the spleen36,37.  The inductive 
microenvironment of the anatomical location influences the probability of a stem cell 
differentiating into a specific lineage11.  If the microenvironment induces lineage specification, it 
can be inferred that a stem cell niche must exist in which the molecular constituents control the 
balance between quiescence, self-renewal, and differentiation.  The functional proof for the stem 
cell niche was provided by McCulloch and colleagues in 196538 and later by Barker39,40.  Mutant 
Sl/Sld mice deficient in the gene which encodes for SCF show changes in the bone marrow stem 
cell niche and a consequent failure of HSC maintenance and reduction in normal bone marrow 
engraftment10,38-40.   
 
1.4.3 Multilineage priming 
Enver and colleagues revealed that hematopoietic stem cells are ‘multilineage primed’, 
expressing low levels of mRNA of various hematopoietic lineages11,41,42.  This implies that a 
single stem cell is capable of transcribing genes of multiple lineage specifications when placed in 
the appropriate inductive microenvironment11,41,42.  Adherent CD34+ cells express genetic 
messages for multiple lineages including haematopoietic, hepatic, pancreatic, cardiac, and neural 
cells11,26.  Applying the theory of multilineage priming, the corresponding genes should be 
available for transcription by adherent CD34+ cells, thus enabling them to contribute to the 
regeneration and repair of injured tissues.  Since the cells are innately primed for multiple 
lineage specification, they lack the need for de-differentiation, transdifferentiation, or cell 
fusion11.   
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1.5 Stem cell DNA replication timing 
Genetic and transcriptional profiling of stem cells has revealed genes which are characteristic of 
stem cells.  Gene profiling does not discriminate between genes subject to active repression and 
those that are not transcribed because activating proteins are limiting.  Epigenetic and 
developmental studies have suggested that unique epigenetic markers may be valuable indicators 
of stem cell identity.  Epigenetic correlations of gene expression are not absolute, but can be used 
collectively to gain insights into the underlying mechanisms that establish gene expression 
patterns through cell division, and suggest how stem cell gene expression is modulated.  
Traditionally, epigenetics is loosely categorized into DNA methylation 43, histone modification44, 
and small interfering RNAs45.  Other features of chromatin behaviour also correlate with gene 
transcription including DNA replication timing46.  
 
 Replication timing is an indicator of chromatin state47.  Recent studies have identified chromatin 
signatures and replication timing profiles of ES cells46 and it has been demonstrated that changes 
in replication timing occur as ES cells differentiate48.  The replication timing of genes depends 
on chromatin state and correlates with histone acetylation, and early replication of a gene does 
not necessarily reflect gene transcription49.  Early replication of genes during S phase of the cell 
cycle is considered to be a feature of transcriptionally active regions of the genome, indicating 
chromatin accessibility, whereas late replication is characteristic of inactive gene regions and 
constitutive heterochromatin46.  During development, pluripotent stem cells give rise to lineage-
restricted progenitors from which more tissue-restricted cells are derived50.  Thus in pluripotent 
ES cells, there is replication of lineage-associated genes early in the S phase, suggesting 
multilineage potential and pluripotency.  Changes in replication timing have been shown to 
accompany differentiation, and activation of tissue specific genes correlates with a switch from 
early to late replication.  
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In ES cells, many genes that encode for transcription factors which are not expressed by ES cells 
but are important for later development, replicate early in ES cells46.  In the same study, 
terminally differentiated T cells had significantly fewer early replicating genes46.  This indicates 
that in tissue-defined cells, genes which are not actively expressed replicate late in the cell cycle, 
and it is likely that only actively transcribed genes replicate early.  Azuara et al46 found that 
genes encoding for neural-specific transcription factors replicated early in ES cells which retain 
neural potential, but replicated late in haematopoietic cells which do not have neural 
differentiation potential.  This assumes that the chromatin structure governing gene expression 
which is not appropriate for a particular lineage undergo changes to switch replication from early 
to late replication as differentiation occurs.  This indicates that chromatin changes occur in ES 
cells as they lose their pluripotency.  Different laboratories have generated similar replication 
timing profiles of ES cell lines, indicating this technique may be potentially useful in defining 
degrees of ‘stemness’ 48,46,51.    
 
 
 
1.6 The nervous system  
The cells of the nervous system were first visualized in 1873 by Camillo Golgi using his silver 
impregnation staining method which stained only selected neurons, raising them above its 
surrounding tissue52.  This was followed by the identification of glia, and microglia; by 1921, the 
various cells of the nervous system were identified52.  In the central nervous system, neurons and 
glia have an interdependent relationship which is highlighted by the pathology of 
neurodegenerative diseases.  Injuries of the nervous system involve damage to multiple cell types 
and often require the repair and regeneration of not only neurons, but also require repair of glial 
cells which provide support to neurons.   
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Macroglia is comprised of astrocytes and oligodendrocytes.  Astrocytes are the predominant cells 
type in the central nervous system (CNS) and, based on morphology, are divided into two types: 
fibrous and protoplasmic53.  The role of astrocytes is necessary for neuron function and survival.  
Astrocytes regulate the extracellular environment including the homeostasis of K+, H+, and 
Ca2+.  They synthesize and secrete essential growth factors in the CNS including nerve growth 
factor (NGF), brain-derived nerve factor (BDNF), vascular endothelial growth factor (VEGF), 
and transforming growth factor beta (TGFβ).  In addition to neuronal support, astrocytes are 
required for synaptogenesis and neurogenesis53,54.   
 
In the CNS, oligodendrocytes are responsible for myelinating axons by unidirectionally 
wrapping layers of myelin around a neuron’s axon, initiated at the site of the axon-glial 
junction55.  In the peripheral nervous system (PNS), Schwann cells produce myelin and are 
responsible for its maintenance.  The myelin sheath consists of many wrappings of glial 
membrane around the axon with little or no cytoplasm remaining between adjacent wraps.  This 
insulates the axon and allows for saltatory conduction and action potentials to propagate more 
efficiently along its length55,56.   
Microglia are unique in that they act as both supportive glia and as immunocompetent cells 
within the CNS57.  The nervous system has historically been regarded as an immune privileged 
site, isolated from peripheral blood-born leukocytes and immune regulatory cells by the blood-
brain barrier.  The fragility of neurons requires protection from activated immune responses from 
peripheral leukocytes.  Neurons also require physical and cytochemical support by glia.  
Microglia are responsible for the immunological and neuromodulatory responses which occur 
after CNS injury58.  They are considered to be the resident tissue macrophages of the CNS, and 
when activated, can act as antigen-presenting cells59.  There are two types of microglia, resident 
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and migrating microglia.  Resident microglia make up the majority of the population within the 
CNS, while migrating phagocytes that enter the CNS, sometimes referred to as migrating 
microglia, are thought to be bone marrow derived and are able to cross the intact blood-brain 
barrier.  CNS macrophages, or their precursors, which circulate in the peripheral blood enter the 
CNS and are recruited by chemokine (CC motif) ligand 2 (CCL2) and chemokine (CXC motif) 
ligand 10 (CXCL10)58.  Under normal conditions, resident microglia are a fairly stable 
population which proliferates to maintain homeostasis.   
1.6.1 Injury in the CNS 
Stem cell biology in regenerative medicine is currently exploring two options in terms of neural 
cell replacement in neurodegenerative diseases.  One method of therapy is transplantation of 
neural stem and progenitor cells derived from embryonic, foetal, and adult tissue.  Another 
option is stimulating innate repair mechanisms in the CNS by exogenous means to accelerate 
endogenous neurogenesis.  Although the potential of stem cell therapy in neurodegenerative 
diseases has shown therapeutic potential in the laboratory, many issues must be properly 
assessed prior to using stem cells in a clinical setting.    
1.6.2 Bone marrow infiltrates in neural injury 
Infiltration of bone marrow-derived microglia into the CNS occurs in two ways.  The first is the 
progressive cellular infiltration that occurs in normal microglial turnover, but cell turnover is 
very low under normal conditions58,60.  The second occurs during acute injury which triggers 
migration of bone marrow cells into the CNS and to the site of injury58.  Studies have shown that 
bone marrow-derived cells contribute to the expansion of the microglial population in the CNS 
and are detectable during the acute phase of injury61.  Infiltration and microglial transformation 
of bone marrow-derived cells occurs in models of major CNS injury such as focal cerebral 
ischaemia, as well as in models of discrete injury such as in anterograde axonal degeneration60,61.  
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Studies have reported up to 13% of microglia are bone marrow-derived in lesioned areas after 7 
days post injury58, and up to 28% 12-14 days post injury60.    
 
Microglia share phenotypic characteristics with mononuclear phagocytes and are of 
haematopoietic origin59,62.  In a study by Hess et al (2004), irradiated mice were transplanted 
with a single HSC expressing enhanced green fluorescent protein (EGFP) in order to observe 
haemopoietic reconstitution.  Two months after transplantation, EGFP+ microglia were found in 
the brain parenchyma. Four months post-transplantation, many EGFP+ cells were found 
scattered throughout the brain parenchyma with morphological and antigenic characteristics of 
microglia.  The EGFP+ cells were ramified in morphology and expressed RCA120 lectin.  After 
4 months, 12% of the total parenchymal microglia cells were EGFP+, and after 12 months, 40% 
of parenchymal microglia were EGFP+.  Interestingly, this illustrates that microglia derived from 
bone marrow HSCs are able to cross the blood brain barrier when there is no CNS injury.  After 
acute focal cerebral ischaemia, an influx of EGFP+ cells was observed in the area of infarction, 
and the cells were closely associated with blood vessel walls.  In the ischaemic tissue, NeuN+ 
neuronal cells were seen to have been phagocytosed by EGFP+ cells62.  This study makes three 
points.  First, at least a proportion of parenchymal microglia originate and migrate from the HSC 
fraction of the bone marrow.   Second, after focal ischaemia, HSCs which have the potential to 
differentiate into microglia migrate from the bone marrow to the ischaemic area.  Third, 
microglia from the bone marrow have phagocytic macrophage-like capabilities.  This evidence 
leads us to speculate that HSCs have potential to differentiate into microglial cells.  It is 
noteworthy that the recipient mice were sublethally irradiated, and the effects of irradiation on 
the permeability of the blood-brain barrier are unclear.  
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1.6.3 Endogenous neurogenesis in injury 
Although the components of the nervous system were identified by 1921, post-natal 
neurogenesis was not established until Eriksson et al (1998) reported the generation of neurons in 
the adult hippocampus63.  The concept of post-natal neurogenesis was firmly established in the 
following years alongside research in stem cell biology.  There are two neurogenic regions in the 
adult brain, the subventricular zone (SVZ) of the hippocampal dentate gyrus, and the olfactory 
bulb which may be associated with memory and smell respectively52.  Adult CNS stem cells 
exhibit the cardinal characteristics of stem cells: self-renewal and pluripotency64,65.   
 
Investigations have shown an increase in cell proliferation and neurogenesis after insult66,67, and 
a mounting number of studies seek to stimulate post-natal neurogenesis as an alternative to stem 
cell therapy.  It has been demonstrated that endogenous neural stem cells proliferate in response 
to acute ischaemia in the forebrain, are recruited to the penumbra region, and give rise to 
hippocampal pyramidal neurons.  Infusion of exogenous growth factors (fibroblast growth factor 
2 (FGF2) and epidermal growth factor (EGF)) led to a 40% recovery of neurons lost due to 
ischaemia.  Newly generated neurons showed functional synapse formation as well as recovery 
of brain function66.  This points to the value of stimulating neurogenesis of endogenous neural 
stem cells using pharmaceutical agents as an alternative to stem cell transplantation.   
 
1.6.4 Extra-cranial sources of stem cells for repair 
The administration of non-neural cells in models of cerebral ischaemia has lead to the notion that 
non-neural cells provide neuroprotection and stimulate endogenous neurogenesis.  It is likely that 
most if not all organs in the body have a reservoir of stem and progenitor cells which are 
mobilized after insult, thus expediting tissue repair and regeneration.  It is known that 
haematopoietic stem and progenitor cells circulate in the peripheral blood.  Kucia et al.68 
hypothesize that CXCR4+/CD45- tissue-specific stem cells also circulate in the non-
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haematopoietic fraction of peripheral blood, maintaining a pool of cells which are easily 
distributed to areas of the body distant from the bone marrow.  Fluorescence-activated cell 
sorting and mRNA analysis shows that within this population is a small population of neural-
tissue committed stem cells which express neural markers GFAP, nestin, β-III tubulin, and 
NeuN.  Of particular interest, after cerebral ischaemia, there is a marked increase in neural 
tissue-specific stem cells in the peripheral blood15.  In vitro analysis of these cells shows that 
after a stroke, neural-tissue committed stem cells respond to chemoattractants SDF-1, HGF, and 
leukemia inhibitory factor (LIF)15.   
 
In vitro investigation has demonstrated that embryonic stem cells and foetal stem and progenitor 
cells, as well as cells from non-neural sources are capable of exhibiting phenotypic, genetic, and 
electrophysiological characteristics of neuronal cells (Figure 3).  Animal models of 
neurodegenerative diseases demonstrate that stem cells are capable of restoring appropriate 
motor function.  Molecular mechanisms of repair remain unknown making the long term effects 
of transplantations uncertain.  The challenge which remains is to achieve the desired final 
outcome which is to restore lost organ function.   
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Figure 3.  Stem cells for in vitro neuronal differentiation.  There are several human stem cell sources 
that have demonstrated motor function in animal models.  Neurons have been generated in vitro from ES 
cells, fetal  tissue, and from cells derived from non-neural sources.  Pluripotent ES cells are able to 
differentiate into cell types from all three germ layers and can be induced into all cells of the neural 
lineage by genetic manipulation or the addition of exogenous cytokines.  Neural stem and precursor cells 
have been isolated from fetal and post-mortem adult brain tissue and has been demonstrated to 
differentiate into terminally differentiated neural cells.  Adult bone marrow, umbilical cord and peripheral 
blood derived stem cells have been demonstrated to express genetic message for neural cells.  Some of 
these stem cell types have been reported to promote motor function in animal models of neurological 
disease.  
 
Literature suggests that bone marrow-derived cells have neural differentiation potential12-15,19,75-
77
.
 Previous data26 demonstrated that adherent CD34+ cells express transcripts for dopamine, 
serotonin, and neurogenin-3, suggesting that adherent CD34+ cells may have the potential for 
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neuronal differentiation.  It was thus reasonable to investigate the neuronal differentiation 
potential of adherent CD34+ cells in vitro, beginning with published neuronal differentiation 
protocols75-77.  
 
1.7 G-CSF mobilization 
Autologous haematopoietic stem cell transplantation is currently used for treatment for 
haematological malignancies19.  Granulocyte colony stimulating factor (G-CSF) mobilization 
with chemotherapy increases the number of CD34+ HSCs in the peripheral blood to levels higher 
than those in the bone marrow.  During steady state conditions, the bone marrow contains a 
higher concentration of CD34+ HSCs than the peripheral blood69,70.  During G-CSF 
mobilization, myeloid hyperplasia occurs in the bone marrow, expanding the haemopoietic 
system including mature and immature myeloid cells.  After 4 to 5 days of G-CSF mobilization, 
the peak number of CD34+ haematopoietic stem cells (HSC) is released from the bone marrow 
into the circulation70.   
 
1.8 Stem cell therapy  
One of the aims of stem cell biology in the context of regenerative medicine is to understand the 
mechanisms which govern self-renewal and differentiation so that stem cells can be used to 
instigate the regeneration of damaged tissues.  In order for stem cells to be used for therapy in 
neurodegenerative diseases, a concerted regeneration of multiple neural cell types must 
occur125,158,159.  Transplanted cells are also required to migrate to sites of injury, differentiate into 
multiple cell types, integrate with existing neural circuitry, and restore saltatory 
conductivity125,158-160.  Animal models of disease have demonstrated the ability of stem cells to 
restore appropriate motor function125,159,160.  Although stem cell transplants have demonstrated 
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restoration of physiological and motor function, it remains to be seen if regeneration due to stem 
cells can contribute to cognitive processes160. 
 
1.8.1 Requirements of stem cells for therapy 
There are several factors which determine the suitability of stem cells for use in a clinical setting 
including accessibility of stem cells, quantity of cells available, isolation efficiency, cell safety, 
and ethical considerations11,125,161,162.   
1.8.1a Ethics 
This includes the ethical acceptability of stem cells in the current regulatory environment.  The 
derivation of pre-natal human tissue may be found offensive to certain communities and this is 
reflected by current legislation.  Adult sources of stem cells are, however, less 
controversial161,162.   
1.8.1b  Accessibility and numbers 
Cells for therapeutic purposes must be derived from an accessible source11,162,163.  The bone 
marrow and peripheral blood are self-renewing sources which can yield large numbers of cells 
with minimally invasive procedures.  Although neural stem cells might be an ideal cell type for 
use in neurodegenerative disease, they are only accessible post-mortem, making donor 
transplants complicated and autologous transplants impossible125.  In contrast, stem cells from 
the bone marrow and peripheral blood are highly accessible and acquired by minimally invasive 
procedures11,162.  Bone marrow harvesting and mobilization are well established techniques 
which are routinely used clinically for therapy of haematological diseases.  The number of stem 
cells derived from a tissue can prove rate limiting.  For example, cell transplants from foetal 
tissues for Parkinson’s disease require tissue from several donors125,159.  This inaccessibility and 
low numbers of stem cells makes the use of this tissue unlikely to be established for routine 
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therapy.  The harvesting of stem cells from blood and bone marrow is logistically advantageous 
and yields much larger numbers of stem cells for therapeutic use.    
 
1.8.1c Tumorigenicity 
Embryonic stem cells might be an ideal stem cell type for tissue regeneration since they can be 
induced to differentiate into tissue from all three germ layers164.  Pluripotent ES cells can be kept 
undifferentiated in culture for prolonged periods of time and differentiated efficiently, but 
chromosomal aberrations have been demonstrated to occur in ES cells in prolonged culture164,165.  
Upon in vivo transplantation, teratomas can form which are benign masses of differentiated ES 
cells164.  Masses with undifferentiated ES cells are called teratocarcinomas and malignant masses 
of undifferentiated cells are embryonic carcinomas164.  In the development of tumors, genetic 
aberrations can affect apoptotic pathways, differentiation, or cell cycle control, consequentially 
leading to precancerous cells and uncontrolled proliferation164.  Adherent CD34+ cells are 
isolated from the donor and are neither passaged nor kept in long term culture, decreasing 
chances of pro-oncogenic genetic alterations.   
 
1.8.1d  Isolation efficiency 
Several stem cell populations have been identified in various organs, but their rarity makes them 
difficult to isolate from the bulk of the tissue.  Stem cell populations are likely heterogeneous, 
requiring multi-parameter separation techniques.  Mesenchymal stem cells are usually isolated 
with plastic adherence and long term culture with defined cytokines.  Stem cells in 
haematopoietic tissue are more easily isolated than those in solid tissues and organs because 
blood and bone marrow are liquid suspensions of cells.  Methods that have been applied include 
FACS sorting, including selection by size, Rhodamine 123 exclusion, or Hoescht expression.  
For example, VSEL cells and side population stem cells are isolated by these criteria.  However, 
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flow cytometry is not acceptable for current good manufacturing practice (cGMP) requirements.  
Stem cells can also be isolated using antibody conjugated magnetic bead isolation.  CD34+ cells 
are routinely isolated by magnetic separation for transplants in haematological diseases.  
Adherent CD34+ cells are isolated magnetically and separated from the bulk of the CD34+ cells 
by adherence to tissue culture treated plastic.  These cells can be isolated in a closed system for 
clinical use with minimal manipulation to donor tissue, adding to their desirability for clinical 
use.   
 
1.8.1e Safety 
Although there is increasing knowledge about stem cells and their molecular control 
mechanisms, there are key factors that exclude the majority of stem cell populations from 
clinical use, particularly tumorigenicity and immune tolerance.  ES cells are pluripotent and their 
differentiation is well controlled in vitro.  In the body, MSCs and ES cells have epigenetic 
mechanisms in place which prevent uncontrolled proliferation.  Their artificial expansion in 
culture is thought to alter these intrinsic epigenetic checkpoints of self-renewal, thus MSC and 
ES cells implanted into animal models have been shown to cause teratoma formation.  Immune 
rejection is also a consideration in donor cell transplants.  In the case of blood or bone marrow 
cell therapy, autologous cell transplants are ideal, but patients may not be well enough to 
undergo G-CSF mobilization for autologous transplants, or may be haematologically depleted 
and yield insufficient cells.  Use of tissue mismatched donors might risk immune rejection and 
the onset of graft versus host disease.  Mesenchymal stem cells are immunosuppressive, but may 
lose this characteristic in mismatch transplants171.  For example, a recent study using MSC to 
prevent graft-versus-host disease (GvHD) in patients with haematological malignancies 
subjected to allogeneic HSC transplant found that without mesenchymal stem cells prevent graft-
versus-host disease, they increase graft-versus-leukemia reactions172,173. 
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1.9 Glioblastoma Multiforme 
Glioblastoma multiforme (GBM) is the most common and most lethal primary malignant type of 
brain tumor in adults.  Prognosis is very poor with a median survival time of less than 15 months.  
A fundamental challenge in the management and treatment of gliomas is the propensity for 
single tumor cells to invade peritumoral and distant brain tissue.  These invasive tumor cells 
evade surgical removal, chemotherapy, and radiation exposure.  Current treatment is surgical 
removal followed by radiotherapy and/or chemotherapy with Temozolomide or Gliadel.  Both 
drugs are generally well tolerated because of their limited systemic toxicity.   
 
Gliomas of astrocytic origin are classified into four grades as defined by the World Health 
Organization.  Pilocytic astrocytomas (grade I tumor) are usually indolent, have a limited 
invasive capacity, and rarely undergo anaplastic progression71.  Pleomorphic xanthoastrocytomas 
(grade II tumor) are low-grade tumors with cellular pleomorphism and have a limited capacity 
for brain tissue invasion.  Diffuse-type astrocytomas have the capacity to disperse into 
surrounding tissue and a high frequency of anaplastic progression71.  Grade II astrocytomas71 are 
well differentiated and have mild to moderate nuclear pleomorphism.  Grade III astrocytomas are 
highly proliferative and commonly have a moderate degree of cellular pleomorphism and are 
more heterogeneous in cell type.  Grade IV glioblastoma multiforme (GBM) is the most 
aggressive glial tumor and is pathologically distinctive with geographic necrosis and 
microvascular hyperplasia, and has marked cellular pleomorphism71.   
 
There has been no significant increase in survival of GBM patients in the 30 years of brain tumor 
research71-74.  Therefore, the development of novel therapeutic approaches is essential.  Genetic 
mutations have been identified in various types of gliomas, most of which are involved in 
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autocrine and paracrine signaling.  These include genes amplifications which lead to 
overexpression of mitogens and their specific receptors including EGF and its receptor (EGFR), 
platelet-derived growth factor (PDGF) and its receptor (PDGFR), insulin-like growth factor 1 
(IGF-1) and its receptor (IGFR)74.  Several angiogenic factors are also overexpressed in gliomas 
including FGF, interleukin 8 (IL-8), PDGF, TGF, and VEGF71.  The combined genetic variations 
of these factors and mitogens lead to subsequent aggressive cellular proliferation, invasion, and 
angiogenesis, rendering malignant gliomas, especially GBM, resistant to current therapies. 
 
Several factors including the immunosuppressive environment of the tumor and the low avidity 
of the T cells for the tumor antigen and may contribute to the poor antitumor efficacy of the 
endogenous immune response135.  Although tumor specific endogenous immunity can be elicited 
in cancer patients by overexpressing tumor antigens, it cannot prevent tumor growth200.  Cancer 
immunotherapy has become a recent focus for the development of glioma treatment.  Tumor-
associated antigens recognized by tumor-reactive cytotoxic T lymphocyes (CTLs) have been 
identified198.  Tumor antigens expressed by human malignant neoplasms can be categorized 
loosely into three different groups; the differentiation antigens; the products of viral, mutated, 
differentially spliced or overexpressed genes; and housekeeping or metabolic pathway 
antigens135, 198-200.   
 
1.9.1 Current clinical cell therapy in GBM 
Active immunotherapy is a strategy where anti-tumor immunity is initiated following 
immunization with tumor antigen, and studies have demonstrated that peripherally administered 
tumor antigen-based immunizations are capable of inducing intracranial anti-tumor 
responses73,139,198.   Dendritic cell therapy is a form of active immunotherapy where large 
numbers of autologous dendritic cells are expanded in vitro from monocytes and loaded with 
tumor antigens.  These are then administered as a vaccine to induce anti-tumor 
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immunity139,199,200.  Clinical trials using dendritic cell vaccination demonstrated increases in 
tumor specific cytotoxicity73,139.  Another cell therapy taken to clinical trial is the use of 
interleukin 4 (IL-4) transfected fibroblasts for autologous transplant, but patients had recurrent 
tumor formation201.  
 
 
1.10 Aims  
Previous studies have demonstrated the ability of adherent CD34+ cells to increase engraftment 
in bone marrow transplant as well as give rise to cells of haematopoietic lineage174, 175.  This 
project contributed to known data about adherent CD34+ cells.  The aims of this project were to 
create a transcription profile of adherent CD34+ cells and compare transcript expression relative 
to non-adherent CD34+ cells.  Previously published transcription data26 showed that adherent 
CD34+ cells express transcription factors which encode for neurons, thus the next aim of this 
project was to determine if adherent CD34+ cells are capable of neuronal differentiation in vitro.  
As these cells are haematopoietic cells, the following aim was to determine if adherent CD34+ 
cells differentiate into microglia, which are of haematopoietic developmental origin.  The final 
aim of this project was to conduct preliminary experiments to determine if either adherent 
CD34+ cells or adherent CD34+ cell derived microglia have potential uses for cell therapy in 
glioblastoma multiforme.   
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Chapter 2 Materials and methods 
 
2.1 Source of material for study 
2.1.1 Leukaphereses 
Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood cells were obtained 
from leukaphereses processed by the Stem Cell Laboratory, Hammersmith Hospital, in excess of 
clinical requirements. Informed consent and local research ethics committee approval were 
granted in all cases.  Ethics reference number 06/Q0406/78. 
 
The leukapherised blood sample was diluted in Hanks’ Buffered Salt Solution (HBSS) 
(Invitrogen, Paisley, UK), layered over Lymphoprep (Axis-Shield, Oslo, Norway) and 
centrifuged at 1800 rpm for 30 minutes.  Mononuclear cells (MNC) were aspirated from the 
interface and washed in HBSS.  Cells were then counted using a haemacytometer after diluting 
in 3% glacial acetic acid (Sigma-Aldrich Company Ltd, Gillingham, UK) to lyse red blood cells.   
 
2.1.2 Fetal human mesenchymal stem cells and human fibroblast cells 
24XY fetal human mesenchymal stem cells (fhMSC) and HS27 human fibroblast (hFib) cells 
were originally obtained from Professor Nick Fisk, and consented use was allowed in 
collaboration with Dr. Deanna Taylor.  Cells were primary cells used between passage 8-13 and 
cultured in D10 medium which consisted of Dulbecco’s minimum essential medium (DMEM) 
(Invitrogen, Paisley, UK) supplemented with 10% FBS (Invitrogen, Paisley, UK), 1% L-
glutamine (Invitrogen, Paisley, UK) and 1% penicillin-streptomycin (Invitrogen, Paisley, UK). 
 
2.1.3 Neural stem cells 
Human neural stem cells R197V (NSC) were provided by Re-Neuron (Surrey, UK) and used in 
collaboration with Dr. Deanna Taylor and Dr. Reaz Vawza.  NSC were used to observe neuronal 
differentiation and as positive staining controls for neuronal differentiation experiments.  Cells 
were cultured in suspension neurospheres and plated onto poly-D-lysine/fibronectin coated wells 
for differentiation purposes.  Cells were maintained and expanded in DMEM supplemented with 
F12 (DMEM:F12) (Invitrogen, Paisley, UK) supplemented with 1% L-glutamine, 1% penicillin-
streptomycin, 1% B27 without vitamin A (Invitrogen, Paisley, UK), 10ng/ml epidermal growth 
36 
 
factor (EGF; Peprotec, London, UK), and 10ng/ml fibroblast growth factor 2 (FGF2)(Peprotec, 
London, UK).  Neural stem cells were used as neural differentiation positive controls to ensure 
that differentiation protocols did induce neurogenesis in cells known to differentiate into neural 
cells. 
2.1.4 Glioblastoma cell lines 
Glioblastoma cell lines U253 and U118 were a kind gift from Dr. Tracy Warr (Institute of 
Neurology, The National Hospital of Neurology and Neurosurgery, Queen Square, London).  
The lines U87, U253, and U118 were cultured in DMED:F12 medium, supplemented with 10% 
FBS, 1% L-glutamine, and 1% penicillin-streptomycin.  Cells were passaged and detached from 
culture dishes with trypsin/EDTA (Sigma-Aldrich Company Ltd, Gillingham, UK) for 8 mins at 
37°C, and subcultured as needed.   
2.1.5 N9 microglia cell line 
N9 rat microglia cells were provided by Dr. Deanna Taylor.  The cells were cultured in DMEM 
supplemented with 5% FBS, 1% L-glutamine, and 1% penicillin-streptomycin.  To subculture, 
cells were gently scraped from the flask with a plastic cell scraper.   
2.1.6 Embryonic stem cells 
Embryonic stem (ES) cells E9 were a kind gift from Dr. Wei Cui as a positive control for Oct4 
and Sox2 protein expression.  The cells provided were plated and fixed for immunofluorescent 
microscopy.  
 
2.2 Isolation of CD34+ cells 
MNCs were labelled for CD34+ isolation using the MiniMacs CD34+ positive isolation kit 
(Miltenyi Biotec Camberley, UK) as detailed in the manufacturer protocol.  For every 108 cells, 
PBMCs were suspended in 300µl Macs buffer (PBS (Invitrogen, Paisley, UK), 0.5% bovine 
serum albumin (PAA laboratories, Pasching, Austria) and 2mM EDTA (Sigma-Aldrich 
Company Ltd, Gillingham, UK), 100µl FcR blocking reagent, and 50µl of monoclonal hapten-
conjugated CD34 antibody.  This was incubated at 4-8ºC for 15 minutes, and washed in Macs 
buffer by centrifugation at 1800 rpm for 3 minutes.  The cells were then resuspended in 500µl 
Macs buffer per 108 cells and passed through a pre-wetted LS MiniMacs column (Miltenyi 
Biotec Camberley, UK) mounted on a Miltenyi magnet.  The column was then washed with 3ml 
Macs buffer three times.  The column was then removed from the magnet and the CD34+ cells 
eluted with 5ml Macs buffer.   
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2.3 Isolation of plastic adherent CD34+ cells 
Isolated CD34+ cells were plated on 35-mm2 Petri dishes in -minimal essential medium ( -
MEM) (Invitrogen, Paisley, UK) and incubated for 30 minutes at 37°C and 5% CO2.  The non-
adherent cell fraction was removed by washing the plates three times with HBSS. Standard 
culture conditions for plastic adherent CD34+ cells include culture in -MEM supplemented with 
30% FBS and cytokines (20 ng/ml stem cell factor [SCF], 1 ng/ml GM-SCF, 5 ng/ml IL-3, and 
100 ng/ml G-CSF) at 37°C in 5% CO2 in air.  
 
2.4 Neural Differentiation  
The details of differentiation protocols are outlined below.  Initial attempts to induce neuronal 
differentiation were conducted using published protocols as described and referenced below.  
Protocols were then derived from published work, using various combinations of cytokines and 
growth factors as detailed below.   
 
Prior to neural differentiation, plastic adherent CD34+ cells were kept in culture in -MEM 
supplemented with 30% FBS and cytokines (20 ng/ml stem cell factor [SCF], 1 ng/ml GM-SCF, 
5 ng/ml IL-3, and 100 ng/ml G-CSF) at 37°C in 5% CO2 in air for 5 days. The medium was then 
removed, and replaced with the appropriate experimental neural induction medium as detailed 
below.  For fMSC neural differentiation, fMSCs were plated onto poly-D-lysine coated glass 
coverslips overnight in DMEM medium supplemented with 10% FBS.  The medium was then 
replaced with the desired neural induction medium.   
 
2.4.1 Neuronal induction protocol 1 
Based on the neuronal induction protocol by Woodbury et al75, adherent CD34+ cells were 
cultured in DMEM, 20% FBS, and 1mM β-mercaptoethanol for 24 hours.  The medium was then 
replaced with medium consisting of DMEM, 2% dimethylsulfoxide (DMSO), and 200 µM 
butylated hydroxyanisole (BHA) and cultured for 2 days.   
 
2.4.2 Neuronal induction protocol 2  
Based on the neuronal induction by Tao et al76, adherent CD34+ cells were plated onto 
fibronectin coated plastic tissue culture treated plates and cultured in DMEM/nutrient mixture 
F12 (DMEM/F12; Invitrogen, Paisley, UK), 25µg/ml insulin, 100 µg/ml transferring, 100 µM 
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putrescine, 0.02µM progesterone, and 0.03 µM sodium selenite (Sigma-Aldrich Company Ltd, 
Gillingham, UK).  The medium was supplemented with 10 ng/ml basic fibroblast growth factor 
(bFGF), 10 ng/ml epidermal growth factor (EGF), and 1 ng/ml platelet derived growth factor 
(PDGF) (R&D Systems, Minneapolis, MN, USA).  The cultures were incubated at 37°C in 5% 
CO2 in air with daily additions of the above stated growth factors and the medium changed every 
2 days.   
 
2.4.3 Neuronal indiction protocol 3  
Based on the neuronal induction protocol by Muñoz-Elias et al77, adherent CD34+ cells were 
plated on poly-D-lysine (Sigma-Aldrich Company Ltd, Gillingham, UK) coated plates and 
cultured in DMEM, 20% FBS supplemented with 5 ng/ml bFGF for 24 hours.  The medium was 
then replaced and supplemented with 100 µM BHA, 10 µM forskolin, N2 medium supplement 
(Invitrogen, Paisley, UK) and incubated at 37°C in 5% CO2.   
 
2.4.4 Neuronal induction protocol 4 
Derived from a neuroectodermal differentiation protocol by Jiang et al12, adherent CD34+ cells 
were cultured in DMEM/F12 medium with N2 medium supplement, 1% glucose (Sigma-Aldrich 
Company Ltd, Gillingham, UK), 1% L-glutamine (Sigma-Aldrich Company Ltd, Gillingham, 
UK).  This was then supplemented with 10 nM bFGF, 10 nM sonic hedgehog (Shh; Peprotec, 
London, UK), 10 nM fibroblast growth factor 8 (FGF8; Peprotec, London, UK), and 1 nM 
retinoic acid (Sigma-Aldrich Company Ltd, Gillingham, UK).  Cells were incubated at 37°C in 
5% CO2.   
 
2.4.5 Neuronal induction protocol 5 
Adherent CD34+ cells were cultured in DMEM/F12 medium with B27 medium supplement 
(Invitrogen, Paisley, UK) and 1% L-glutamine, supplemented with an additional 10 nM bFGF.  
Cells were incubated at 37°C in 5% CO2.   
 
2.4.6 Neuronal induction protocol 6 
Based on the neural stem cell expansion and differentiation methods of Svendsen et al78, 
Adherent CD34+ cells were cultured in DMEM/F12 medium with B27 medium supplement and 
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1% L-glutamine, supplemented with an additional 10 nM bFGF, and 10 nM EGF.  Cells were 
incubated at 37°C in 5% CO2.   
 
2.4.7 Neuronal induction protocol 7 
Derived from a differneitation protocol by Shihabuddin et al79, adherent CD34+ cells were 
cultured in DMEM/F12 medium with N2 medium supplement, 1% L-glutamine and 1% glucose, 
supplemented with an additional 10 nM bFGF.  Cells were incubated at 37°C in 5% CO2.   
 
2.4.8 Neuronal induction protocol 8 
Adherent CD34+ cells were cultured in DMEM/F12 medium with N2 medium supplement, 1% 
L-glutamine and 1% glucose, supplemented with an additional 10 nM bFGF.  Cells were 
incubated at 37°C in 5% CO2 for 7 days, then the medium replaced with DMEM/F12 medium 
with N2 medium supplement, 1% L-glutamine and 1% glucose.  Cells were incubated at 37°C in 
5% CO2.   
 
2.4.9 Neuronal induction protocol 9 
Adherent CD34+ cells were cultured in DMEM/F12 medium with N2 medium supplement and 
1% L-glutamine, supplemented with an additional 10 nM bFGF, and 10 nM EGF.  Cells were 
incubated at 37°C in 5% CO2.   
 
2.5 Microglial differentiation  
Differentiation of bone marrow derived cells was performed as described by Davaust et al 
(2006). To induce microglial differentiation, cells were cultured in 50% astrocyte conditioned 
medium (ACM) and 50% DMEM/F12 and incubated at 37°C in 5% CO2.  Half the medium in 
culture was replaced every 3-5 days.   
 
2.5.1 Astrocyte conditioned medium 
Four day old rat pups were decapitated and their heads placed in dishes with HBSS.  The skin 
was cut to reveal the skull which was cut along the midline and sides and removed.  Next, the 
cerebellum was removed and discarded.  The cortex and midbrain were removed and placed in a 
dish with HBSS (without Phenol red) on ice.  Under a dissecting microscope, the hemispheres 
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were separated and the meninges and midbrain were removed and discarded.  The hippocampus 
was dissected out and the cortices placed in a petri dish in a solution containing 100ml HBSS, 
300mg bovine serum albumin (BSA) (Sigma-Aldrich Company Ltd, Gillingham, UK), and 2mg 
DNAse (Qiagen, Crawley, UK).  The hippocampus was physically dissociated with sterile 
scissors and pipetted up and down with a 1 ml Gilson pipette.  The suspension was transferred to 
a 50ml Falcon tube and centrifuged at 2000rpm for 5 minutes at 4ºC.  The supernatant was 
removed and pellet resuspended in a solution of 20ml HBSS, 600µl BSA, 3.400mg DNAse, and 
5mg trypsin.  This was passed through a Gilson pipette to remove clumps, then incubated at 37ºC 
for 5 minutes, then 1ml FBS was added to neutralize the trypsin.  The tissue was collected and 
centrifuged at 2000rpm for 5 minutes at 4ºC.  The pellet was resuspended in 10ml HBSS, 30mg 
BSA, and 0.2mg DNAse and left for 2 minutes to allow heavy clumps to settle and the 
supernatant  replaced into a new Falcon tube.  The debris was resuspended in 10ml HBSS, 30mg 
BSA, and 0.2mg DNAse.  After a further 2 minutes to allow heavy clumps to settle, the 
supernatant was collected.  This was repeated once more.  The pooled supernatants were 
centrifuged at 2000rpm for 5 minutes at 4ºC.  The resulting pellet was resuspended in MEM with 
L-valine, passed through a nylon mesh filter, and plated out in tissue culture treated T75 flasks.  
On day 7, flasks were shaken for 18 hours at 200 on a rocking platform and each flask was split.  
The medium on the remaining astrocytes was changed and left uninterrupted for 4 weeks.  
Medium was harvested from the culture after 4 weeks (astrocyte conditioned medium, ACM), 
filtered, and used in differentiation experiments.   
 
2.6 RNA Isolation 
RNA was isolated from newly isolated adherent CD34+ cells and non-adherent CD34+ cells 
using the RNeasy minikit according to the manufacturer's instructions (Qiagen, Crawley, UK).  
For each sample to be analyzed, cells were spun down into a pellet and the supernatant removed.  
For each 100µl of Buffer RLT used, 1µl β-mercaptoethanol (BME) was added.  A total 350µl of 
RLT/BME lysis buffer was added to the cell pellet, and a needle and syringe was used to shred 
the lysate, and it was resuspended in 70% ethanol.  The mixture was applied to an RNeasy spin 
column and centrifuged for 15sec at 10,000 rpm, and the flow through discarded.  700ul of 
Buffer RW1 was added to the column, centrifuged, and the flow through discarded.  To the 
column, 80µl of DNAse (Promega, Southampton, UK) was added and incubated for 15min at 
room temperature.  To wash, 350µl Buffer RW1 was added and centrifuged.  The column was 
then washed with 500µl Buffer RPE twice.  The RNA was eluted by adding 50µl RNAse free 
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water (Qiagen, Crawley, UK) to the column, and centrifuged for 1min at 10,000rpm.  Eluted 
RNA quality was assessed using the RNA 6000 Pico Assay (Agilent Technologies) on the 
Bioanalyser 2100.   
 
2.6.1 RNA salt precipitation 
To concentrate RNA in dilute samples, the salt precipitation technique was used.  First, 3M 
sodium acetate (pH5.2) in amounts equal to 1/10th of the volume of the diluted RNA was added 
to the RNA.  Three volumes of 100% ethanol was added, mixed, and stored overnight at -20ºC.  
The mixture was spun at 13,000rpm for 10min at 4ºC.  The supernatant was aspirated and the 
pellet washed in 70% ethanol and spun down.  The ethanol was aspirated and the pellet dried, 
and resuspended in an appropriate amount of RNAse free water to give the desired 
concentration.   
 
2.6.2 Agilent 2100 Bioanalyser, RNA 6000 Pico/Nano Assay  
Total RNA quality was measured using the RNA 6000 Pico Assay or the RNA 6000 Nano Assay 
on the Agilent 2100 bioanalyzer (Aglient technologies, Santa Clara, CA, USA).  To prepare the 
gel-dye for the RNA 6000 Pico Chip, RNA 6000 Pico dye concentrate was vortexed for 10sec 
and spun down.  1µl of RNA 6000 Pico dye concentrate was added to 65µl of filtered gel.  The 
mixture was spun for 10min at 13000g.  The RNA Pico chip was loaded using the Chip Priming 
Station, where 9µl of the gel-dye mix was dispensed into the designated well, and plungered for 
30sec.  Additional gel-dye mix and the RNA 6000 Pico Conditioning Solution were placed into 
the appropriate well.  5µl of the RNA 6000 Pico marker was added into all remaining wells.  1µl 
diluted RNA 6000 ladder was added to the ladder well, and 1µl of each sample was added to 
appropriate wells.  The RNA 6000 Pico chip was analyzed with the Bioanalyzer 2100.   
 
2.7 Microarray small sample preparation protocol 
Total RNA extracted from cell samples was prepared for cDNA microarray analysis using the 
Gene expression small sample protocol 1 as described by the MRC Microarray Centre 
(http://microarray.csc.mrc.ac.uk).   
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2.7.1 First round amplification: First strand cDNA synthesis 
For each sample, preparation of RNA for microarray analysis began with 100ng of total RNA in 
a 0.2ml PCR tube, 5pmol T7 Oligod(T) primer (provided by the microarray center), and 0.5µl 
small sample prep (SSP) diluted Poly A+ Cocktail (provided by the microarray center).  This was 
mixed by pipetting and incubated in a thermal cycler at 70ºC for 6 mins, cooled to 4º for 2 mins, 
and spun.  The master mix for each reaction consisted of 0.375µl RNase free dH2O, 1µl 5X First 
Strand Buffer, 0.5µl (0.1M) DTT, 0.375µl (10mM) dNTP Mix (Invitrogen, Paisley, UK), 0.25µl 
(40U/µl) RNase Inhibitor (Ambion, Warrington, UK), and 0.5µl (200U/µl) Superscript II 
(Invitrogen, Paisley, UK).  This master mix was mixed and spun before adding 3µl to each 
reaction tube, and incubated at 42ºC in a thermal cycler with a heated lid for 1 hour.  The sample 
was brought up to 70ºC in the thermal cycler for 10 mins to inactivate the Superscript II, spun 
and cooled to 4ºC before proceeding. 
 
2.7.2 First strand cDNA synthesis 
For each reaction, the master mix for this reaction consisted of 22.75µl RNase free dH2O, 7.5µl 
5X Second Strand Buffer, 0.75µl (10mM) dNTPs Mix, 0.25µl (10U/µl) DNA ligase, E.coli,, 1µl 
(10U/µl) DNA polymerase, E.coli,  and 0.25µl (2U/µl) RNase H (Invitrogen, Paisley, UK) to 
make up 32.5µl master mix per reaction.  This was mixed and 32.5µl was added to each reaction 
tube from the First Strand Synthesis, mixed by pipetting and spun down.  This was incubated at 
16ºC in a thermal cycler without a heated lid for 2 hours and placed in ice before proceeding to 
the clean-up of double stranded cDNA.  
 
2.7.3 Clean-up of double stranded cDNA 
The product from the second strand synthesis (37.5µl) was transferred into a clean RNase/DNase 
free 1.5ml microfuge tube. Each product reaction tube was diluted by adding 82.5µl RNase free 
dH2O and mixed by pipetting.  Each reaction then received 2µl Glycogen (5mg/ml), 0.6X 
volumes 5M NH4OAc (72µl) (Ambion, Warrington, UK), 2.5X volumes cold 100% ethanol 
(480µl), then mixed by pipetting.  This was incubated for 1 hour at -20ºC to precipitate the 
double stranded cDNA.  To collect the cDNA, the reaction tubes for each sample were 
centrifuged at 14,000 rpm for 20 mins at 4ºC, and the supernatant was gently aspirated with a 
pipette.  The remaining pellet was washed with 800µl of 70% cold ethanol and centrifuged at 
14,000 rpm for 20 mins at 4ºC, the supernatant aspirated, and all traces of ethanol removed by air 
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drying the pellet for 5-10 mins at room temperature.  The tubes were then placed on ice to 
proceed to the in vitro transcription reaction.   
 
2.7.4 In vitro transcription 
The reagents used in this step was from the MEGAscript T7 Kit (Ambion, Warrington, UK).  For 
each reaction, the master mix consisted of 4µl RNase free dH2O, 1µl T7 ATP Solution (75mM), 
1µl T7 CTP Solution (75mM), 1µl T7 GTP Solution (75mM), 1µl T7 UTP Solution (75mM), 
and 1µl T7 10X Reaction Buffer.  Then 9µl of the master mix was added to each purified cDNA 
pellet from the previous step, and mixed thoroughly by pipetting to completely dissolve the 
pellet.  Next, 1µl T7 10X Enzyme Mix was added to each sample, mixed, and spun briefly.  This 
was then incubated at 37ºC for 5 hours in a thermal cycler with a heated lid.  For every hour of 
this incubation, the reactions were gently mixed by tapping the tube and spinning briefly.   
    
2.7.5 Clean-up of amplified cRNA 
The reagents used for this step were from the RNeasy Mini Kit (Qiagen, Crawley,UK).  Before 
beginning the reaction the RLT Buffer was prepared by adding 1µl β-mercaptoethanol for each 
100µl RLT Buffer to be used.  For the in vitro transcription, into each reaction tube, 90µl RNase 
free dH2O and 350µl RLT Buffer was added and mixed by pipetting.  Next 250µl of 100% 
ethanol was added, the entire mixture was transferred onto a RNeasy Spin Column, and spun at 
maximum speed for 15 seconds at room temperature.  The collection tubes were emptied and 
500µl RPE Buffer was added to the column.  This was spun at maximum speed for 2 minutes at 
room temperature, the collection tube replaced with a new one, and spun again for 1 minute at 
room temperature.  The spin column was again transferred to a fresh collection tube.  To elute 
the cRNA, 30µl RNase free dH2O was pipetted onto the middle of the spin column membrane, 
incubated for 4 minutes at room temperature, and spun at maximum speed for 1 minute.  The 
cRNA was eluted again by adding a further 20µl RNase free dH2O onto the middle of the 
membrane of the spin column, incubated for 4 minutes at room temperature, and spun for 1 
minute at maximum speed. The total eluate (~50µl) was taken and pipetted onto the middle of 
the membrane of the same spin column, incubated for 4 minutes at room temperature, and spun 
for 1 minute at maximum speed.   
 
An aliquot of the eluate was diluted with RNase free dH2O and the absorbance at 260nm and 
280nm was measured with the NanoDrop device as well as the final yield.  Acceptable yields 
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after this first round amplification was between 1-2µg.  Lower yields indicated problems with the 
reactions.  Quality control was measured using the RNA 6000 Pico Assay on the Agilent 2100 
Bioanalyser to identify any genomic degradation, product contamination, and measure cRNA 
quantity.   
 
2.7.6 Second round amplification: First strand cDNA synthesis 
The starting amount of cRNA for each sample in this reaction was 1µg cRNA in a total volume 
of 4µl.  The volume was adjusted with RNase free dH2O as necessary.  To each cRNA sample 
(1µg in 4µl), 1µl Random Primers (0.2µg/µl) (provided by the microarray center) was added, 
mixed thoroughly, incubated at 70ºC for 10 minutes, then cooled on ice for 2 minutes.  For each 
sample, the master mix for this reaction consisted of 2µl 5X First Strand Buffer, 1µl (0.1M) 
DTT, 0.5µl (10nM) dNTP Mix, 1µl (200U/µl) SuperScript II (Invitrogen, Paisley, UK), and 
0.5µl (40U/µl) RNase Inhibitor (Ambion, Warrington, UK), to make up a total volume of 5µl 
master mix per sample.  To each sample, 5µl of master mix was added to the amplified 
cRNA/primer mixture at room temperature, mixed, spun briefly, and incubated at 42ºC for 1 
hour in a thermal cycler with a heated lid.  Next 1µl RNase H (2U/µl) (Invitrogen, Paisley, UK) 
was added, pipetted, spun briefly, and incubated at 37º for 20 minutes.  The sample was then 
heated to 95ºC for 5 minutes to inactivate the RNase H, then cooled on ice for 2 minutes and 
spun down.  This was kept on ice until the next step. 
 
2.7.7 Second strand cDNA synthesis 
To the first strand reaction tubes from the previous step, 2µl (5pmol/µl) T7 Oligo (dT) Primer 
(provided by the microarray center) was added, mixed by pipetting, and spun briefly.  This was 
incubated at 70ºC for 6 minutes, cooled on ice for 2 minutes, and spun down.  For each reaction, 
the master mix consisted of 43.5µl Nuclease-free water, 15µl 5X Second Strand Buffer, 1.5µl 
(10mM) dNTP Mix, 2µl (10U/µl) DNA Polymerase I, E. coli (Invitrogen, Paisley, UK) for a 
final volume of 62µl for each sample.  Next, 62µl master mix was added to the sample, mixed, 
and incubated at 16ºC for 2 hours in a thermal cycler without a heated lid.   
 
2.7.8 Clean-up of double stranded cDNA 
To each sample reaction tube, 2µl (5mg/ml) glycogen, 45µl (0.6X volumes) NH4OAc (Ambion, 
Warrington, UK), 300µl (2.5X volumes) of cold 100% ethanol was added and mixed by 
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pipetting.  The ds cDNA was precipitated at -20ºC for 30 minutes.  The samples were then 
centrifuged at 14,000 rpm for 20 minutes at 4ºC.  The supernatant was removed, the pellet 
washed with 800µl of 70% cold ethanol, and centrifuged at 14,000 rpm for 5 minutes at 4ºC.  All 
traces of ethanol was aspirated and the pellet left to air dry at room temperature for 5-10 minutes.   
 
2.7.9 In vitro transcription 
The reagents used for this in vitro transcription was from the Enzo Bioarray High Yield RNA 
Transcript Labelling Kit (Affymetrix, Santa Clara, CA, USA).  For each reaction, the master mix 
consisted of 22µl nuclease free dH2O, 4µl (10X) HY Reaction Buffer, 4µl (10X) Biotin-labelled 
ribonucleotides, 4µl (10X) DTT, and 4µl (10X) RNase Inhibitor Mix.  Into each reaction tube, 
38µl master mix was added to the purified ds cDNA from the previous step and mixed by 
pipetting.  Next 2µl (20X) T7 RNA  Polymerase was added and the samples mixed and spun 
briefly.  This was then incubated at 37ºC for 5 hours in a thermal cycler with a heated lid.  At 
each hour of the incubation, the reaction was gently mixed by tapping the tube and spinning 
briefly.   
 
2.7.10 Clean-up of amplified cRNA 
The regents used in this step were from the RNeasy Mini Kit (Qiagen, Crawley, UK).  Prior to 
proceeding, 1µl β-mercaptoethanol was added to each 100µl RLT Buffer to be used.  For the in 
vitro transcription, each sample tube from the previous step received 60µl RNase free dH2O and 
350µl Buffer RLT (with β-mercaptoethanol).  Next 250µl of 100% ethanol was mixed into the 
reaction, and the entire sample was then pipetted onto the RNeasy Spin Column and spun at 
maximum speed for 15 seconds at room temperature.  The collection tube was emptied, then 
500µl RPE Buffer was added to the column, spun at maximum speed for 15 seconds, the 
collection tube emptied, and an additional 500µl Buffer RPE added to the column.  This was 
spun at maximum speed for 2 minutes and the spin column transferred to a fresh collection tube 
and spun for an additional 1 minute.  The spin column was transferred to a new collection tube.  
To elute the cRNA, 30µl RNase free dH2O was pipetted onto the middle of the membrane of the 
spin column, incubated at room temperature for 4 minutes, and spun at maximum speed for 1 
minute.  An additional 20µl of RNase free dH2O was added to the membrane of the spin column, 
incubated for 4 minutes at room temperature, and spun at maximum speed for 1 minute.   
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An aliquot of cRNA eluate was diluted with RNase free dH2O to assess the quality on the 
NanoDrop.  The absorbance at 260nm and 280nm was measured and the acceptable ratio of the 
absorbances ranged from 1.9 to 2.1.  The final cRNA yield from 1µg cRNA from the first round 
amplification was between 40-100µg.  An aliquot of each sample was run for quality on the 
RNA 6000 Nano Assay on the Agilent 2100 Bioanalyser as previously described.  The minimum 
concentration was 1.25µg/µl.   
  
2.7.11 Bioinformatics 
Analysis of the gene arrays were analyzed using Rosetta Resolver program.  This was validated 
by the Bioinformatics Support Centre using Genespring and R Statistical programme.  Further 
analysis and classifications of biological functions were complete using the Database for 
Annotation, Visualization, and Integration Discovery (DAVID) (http://david.abcc.ncifcrf.gov) to 
classify functional annotation clustering using the Gene Ontology terms.   
 
2.8 Immunofluorescence 
2.8.1 Immunofluorescence staining of live cells 
For immunofluorescence using live cells, cells were rinsed once with modifies eagle’s medium 
(MEM), and placed on ice for the remainder of the staining process.  Both primary and 
secondary antibodies were diluted in 3% bovine serum albumin (BSA) in MEM and incubated 
for 20 minutes on ice.  After 20 mins, excess liquid on the cells was gently removed and the cells 
then rinsed 3 times for 5 minutes with 3% BSA in MEM.  Cells were then incubated in 
secondary antibody for 30 minutes, washed 3 times, and then fixed in 4% PFA for 10 minutes.  
Fixed cells were washed twice in PBS for 5 minutes.  For nuclear staining, cells were incubated 
in DAPI 1:1000 for 2 minutes.  Cells were again washed 3 times and mounted on glass slides.   
 
2.8.2 Immunofluorescence staining of fixed cells 
For immunofluorescence using fixed cells, the cells were fixed in 4% paraformaldehyde for 10 
minutes at room temperature and washed three times in PBS for five minutes.  Cells were then 
permeabilized and blocked in one step using a solution of 5% normal goat serum and 0.1% 
Triton-X 100 for 30 minutes at room temperature.  The primary antibodies were added 
immediately afterwards and incubated for one hour at room temperature.  The cells were washed 
3 times in 5% normal goat serum in PBS for 5 minutes.  They were then incubated in secondary 
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antibody for 45 minutes, washed 3 times in 5% normal goat serum in PBS for 5 minutes.  For 
nuclear staining, cells were incubated in DAPI 1:1000 for 2 minutes.  Cells were again washed 3 
times in 5% normal goat serum in PBS, then washed once in PBS for 5 minutes.  Cells on slides 
were then mounted with Vectashield (Vector Labs, Peterborough, UK).  Cells in 96 well plates 
were covered with 50µl PBS and immediately analysed with microscopy.   
 
The details of the antibodies used for immunofluorescent staining are detailed below.   
Immunofluorescent stained cells were visualized on a Zeiss fluorescent microscope and analyzed 
using the Metamorph and Photocapture programs.  Quantification of results was statistically 
analyzed using Student’s t-test.  
 
 
Table 1.  Summary of antibodies used and their working dilutions.   
Antibody Species Manufacturer Dilution Cell type by which antigen 
is expressed 
Anti-nestin Mouse Abcam 1:100 Stem cell 
Anit-nestin Mouse Chemicon 1:100 Stem cell 
Anti-Oct4 Mouse Abcam 1:50 Stem cell 
Anti-SSEA3 Mouse Santa Cruz 1:50 Stem cell 
Anti-SSEA4 Mouse Santa Cruz 1:50 Stem cell 
Anti-Cripto1 Mouse Abcam 1:100 Stem cell 
Anti-Sox2 Mouse Abcam  1:100 Stem cell 
Anti-olig2 Mouse Chemicon 1:100 Early oligodendrocyte 
Anti-galC Rabbit Chemicon 1:25 Late oligodendrocyte 
Anti-O4 Mouse * Not diluted Oligodendrocyte 
Anti-A2B5 Mouse * Not diluted Oligodendrocyte 
Anti-O1 Mouse * Not diluted Oligodendrocyte 
Anti-PSA-NCAM Mouse *  Not diluted Neuronal 
Anti-GFAP Rabbit Dako 1:500 Astrocyte 
Anti-Β-III tubulin Mouse Chemicon 1:200 Early neuron 
Anti-S100β Mouse Abcam  1:100 Astrocyte 
Anti-Ox42 Mouse Abcam  1:50 Microglia 
Anti-Ox42 Mouse * Not diluted Microglia 
Anti-Iba-1 Mouse Abcam 1:50 Microglia 
Anti-CCR1 Rabbit Abcam 1:300  
Anti-BMPR2 Goat Santa Cruz 1:100 Early B cell receptor 
Anti-CD34 Mouse   Stem cell 
Anti-CD68 Mouse Abcam 1:100 Microglia 
Anti-Iba1 Rat Abcam 1:50 Microglia 
Anti-CD80 Mouse Abcam 1:100 B7.1/co-stimulatory 
Anti-HLA-DR Mouse BD 1:100 MHCII 
Anti-CD133 Rabbit Abcam 1:100 Stem cell 
Anti-TLR4 Goat Abcam 1:100 Activation marker 
Anti-Ki-67 Mouse Abnova 1:100 Cell cycle 
Alexa 488 Rabbit Invitrogen 1:500 Secondary  
Alexa 594 Rabbit Invitrogen 1:500 Secondary 
Anti-mouse IgG 
whole molecule, 
Goat Sigma 1:100 Secondary against mouse 
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FITC conjugated 
Anti-rat whole 
molecule, TRITC 
conjugated 
Goat Abcam 1:100 Secondary against rat 
Anti-goat whole 
molecule FITC 
conjugated 
Mouse BD 1:100 Secondary against goat 
Anti-rabbit IgG 
whole molecule, 
TRITC conjugated 
Goat Sigma 1:100 Secondary against rabbit 
*Supernatant antibodies were supplied by laboratory of Prof Richard Reynolds 
 
2.8.3 Fluorescent activated cell sorting  
Cells prepared for FACS analysis were labelled using the Fix and Perm® cell labelling kit 
(Caltag Laboratories, Buckingham, UK).  For labelling of extracellular antigens, cells were 
incubated with the appropriate antibody for 20 minutes at room temperature.  They were then 
washed in 3ml PBS and centrifuged at 1800rpm for 3 minutes.  Cells were then incubated in 
Reagent A for 15 minutes at room temperature, washed in 3ml PBS, centrifuged at 1800rpm for 
3 minutes, and re-suspended in 300µl PBS for analysis.  For intracellular antigens, cells were 
first fixed with Reagent A for 15 minutes and washed as above.  Then cells were incubated with 
the permeabilization Reagent B and the appropriate amount of primary antibody for 15 minutes 
at room temperature.  The cells were then washed with 3ml PBS and centrifuged at 1800rpm for 
3 minutes.  Cells were then incubated with Reagent B and the appropriate amount of secondary 
antibody for 15 minutes at room temperature, washed, centrifuged, and re-suspended in 300µl 
PBS.  Labelled cells were analyzed with the BD FACSCalibur (BD Bioscience) with Cell Quest 
Pro software. 
 
 
2.9 Cell function 
2.9.1 Lipopolysaccharide stimulation of cytokine production 
To measure cell activation, cells were stimulated with lipopolysaccharide (LPS) (Axxora, 
Nottingham, UK).  LPS was added to culture medium at a working concentration of 1µl/ml and 
left in culture medium for 8, 16, or 32 hours, then the cells and supernatants were collected for 
analysis. 
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2.9.2 Measurement of cytokines 
2.9.2.1 Enzyme-linked Immunosorbent Assay   
Enzyme-linked immunosorbent assays (ELISA) were performed according to manufacturer’s 
protocols, using commercial kits for specified cytokines (R7D Systems, Abingdon, UK).  
Briefly, supernatants to be assayed were collected, spun down, and filtered to remove 
contaminating cells.  After reconstitution and preparation of reagents, a 96well plate was 
prepared first by adding 50µl of Assay Diluent to each well.  Next, 200µl of standard, control, or 
sample supernatant was added to appropriate wells and incubated for 2hrs.  The plate was 
washed four times with Wash Buffer, and blotted before 200µl of Antibody Conjugate was 
added to each well, incubated for 1hr, and washed four times.  200µl of Substrate Solution was 
added and incubated for 20mins at room temperature in the dark.  To stop the reaction, 50µl of 
Stop Solution was added to each well.  Optical density was determined using an OPTImax 
Tunable microplate reader with absorbance set at 450nm.   
 
2.9.2.2 Human cytokine array 
All reagents used in the human cytokine array constituted a component of the Proteome Profiler 
Human Cytokine Array Panel A Array Kit (R&D Systems, Minneapolis, MN, USA).  Into each 
well of the 4-well multi-dish provided, 2ml Array Buffer 4 and array membranes were placed 
and the dish incubated for 1 hour at room temperature.  Samples were prepared by adding 1ml of 
each sample to 0.5ml of Array Buffer 4.  Next, 15µl of reconstituted Cytokine Array Panel A 
Detection Antibody Cocktail was added to each prepared sample and incubated for 1 hour at 
room temperature.  After one hour, Array Buffer 4 was aspirated off the membranes in the multi-
dish and the sample mixture was added to the membrane.  This was incubated overnight at 2-8ºC 
on a rocking platform.  Each membrane was removed and washed in 20ml of 1X Wash Buffer 
for 10 minutes on a rocking platform shaker.  Membranes were washed three times.  The 
streptavidin-HRP provided was diluted in Array Buffer 5, and 1.5ml of diluted streptavidin-HRP 
was added into each well of the multi-dish, and the membranes placed into each well of the dish.  
This was incubated for 30 minutes at room temperature and washed three times as previously 
described.  Each membrane was removed from the wash container and incubated with a 
chemiluminescent detection reagent and placed protein side up in an X-ray film cassette and 
exposed to film for 1-5 minutes.   
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2.9.3 Migration assays 
Migration assays were conducted using polycarbonate membrane inserts (Nunc, Roskilde, 
Denmark) which were used in standard 24 well cell culture plates.  Appropriate cells were 
prepared and seeded into the bottom of the 24 well plates at 5 x 103 cells per well.   
Polycarbonate membrane inserts were placed above the plated cells and 500 µl of stem cell 
suspension (1x105 cells/ml) was placed within the insert.  After 5-8 hours, the inserts were 
discarded and the cells in the 24 well plates were fixed and analysed.   
 
2.9.4 Invasion assays 
Invasion assays were conducted using the BD BioCoat™ Matrigel™ Invasion Chamber (BD 
Bioscience, Oxford, UK).  The chambers were allowed to rehydrate using PBS for 2 hours at 
37ºC.  After rehydration, either cancer cell lines were plated into the bottom well, or conditioned 
medium or culture medium was put in the bottom well.  Cell suspensions were then prepared at 
seeding densities of 1x105 cells/ml and placed within the transwell.  The entire chamber system 
was incubated at 37ºC for 24 hours.  After incubation, the non-invading cells were removed from 
the upper surface of the Matrigel membrane by using a cotton tipped swab to scrape the cells off 
the membrane with firm but gentle pressure.  This was repeated with a swab moistened with 
culture medium.  Cells on the lower surface of the membrane were fixed with 100% methanol 
for 30 seconds and stained with 1% Toluidine blue for 2 minutes.  The membranes were then 
washed in water and air dried.  To count the cells, the membranes were removed from the insert 
housing using a scalpel and mounted on a microscope slide.  To calculate the percent invasion of 
cells, the following formula was used 
% invasion = (mean # stem cells invading through Matrigel insert membrane/ mean # cells 
migrating through control Matrigel insert membrane) x 100 
The invasion index = (% invasion stem cell/ % invasion control cell) 
 
2.9.5 Mixed Lymphocyte Reaction 
Two samples of peripheral blood mononuclear cells (PBMC) were derived from whole blood of 
excess clinical samples and suspended in RPMI 1640 (Invitrogen, Paisley, UK) supplemented 
with 10% FCS and 1% penicillin/streptomycin.  The PBMCs were then diluted to a final 
concentration of 5 x 105 cells/ml (100µl = 5 x 104 cells).  The stimulator cells were then 
irradiated to 60cGy.  In a 96 well round bottom plate, 100µl of medium was dispensed into three 
wells as background control, 100µl of the responder cell suspension was dispensed into three 
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wells, 100µl of the stimulator cell suspension was dispensed into three wells, 100µl of each 
responder and stimulator cell suspension was dispensed into three wells.  An additional 100µl of 
medium was added to ensure there was 200µl in each well.  The assay was incubated at 37ºC, 
5% CO2 for five days.  On day five, each well in the assay was pulsed with 25µl of tritiated 3H-
Thymidine (1µCi).  The assay was incubated for an additional 18 hours and the cells harvested in 
a cell harvester in filter-mat and the scintillaion results read in the beta reader. 
 
2.10 DNA replication timing 
2.10.1 BrdU labeling 
Replicating cells were grown in culture until they reached 80% confluence.  After a change of 
culture medium, 1.5 mg/ml BrdU (Beckton Dickson, Oxford, UK) per 10 ml culture medium was 
added (final concentration of 50µM) and incubated at 37ºC for 90 minutes.  Cell cultures were 
trypsinized until a single-cell suspension was achieved  
 
2.10.2 Flow cytometric sorting 
The ethanol fixative was washed out with cold PBS Ca2-, Mg2- by centrifuging at 1700 rpm for 
10 minutes at 4ºC.  The cells were washed twice.  After the last wash, 1ml of staining buffer per 
106 cells was added.  Each 10ml of staining buffer was made up of 9.4ml buffer 40/8/21, 0.5ml 
(1mg/ml) propidium iodide (PI), 0.1ml 5% NP-40, 1ml (10mg/ml) RNasaA.  The cells were 
declumped by squeezing them through a G25 needle with a 1ml syringe and left for 10 minutes 
on ice in the dark.  After staining, the cells were filtered through a mesh to remove clumps, and 
placed in a new tube for cell sorting.  Cell sorting was conducted as a service by the MRC FACS 
suite.  Cells were sorted and fractionated according to cell cycle status, resulting in six fractions 
corresponding to cell cycle stage G0/G1, S1, S2, S3, S4, G2/M.  Each fraction contained 
between 20,000 -50,000 cells. 
 
After sorting, each fraction was resuspended in 4ml of lysis buffer which consisted of 800µl 5M 
MaCl, 80µl 0.5M EDTA pH8, 200µl 1M Tris-Cl pH8, 100µl 20% SDS, 2.46ml dH2O, 160µl 
(10mg/ml) proteinase K, 200µl sonicated salmon sperm.  The cells were incubated in lysis buffer 
for 2 hours at 50ºC.   
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2.10.3 DNA extraction and precipitation 
After incubation in lysis buffer, each tube of fractionated cells received 7.5ng/104 cells of control 
Drosoph BrdU labelled DNA, 400µl Phenol, shaken for 1 minute, then centrifuged at maximum 
speed for 5 minutes.  This resulted in a separation of the organic and aqueous phases of the 
solution, and the organic phenol layer was removed.  Next, 400µl of Chloroform was added, 
shaken for 1 minute, and spun at maximum speed for 5 minutes.  The aqueous phase of the 
solution was removed, transferred to a new collection tube, and 800µl ice cold 100% ethanol was 
added.  This was incubated at -20ºC for 2 hours to allow the DNA to precipitate.  The samples 
were then centrifuged at maximum speed for 30 minutes at 4ºC, and the ethanol was aspirated.  
An additional 1ml of 70% cold ethanol was added and the samples were centrifuged at maximum 
speed for 30 minutes at 4ºC.  The ethanol was aspirated and the pellets were resuspended in 
480µl TE buffer pH8 and incubated at 37ºC for 30 minutes.  Next, 20µl sonicated salmon sperm 
DNA (10mg/ml) was added and the samples were incubated for an additional 30 minutes at 
37ºC.   
 
2.10.4 BrdU Immunoprecipitation 
Samples were each sonicated for 45 seconds at 30 Hz. 
Sonicated samples were heated to 95ºC for 5 minutes, transferred to ice for 2 minutes, and spun 
down.  Next, 50µl adjuster buffer and 80µl anti-BrdU (Becton Dickinson, Oxford, UK) were 
added, and the samples incubated for 20 minutes on a rotating platform.  Then 35µg anti-mouse 
IgG (Sigma-Aldrich, Dorset, UK) was added, samples incubated for 20 minutes on a rotating 
platform, and spun at maximum speed for 20 minutes at 4ºC.  The supernatant was aspirated, the 
pellets washed with 1ml wash buffer, and centrifuged for an additional 20 minutes at 4ºC.  The 
wash buffer was aspirated, the BrdU labelled DNA pellet resuspended in 300µl lysis buffer, and 
incubated for 2 hours at 50ºC.   
 
2.10.5 DNA purification  
This step was completed using components of the Qiagen Gel Extraction Kit (Qiagen, Crawley, 
UK).  First, 900µl Buffer was added to the samples and mixed.  The solutions were transferred to 
mix columns and spun at maximum speed for 1 minute.  The columns were then washed with 
750µl Buffer PE, spun for 1 minute, the collection tubes emptied, and the columns spun again for 
1 minute 30 seconds.  To elute the DNA, TE buffer pH8 was used at 1µl per 150-200 cells in the 
original sorting fraction.  Half the volume of TE was placed on the spin column, incubated for 1 
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minute, spun at maximum speed for 1 minute, and repeated.  The DNA was then stored at 4ºC 
until SybrGreen analysis.  
 
2.11 Real-time quantitative PCR 
Quantitative SyberGreen PCR was conducted as described by the manufacturer’s protocol 
(Sigma-Aldrich, Dorset, UK).  Briefly, a master mix was made consisting of 15µl SyberGreen 
(Sigma-Aldrich, Dorset, UK) and 11.2µl H2O for each replicate.  For each gene, 0.9µl forward 
primer and 0.9µl reverse primer was added.  Finally, 2µl cDNA of the appropriate sample was 
added.  Analysis was conducted using an Opticon II plate reader and its accompanying software.   
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Chapter 3 Characterization of adherent CD34+ cells 
 
Chapter summary 
In this chapter it is demonstrated that adherent CD34+ cells are transcriptionally distinct from 
their non-adherent CD34+ cell counterparts.  Analysis of genes associated with stem cell 
function support previous data that adherent CD34+ cells are more primitive than non-adherent 
CD34+ cells.  DNA replication timing analysis various stem cells revealed that adherent CD34+ 
cells replicate genes associated with pluripotency in a similar pattern to ES cell controls, further 
validating their primitive state.  The following results are revealed and discussed in this chapter: 
• cDNA microarray analysis of transcriptional expression 
• Transcriptional analysis of stem cell associated genes 
• Transcriptional analysis of cell surface receptors 
• DNA replication timing of stem cells 
  
 
3.1 Transcriptional profiling 
The detection of various stem cell populations in adult humans has lead to studies which have 
attempted to define and subsequently to isolate putative stem cell populations in vitro.  In the 
haematopoietic system, there has been a search for markers which are selectively expressed by 
primitive haematopoietic stem/progenitor cells.  They include markers of efficient efflux 
pumping of Rhodamine 123 or Hoescht dyes, isolation by immune antigens such as CD34 and 
CD133, and cell sorting of the side-population of haematopoietic stem cells.  There have been 
efforts to understand molecular mechanisms and genetic regulation of the stem cell state by 
analyzing transcriptional profiles of stem cell populations using cDNA microarrays.   
 
Expression profiling provides information about the genes that are expressed by a particular cell 
type and their relative abundance.  Transcriptional and genetic profiling of stem cell populations 
has not yet unequivocally identified a common signature of ‘stemness’ outside the context of 
embryonic stem cells, and a definition of the molecular nature of pluripotency in adult derived 
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stem cells remains ambiguous.  Transcriptional information was scanned for those documented 
to be involved in stem cell function, including genes involved in quiescence and cell cycle, 
transendothelial migration, and adhesion to bone marrow which are likely to be relevant to 
clinical stem cell application.   
 
Microarrays are typically used to screen for large numbers of genes expressed in a tissue of 
interest.  Here the Affymetrix U133 plus 2 whole human genome array was used to compare the 
entire genome of adherent CD34+ cells and non-adherent CD34+ cells.  To use the Affymetrix 
U133 plus 2 array platform, RNA was first isolated from the target tissue, processed and 
amplified, then added to the chip surface for hybridization.  The chip consists of thousands of 
probes, each of which is a distinct DNA sequence.  The basic principle is that of selective 
binding of nucleic acid molecules to complementary sequences.  When the tissue-derived pool 
of RNA is added to the surface of the chip, a highly sensitive search and sorting of molecular 
partners, probes with their complementary targets, is performed.  Each single location on the 
array is made up of large numbers of probes (about 10 million), thus enabling quantification of 
expression.  The larger the number of copies of a particular nucleic acid sequence in a sample, 
the more the binding to the particular matching probes on the chip.  Fluorescence-based 
detection schemes use lasers to excite fluorescently labeled RNA molecules in order to quantify 
bound RNA transcripts. 
 
3.1.1 DNA replication timing  
DNA replication timing can be used to indicate whether particular cell types are more or less 
likely to differentiate into one or another lineage.  The replication timing of genes depends on 
chromatin state and correlates with histone acetylation, and early replication of a gene does not 
necessarily reflect gene transcription49.  Early replication of genes during S phase of the cell 
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cycle is considered to be a feature of transcriptionally active regions of the genome, indicating 
chromatin accessibility, whereas late replication is characteristic of inactive gene regions and 
constitutive heterochromatin46.  During development, pluripotent stem cells give rise to lineage-
restricted progenitors from which more tissue restricted cells are derived50.  Thus, in pluripotent 
ES cells, there is replication of lineage-associated genes early in the S phase, suggesting 
multilineage potential and pluripotency46,50.   
 
Based on previously observed differences in function26, including adhesion and proliferation, it 
is reasonable to hypothesize that adherent CD34+ cells are genetically distinct from their non-
adherent CD34+ cell counterparts.  The aims of this study were to identify genes which are more 
or less highly expressed by adherent CD34+ cells relative to non-adherent CD34+ cells, and to 
identify genes which may play a role in stem cell function within this gene subset.  DNA 
replication timing was also conducted to determine if the chromatin state of adherent CD34+ 
cells and non-adherent CD34+ cells allows the active transcription of pluripotent stem cell-
associated genes.   
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3.2 Results 
3.2.1 cDNA Microarray analysis of gene expression  
3.2.1.1 Quality control  
Total RNA was extracted from adherent CD34+ cells and corresponding non-adherent CD34+ 
cells from three blood samples.  Total RNA was subjected to cDNA synthesis, amplification, 
double strand cDNA clean up, and cRNA synthesis and clean-up.  A number of quality control 
measures were performed throughout the procedure in order to assess the quality of the total 
RNA, cDNA, and cRNA samples prior to hybridization onto chip arrays.  The strict quality 
control measures were required by the MRC Microarray Centre.  These requirements comprised 
(i) the ratio of the absorbance at 260nm and 280nm (A260/A280) to be within a range of 1.9 and 
2.1; (ii) a cRNA yield after first round amplification from 100ng total RNA between 1-2µg; (iii) 
bioanalyser traces of total RNA, first round cRNA and second round cRNA with no ribosomal 
bands.     
 
Quality control entailed analysing total RNA using the Agilent 2100 Bioanalyser (Agilent 
Technologies).  The Bioanalyser is a microfluidics-based platform which uses electrophoretic 
separation to create an electropheretogram of nucleic acid samples.  250ng total RNA was 
loaded onto a Nano Assay LabChip (Agilent Technologies) to create electropheretograms of 
total RNA from the samples.  The process was repeated after both the first round of 
amplification and the second round of amplification to create a gel electropheretogram of cRNA 
products.  Poly A+ controls were used to monitor genomic stability during the processing of 
samples.  All quality control measures were assessed by staff at the MRC Microarray Centre 
before proceeding to the next stage.  Figure 4 shows Bioanalyser traces which verify the good 
quality total RNA extraction and successful cRNA synthesis and yield.   
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Figure 4.  RNA quality control.  To ensure the highest quality of the total RNA isolated from donor 
CD34+ cells, total RNA analyzed with the Bioanalyser 2100 (Agilent) for contamination, degradation, and 
proper 260/280 ratio.  Samples were analyzed to ensure no contamination from PCR product.  The cDNA 
products after the first and second rounds of amplification were examined for quality and quantity.  These 
traces show no degradation of total RNA (A), proper amplification and quality after the first round 
amplification (B), and adequate amplification and quality after the second round amplification (C).   
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3.2.1.2  Adherent CD34+ cells are genetically distinct from non-adherent CD34+ cells 
To determine differences in gene expression between adherent CD34+ cells and non-adherent 
CD34+ cells, CD34+ cells were isolated from the mobilized peripheral blood of samples.  Gene 
trend analysis was done using Rosetta Resolver.  Transcripts that were differentially expressed 
by ≥2 fold by adherent CD34+ population relative to non-adherent CD34+ cells, and were 
within a 95% confidence level by Student’s t-test were defined as significantly differentially 
expressed.  The upregulation of some genes and downregulation of others is important because 
of positive and negative influences on cell function.  Figure 5a shows a graphic representation of 
resulting gene expression profiles for each sample.  Each spot represents the relative expression 
of each gene of both adherent CD34+ and non-adherent CD34+ expression.  Adherent CD34+ 
cell expression is on the x-axis, and non-adherent CD34+ cell expression is on the y-axis.  Each 
spot represents one of 47,000 gene probes on the array.  Blue spots represent those genes not 
expressed by either CD34+ population.  Red spots are genes more highly expressed by adherent 
CD34+ cells by ≥2 fold relative to non-adherent CD34+ cells.  Green spots are genes expressed 
by non-adherent CD34+ cells by ≥2 fold relative to adherent CD34+ cells.  Yellow spots are 
those not statistically significantly more highly expressed by one population or the other.  
Filtering by Rosetta Resolver revealed that 562 genes were consistently more highly upregulated 
in adherent CD34+s, and 338 genes were more highly upregulated in non-adherent CD34+ cells 
(Figure 5b and c).  Consequently, genes which were upregulated by non-adherent CD34+ cells 
were downregulated by the adherent CD34+ cells.   The adherent CD34+ cells and non-adherent 
CD34+ cells expressed equivalent levels of 10,669 genes.  The complete gene expression data 
are available at the MRC Microarray Centre, Imperial College London 
(http://mimironline.csc.mrc.ac.uk/  experiment EXP_CFMG_1006_01).  The final results were 
validated and re-analysed using the R software by the MRC Bioinformatics support center.  The 
re-analysis of results by professionals with different software strengthens the validity of the data.  
Only consistent results amongst the three samples were used.   
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3.2.1.3 Intensity subsets of genes 
Following analysis of gene expression using Rosetta Resolver software, the resulting molecular 
profiles (562 genes preferentially expressed by adherent CD34+ cells, and 338 genes 
preferentially expressed by non-adherent CD34+ cells) were divided into functional categories 
as defined by the Gene Ontology database (www.geneontology.org).  It was presumed that 
adherent CD34+ cells are a primitive stem cell population, and subsequent analysis focused 
primarily on genes which are involved in quiescence, cell cycle, homing and adhesion which are 
likely to be relevant to adherent CD34+ cells’ suitability for clinical application.   
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Figure 5.  Differential gene expression by adherent CD34+ cells and non-adherent CD34+ cells.  
A representation of the relative gene expression by adherent CD34+ and non-adherent CD34+ cells 
as analysed with Rosetta Resolver (A).  Transcripts were filtered from 47,000 possible expressed 
genes by identifying those which were expressed by ≥2 fold by one population relative to the other 
and were within a 95% confidence level by Student’s t-test.  Adherent CD34+ cells more highly 
expressed 562 genes by ≥2 fold relative to non-adherent CD34+ genes (B).  The Venn diagram (C) 
depicts the number of genes differentially expressed in adherent and non-adherent CD34+ cells.  
There were 562 genes significantly upregulated in plastic adherent CD34+ cells which were not 
highly expressed by non-adherent CD34+ cells.  There were 338 genes significantly upregulated in 
the non-adherent fraction of CD34+ cells that were not highly expressed in the plastic adherent 
fraction.  The number of genes expressed by both populations was 10,669.   
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3.2.1.4 Stem cell  genes 
Genetic and transcriptional profiling of stem cells has revealed genes which are characteristic of 
stem cells.  Although there are no discrete stem cell genes, some genes are associated with 
pluripotent stem cells, specifically POU5F1 (Oct4),  NANOG, ZFP42 (Rex1), SOX2, SSEA1, 
SSEA3, and SSEA480-82.  The microarray data was examined for expression of these pluripotent 
stem cell-associated genes, and the expression of POU5F1,  NANOG, ZFP42, SOX2, SSEA1, 
SSEA3, and SSEA480-82 were not high enough in either adherent CD34+ cells or non-adherent 
CD34+ cells to be detected by the microarray.   
 
To determine if adherent CD34+ cells and non-adherent CD34+ cells express low levels of 
SOX2, NANOG, ZFP42 (Rex1) and POU5F1 (Oct4), Syber green real-time PCR was conducted 
and relative expression in between the populations was compared (Figure 6).  Adherent CD34+ 
cells expressed relatively higher levels of SOX2, NANOG, and POU5F1 than non-adherent 
CD34+ cells, but non-adherent CD34+ cells expressed slightly higher levels of ZFP42 than 
adherent CD34+ cells.  This was an average of only two experiments and is not very convincing.  
Although the trend seems to indicate that adherent CD34+ cells may express slightly higher 
levels of the genes in question, there are not enough replicates to indicate significance.  These 
real-time PCR results indicate that adherent CD34+ cells express some of the genes closely 
associated with pluripotent stem cells.   
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Figure 6.  Real-time qPCR for pluripotency associated genes in adherent CD34+ cells and non-
adherent CD34+ cells.   Relative expression of SOX2, NANOG, ZFP42 (commonly known as Rex1), and 
POU5F1 (commonly known as Oct4) was compared between adherent CD34+ and non-adherent CD34+ 
cells were measured with Syber green real-time PCR.  Levels of expression were normalized to levels of 
housekeeping genes GAPDH and HPRT.   
 
 
 
To confirm the expression of stem cell associated genes on the protein level,  
immunofluorescence microscopy for stem cell associated antigens Sox2, SSEA3, SSEA4, 
Cripto1, and Oct4 was conducted (Figure 7).  The results revealed that 63% ± 8% of adherent 
CD34+ cells expressed Oct4 protein, relative to 0% ± 3% of non-adherent CD34+ cells.  
Developmental stem cell marker Sox2 was expressed in 67% ± 12% of adherent CD34+ cells 
versus 31% ± 7% of non-adherent CD34+ cells.  SSEA3 was expressed on 62% ± 11% of 
adherent CD34+ cells, but only on 8% ± 4% of non-adherent CD34+ cells.  SSEA4 was not 
discriminatory between the two populations as it was expressed by 88% ± 13% of adherent 
CD34+ cells and by 83% ± 9% of non-adherent CD34+ cells.  Cripto1, a transcription factor 
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associated with embryonic stem cells also did not discriminate between adherent and non-
adherent CD34+ cells, and was expressed by 34% ± 6% of adherent CD34+ cells (Cripto1dim) 
and 31% ± 9% of non-adherent CD34+ cells (Cripto1dim).  The final panel of candidate markers 
specific for adherent CD34+ cells are comprised of Oct4, Sox2, SSEA3, and BMPR2 (Figure 
7b).  The analysis of each marker was conducted on at least three biological samples, but 
markers were not necessarily immunostained in parallel in all instances.  These 
immunofluorescence results did not agree with the previously conducted real-time qPCR results 
which indicated that both adherent CD34+ cells nor non-adherent CD34+ cells express relatively 
low amounts of SOX2 and ZFP42.  The real-time qPCR results also indicate that non-adherent 
CD34+ cells express POU5F1, but relatively much less than adherent CD34+ cells.  This 
suggests that non-adherent CD34+ cells might transcribe POU5F1, but that it is not translated to 
the Oct4 protein.   
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Figure 7.  Protein expression of stem cell associated markers by adherent CD34+ cells.  To further 
validate the stem cell qualifications of adherent CD34+ cells, immunofluorescent microscopy and 
FACS analysis were used to detect if a panel of markers known to be associated with stem cells is 
expressed by adherent CD34
+
 cells.  We immunostained for Oct4, Sox2, SSEA3, SSEA4, Cripto1 
and BMPR2 and found that adherent CD34+ cells more highly express Oct4, Sox2, SSEA3, and 
BMPR2 relative to non-adherent CD34+ cells.  The frequency of protein expression was analysed 
with microscopy (A) and validated with FACS (B).  Antibodies were IgG monoclonal antibodies, and 
the FACS histogram represents the IgG control for all antibodies used for FACS in panel B.  Positive 
antibody controls for Oct4, Sox2, and Cripto1 were human embryonic stem cells provided by Dr. Wei 
Cui, and positive antibody controls for SSEA3 and SSEA4 were foetal mesenchymal stem cells 
provided by Dr. Nick Fisk.  
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3.2.1.5 Cell Cycle Regulation 
Compared to non-adherent CD34+ cells, plastic adherent CD34+ cells expressed significantly 
higher levels of 6 genes involved in the negative regulation of progression through the cell 
cycle, MTSS1, GAS7, CDKN1C (p57), GAS2L1, PHB, and FOXN3 (also known as CHES1).   
The absence or downregulation of metastasis suppressor 1 (MTSS1 or MIM) is associated with 
bladder and hepatocellular carcinomas83,84.  GAS7 is predominantly expressed in the brain and 
its expression is associated with differentiating, non-proliferating cells85.  CDKN1C, commonly 
known as p57, is correlated with cell cycle arrest in side-population haematopoietic stem cells86.  
FOXN3 encodes for checkpoint suppressor 1 which induces cell cycle arrest at G1 and G287.  
PHB (prohibitin) regulates E2F1 function and binds to Rb family members88. 
 
The GO mapping analysis of cell cycle regulatory mechanisms revealed 23 genes that are more 
highly expressed by non-adherent CD34+ cells and less by adherent CD34+ cells which are 
involved in the regulation of the cell cycle.  These genes are TOP3A, ANAPC5, PAPD5, EML4, 
NUSAP1, RAD54L, CIT, TPX2, CDC25A, CDC25C, CCNA1 (cyclin A1), NEK4, APBB2, 
GTSE1, CHAF1B, MCM2, UHRF1, NERCC1, CCNE1 (CyclinE1), SQSTM1 (p60), E2f1, 
KIF15, and MYC.  Cyclin A1, which is encoded by CCNA1, binds to cell cycle regulators Rb 
family proteins and p21 family proteins89.  MYC is a transcription factor linked to cell cycle 
regulation, proliferation, and cell fate decision90.   
 
Conversely, these proliferation-promoting genes are downregulated in the adherent CD34+ cells, 
indicating a potential difference in cell proliferation kinetics between adherent CD34+ and non-
adherent CD34+ cells.   
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In addition to cell cycle promoting genes, non-adherent CD34+ cells overexpressed 6 genes 
involved in DNA replication.  These were PRIM1, RRM2, CHAF1B, MCM2, POLG, and POLE.  
In addition, non-adherent CD34+ cells differentially expressed CD135 (fms-related tyrosine 
kinase 3) which, when co-expressed with CD34, may represent early cycling, but not quiescent 
stem cells.  CD135 was not significantly upregulated by plastic adherent CD34+ cells, further 
suggesting that plastic adherent CD34+ cells may be quiescent stem cells.  This observation 
supports the hypothesis that plastic adherent CD34+ cells may be suspended in G0, while non-
adherent CD34+ cells are mitotically active.   
 
To verify the microarray analysis, a selection of cell cycle genes was chosen and their relative 
expression was compared using SybrGreen real-time PCR.  Real-time PCR was conducted with 
cDNA synthesised from the same total RNA isolated for microarray experiments above.  The 
data below show the average results from three samples (Figure 8).  The cell cycle data 
produced by the microarray imply that adherent CD34+ cells may be slowly cycling or arrested 
in G0, whilst the non-adherent CD34+ fraction may be actively cycling.  Real-time qPCR of 9 
cell cycle-regulating genes, identified by microarray, was conducted.  GAS2L1, PHB, CHES1, 
and p57 are involved in the negative regulation of the cell cycle, while MYC, CDC25a, CDC25c, 
MCM2, and CCNA1 (CyclinA1) promote cell cycle progression (Figure 3).  The genes involved 
in the negative regulation of the cell cycle, GAS2L1, PHB, CHES1, and p57, were more highly 
expressed by ≥2 fold by the adherent CD34+ cells relative to the non-adherent CD34+ cells.  
The genes involved in cell cycle progression MYC, CDC25a, CDC25c, MCM2, and CCNA1 
(CyclinA1) were more highly expressed by the non-adherent CD34+ cells by ≥2 fold.   
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3.2.1.6 Adherent CD34+ cells lack Ki-67 
In addition to molecular screening and characterization, Ki-67 expression was investigated at the 
protein level.  Subpopulations of CD34+ HSCs have been demonstrated to lack Ki-67 
expression, indicating that they are suspended in Go91.  The Ki-67 protein is present during the 
G1, S, G2, and M phases of the cell cycle and is not expressed during G0 phase92.  Thus, cells 
negative for Ki-67 are assumed to be arrested in G0.  Only 24% of plastic adherent CD34+ cells 
were Ki-67+, while 61% of non-adherent CD34+ cells were Ki-67+ (Figure 9).  Positive 
expression of Ki-67 confirms on the protein level that most that non-adherent CD34+ cells were 
mitotically active.  The absence of Ki-67 protein in plastic adherent CD34+ cells indicates that 
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Figure 8. Real-time qPCR relative expression of cell cycle regulation genes.  SybrGreen real-time 
PCR was conducted on a subset of genes identified by the Affymetrix U133 plus 2 gene array to 
validate gene expression in both adherent CD34+ cells and non-adherent CD34+ cells.   
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most plastic adherent CD34+ cells were arrested in G0.  This experiment validated gene 
expression data which indicated that the non-adherent CD34+ cells over express genes involved 
with the initiation of the cell cycle.    
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Figure 9. Quiescent adherent CD34+ cells do not express Ki67 protein.  Immunofluorescent staining 
shows that only 24% of plastic adherent CD34+ cells are Ki-67+, while 61% of non-adherent CD34+ cells 
express Ki-67.  This may be an indication that plastic adherent CD34+ cells are in a quiescent state.  
K562 cell line was used as a positive staining control for Ki-67, as cell lines are expected to express Ki-
67.  Ki-67 expression was quantified with immunofluorescent microscopy by counting 300 cells across 5 
fields of view for each condition. Results are representative of three replicate experiments.   
 
3.2.1.7 Cell adhesion  
 Adherent CD34+ cells highly expressed 22 genes implicated in cell adhesion to the bone 
marrow microenvironment.  These are CTNND1, CCR1, CCL2, FN1, ADAMDEC1, CSPG2, 
DSC3, SLAMF7, CD61, BMPR2, PCDH9, CD62, ITGA7, TAOK2, ITFG2, THBS1, CD41, GP5, 
PGM5, CTNNA1 and Tie2.  Tie2 is an important adhesion molecule since it is involved in 
retaining CD34+ cells in the stem cell niche in the bone marrow and is implicated in the 
Plastic adherent 
CD34+ 
Non adherent 
CD34+  
Positive control 
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maintenance of stem cell quiescence93,94.  Non-adherent CD34+ cells do not significantly express 
these adhesion molecules, according to the microarray results. 
3.2.1.8 Transendothelial migration 
Tropism to sites of injury is a desirable property of stem cells.  The homing and migration 
potential of these cells at the genetic level was examined.  22 genes related to leukocyte 
transendothelial migration were examined, of which 16 were more highly expressed by adherent 
CD34+ cells.  These genes were CTNND1, CXCL4, PIK3CB, PIK3R5, CXCL7, PRKCB1, MSN, 
NCF2, CYBB, CCR1, ACTN4, CXCL16, MMP9, MAPK13, CTNNA1, and CCRL2.  The 
chemokines CXCL4 and CXCL7 promote immune cell adhesion and transendothelial migration 
95
.  Only 6 genes related to leukocyte transendothelial migration were more highly expressed by 
non-adherent CD34+ cells.  These were RASSF5, ITGAL, CXCL13, PTK2B, PIK3R2, and PXN.  
 
3.2.1.9 Chemokine activity 
GO term analysis revealed that adherent CD34+ cells highly expressed genes which encode for 
chemokines CXCL4, CCL2, CXCL16, CXCL5, CCL3, CCL8, CXCL7, CCL3L1, IL8, and 
CXCL3.  Non-adherent CD34+ cells did not preferentially express genes which encode for 
chemokines.  Chemokines are essential for recruitment of immune cells to aid tissue repair and 
regeneration.  These data suggest that adherent CD34+ cells may be attracted towards sites of 
injury by the synthesis and release of chemokines.  
 
3.2.1.10 Apoptosis 
Plastic adherent CD34+ cells more highly expressed 23 genes associated with the regulation of 
apoptosis.  These genes were IFG1R, CASP10, CCL2, SERPINB2, DIDO1, DNAJA3, IER3, 
SERPINB9, BIRC4, STK17A, ALK7, DAPK1, CTSB, SLAMF7, HIPK2, CARD9, MAPK1, PHB, 
HSPA1A, MTCH1, DPF2, PRKCE, and CASP2. The non-adherent CD34+ cells highly 
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expressed 8 genes which regulate apoptosis, but did not share the same genes as the adherent 
CD34+ cells.  These genes were FOXO3A, NF346, FAS, MPO, RNASE3, DOCK1, CD38,and 
NALP1. In either population, it remains unclear if expression of these genes induce self-
apoptosis, or induce the cell to cause apoptosis of neighboring cells.     
 
3.2.2 Cell surface receptors 
An interest of the group is to identify surface markers expressed on plastic adherent CD34+ 
cells.  Identifying such ligands or receptors is desirable as they may provide alternative methods 
for identifying and isolating plastic adherent CD34+ cells.  Accordingly, the microarray results 
were examined for cell surface markers which were more highly expressed in plastic adherent 
CD34+ cells relative to non-adherent CD34+ cells. Arrays revealed that CCR1, BMPR2, IL1R, 
and CCRL2 were differentially upregulated in plastic adherent CD34+ cells.  To validate this, 
immunofluorescence microscopy was used to determine the presence of these antigens at the 
protein level.  Only BMPRII was expressed at statistically different levels between the two cell 
populations.  BMPs belong to the TGFβ superfamily of growth factors.  BMPs bind to two kinds 
of serine/threonine kinase receptors, type 1 and type 2.  Activation of BMP receptors stimulates 
MAP kinase and Smad dependent pathways96.  BMPR-II forms a complex with c-Kit which 
regulates differentiation of haemopoietic cells.  Downstream activation of the Smad-dependent 
signalling results from BMPR-II activation.  Smad activation requires stimulation of BMPR-II, 
but Smad signalling is increased when both c-Kit and BMPR-II are activated96.   
 
In comparing BMPR2 expression between plastic adherent and non-adherent CD34+ cells, a 
significantly greater percentage of plastic adherent CD34+ cells was found to express BMPR2 
relative to non-adherent CD34+ cells (p=0.0006).  Quantifying immunofluorescence images for 
BMPR2 expression, 79.7±2.6% of plastic adherent CD34+ expressed BMPR2+, 12.6±2.2% of 
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non-adherent CD34+ cells expressed BMPR2+, 10.4±3.43% of CD34- cells expressed 
BMPR2+, and 2.8±0.63% of total CD34+ cells expressed BMPR2+ (Figure 10).  The relative 
expression of BMPR2 in different fractions of the mononuclear fraction of mobilized peripheral 
blood help illustrate that BMPR2 could potentially be used as a specific marker for plastic 
adherent CD34+ cells. 
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Figure 10.  BMPRII protein expression by various fractions within PBMCs. To find cell surface markers 
which would help identify plastic adherent CD34+ cells, BMPRII was immunocytochemically analyzed to 
validate its protein expression.  In viewing these results, it is important to acknowledge that the total 
proportion of plastic adherent CD34+ cells is only 0.2% of the mononuclear cells in peripheral blood. 
Analysis of different fractions of mobilized peripheral blood for BMPR2 indicated that only a small 
percentage (1.3%) of total mononuclear cells expressed BMPR2, indicating that this receptor may be an 
appropriate marker for plastic adherent CD34+ cells.  Results are representative of four replicates.  P-
values refer to significant differences from adherent CD34+ cells and were determined using the 
Student’s t-test.   
 
p=0.0006 p=0.0002 p=0.0005 
p=0.0006 
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To validate the immunofluorescence quantification data, FACS analysis of adherent CD34+ 
cells versus non-adherent CD34+ cells for relative BMPRII expression was conducted (Figure 
11). It was observed that 87% of plastic adherent CD34+ cells are BMPR2+, while 41% of non-
adherent CD34+ cells are BMPR2+, supporting the previous observation although the difference 
was less clear cut.  By flow cytometry, the mean fluorescence intensity was ~50 fold greater 
than that in the non-adherent CD34+ fraction.  The disparity in BMPR2 expression between the 
immunofluorescence data and the FACS analysis may be due to the different sensitivities of the 
methodologies, or may represent variations between donor samples.  Both results demonstrate 
that plastic adherent CD34+ cells more highly express BMPR2 than the non-adherent CD34+ 
cells, making BMPR2 a possible candidate marker for plastic adherent CD34+ cells.   
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Figure 11.  FACS analysis of BMPRII expression in adherent CD34+ cells versus non-adherent CD34+ 
cells.  The CD34+ cells found in mobilized peripheral blood are small and lymphocyte-like in morphology 
(A).  FACS analysis of relative BMPR2 expression in plastic adherent CD34+ cells versus non-adherent 
CD34+ cells show that 87.88% of plastic adherent CD34+ cells express BMPR2 (C), while 41.29% of 
non-adherent CD34+ cells express BMPR2 (D).  Panel B represents the IgG control used to set the gate.  
This data is also represented in the histogram (E) which shows a clear shift in the peak fluorescence 
between the adherent and non-adherent CD34+ cells.  FACS was conducted by Dr. Stephen Marley 
A B 
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3.2.3 Chromatin state of bone marrow derived cells  
Early replication of genes during S phase of the cell cycle is considered to be a feature of 
transcriptionally active regions of the genome, indicating chromatin accessibility, whereas late 
replication is characteristic of inactive gene regions and constitutive heterochromatin46. 
 
Total CD34+ cells, adherent CD34+ cells, and non-adherent CD34+ cells were examined to 
determine if these cells have epigenetic features which associate them with pluripotent 
embryonic stem (ES) cells, or with more restricted neural stem cells (NSC).  The timing of DNA 
replication was assessed by pulse-labeling cell populations with BrdU, and fractionating them 
according to cell cycle stage (Figure 12a).  The relative abundance of chosen sequences within 
newly synthesized DNA are then determined using real-time qPCR (Figure 12b).  Early 
replication during G1/S1 phase is considered to be associated with transcriptionally active 
regions of the genome, and indicative of accessible chromatin.  Late replication is associated 
with constitutively expressed genes and genes that are actively supressed46.   Replication timing 
is represented as a color code with green representing early replication and red as late replication 
(Figure 12c).   
3.2.3.1 Bone marrow derived cells and NSC replicate Oct4 and Nanog early 
Figure 13 represents the replication profiles for total CD34+ cells, adherent CD34+ cells, non-
adherent CD34+ cells, and ES cells.  The CD34+ cells have similar replication timing profiles of 
genes associated with pluripotency.  Appropriate controls of early replication (α-globin) and late 
replication (β-amylase) were used during analysis of all cell populations.  The α-globin gene is 
replicated early in the cell cycle.   
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Genes associated with ES cells POU5F1 (Oct4) and Nanog replicated early in G1/S1 in total 
CD34+ cells, adherent CD34+ cells, non-adherent CD34+ cells, and ES cells.  ZFP4 (Rex1) did 
not replicate until middle-late/late part of the cell cycle.  This indicates that these cells have a 
propensity for expressing the POU5F1 and Nanog genes, but not ZFP4 (Figure 13 and Figure 
14).   
 
Replication timing data is supported by previously conducted real-time qPCR for relative 
expression of SOX2, NANOG, ZFP42, and POU5F1 by adherent CD34+ cells and non- adherent 
CD34+ cells (Figure 6).  The gene expression data validates the positive expression of these 
genes in adherent CD34+ cells, but none of the genes tested were expressed early by adherent 
CD34+ cells compared to non-adherent CD34+ cells.    
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Figure 12.  Explaination of DNA replication timing.  Stem cells in question were pulse-labelled with 
BrdU, stained with PI, and separated by cell sorting into six fractions corresponding to cell cycle stages 
(G1, S1, S2, S3, G2/M) (A).  The abundance of locus-specific DNA was compared between cell cycle 
fractions using real-time PCR analysis of anti-BrdU purified templates.  Constitutively early replicating (α-
globin) and late replicating (β-amylase) loci were used as controls (B).  The replication timing of each 
gene was defined according to its peak abundance in G1/S1 (early), S2 (mid-early), S2 and S3 (middle), 
S3 (mid-late), and S4/G2 (late) phases and represented as a colour code (C).   
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Figure 13.  Replication timing ofOct4, Nanog, and Rex1 by bone marrow derived stem cells.  Adherent 
CD34+ cells, non-adherent CD34+ cells, and fhMSCs were labelled with BrdU, stained with PI and 
separated into six fractions corresponding to cell cycle stages.  The abundance of Oct4, Nanog, and 
Rex1 DNA was compared between cell cycle fractions.  The replication timing of each gene was defined 
according to its peak abundance.  Oct4 and Nanog were replicated early in G1 by adherent CD34+ cells, 
non-adherent CD34+ cells and fhMSCs indicating that the chromatin states of these genes allow their 
transcriptional accessibility in these cells.  The relative abundance of Rex1 was highest late in the cell 
cycle in all three cells, at S4 in adherent CD34+ cells, and at S3 in non-adherent CD34+ cells and 
fhMSCs indicating this gene in not likely to be transcribed.  
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Figure 14.  Summary of DNA replication timing results.  DNA replication timing is summarized as a 
colour code.  The figure summarizes the findings which indicate that ES cells and CD34+ cells replicate 
genes associated with pluripotent ES cells, POU5F1 and NANOG, early in the cell cycle, but not ZFP4 
(Rex1).  The subpopulations of CD34+ cells replicate haematopoietic genes EBF and IKAROS early in 
G0/G1 or G2, but ES cells replicate these genes late at S3.  Analysis of the DNA replication timing of 
haematopoietic genes by CD34+ cells provides a control for the assay.   
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3.3 Discussion 
 Adherent CD34+ cells are a transcriptionally distinct subpopulation of CD34+ G-CSF 
mobilized peripheral blood.  This was supported in this study by the identification of subsets of 
562 transcripts which are more highly expressed, and 338 transcripts which are less highly 
expressed by adherent CD34+ cells relative to non-adherent CD34+ cells.  Within these subsets 
of genes are genes which are involved in stem cell functions including quiescence, migration, 
and adhesion to bone marrow.   
 
3.3.1 Adherent CD34+ cells express pluripotency associated markers  
Molecular analysis of stem cell and pluripotent cell associated markers has lead to protein 
analysis and identification of an adherent CD34+ cell phenotype.  Although it was assumed that 
adherent CD34+ cells were more primitive than non-adherent CD34+ cells97,98, PCR and 
immunofluorescence microscopy revealed that adherent CD34+ cells express developmental 
markers Oct4 (encoded by POU5F1), Sox2, and Nanog.  Oct4, Sox2 and Nanog are currently 
considered to be core regulators in pluripotent stem cells99,100.  In studies of embryonic stem 
cells, the quantitative expression of Oct4 maintains pluripotency, and its down-regulation in 
pluripotent embryonic stem cells leads to trophectoderm differentiation 82,101.   Nanog promotes 
pluripotent cell self-renewal100.  Although Sox2 is not exclusive to embryonic stem cells, it is 
necessary in the maintenance of pluripotency100.    
 
DNA replication timing introduces another method for determining potential cell plasticity by 
examining an epigenetic control mechanism of transcription.  The replication timings of the 
genes which encode for Oct4, Nanog, and Rex1 were examined in adherent CD34+ cells, non-
adherent CD34+ cells, and fhMSCs.  Oct4 was replicated early by all three stem cell types and 
this result supports the results of real-time qPCR (Figure 6).  The immunofluorescence data 
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indicated that Oct4 is expressed by the majority of adherent CD34+ cells, but not by non-
adherent CD34+ cells.  This discrepancy in results suggest that perhaps although Oct4 was 
replicated early in all populations tested, the message was only translated into protein by the 
adherent CD34+ cells.   
 
Primitive cells thought to be precursors of germ cells, including oocytes and spermatogonial 
cells, have been identified in the bone marrow17,18.  One interpretation of the multiplicity of stem 
cell types in the marrow is that bone marrow is a general repository for stem cells that can be 
mobilized for various purposes during adulthood25.  The high frequency of Oct4+, Sox2+, and 
Nanog+ cells in the adherent CD34+ cell fraction suggests that these cells may be the result of 
“developmental migration25” and residual cells from development.  Stem cell genes which 
include NOTCH1, WNT1, CXCR4, GATA2, and members of the HoxA and HoxB families were 
equally highly expressed in adherent and non-adherent CD34+ cells.  These genes are associated 
with proliferation, differentiation regulation, and migration of embryonic,  neural, mesenchymal, 
and haematopoietic stem cells102-109.  Our data indicate that there is no difference in transcription 
expression between adherent CD34+ cells and non-adherent CD34+ cells in the expression of 
transcripts which encode for stem/progenitor proliferation.   
   
3.3.2 Cell cycle control 
Our genetic analysis of the genes involved in cell cycle control revealed that adherent CD34+ 
cells more highly expressed genes involved in the negative regulation of the cell cycle, while 
non-adherent CD34+ cells more highly expressed genes which promote progression through the 
cell cycle (Figure 15).  Non-adherent CD34+ cells highly express genes which encode for cyclin 
a1 and cyclin e1.  Conversely, adherent CD34+ cells expressed significantly lower levels of 
these genes.  At the same time, adherent CD34+ cells express high levels of p57, whose 
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expression results in the inhibition of cyclin e1 and cyclin a1, leading to a decrease in DNA 
synthesis and cell proliferation110.  This finding was validated by the Ki-67 immunofluorescence 
data which indicated that adherent CD34+ cells are arrested in G0, while non-adherent CD34+ 
cells are actively cycling.   
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Figure 15.  Cell cycle-associated genes are differentially expressed by adherent CD34+ cells and non-
adherent CD34+ cells.  Genes whose expression is higher in adherent CD34+ cells and genes involved 
in the negative regulation of the cell cycle are in red.  Those more highly expressed by non-adherent 
CD34+ cells and cell cycle promoting genes are in black.     
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3.3.3 Mitotic quiescence is a property of plastic adherent CD34+ cells 
Cell cycle distribution studies on peripheral blood CD34+ cells and bone marrow CD34+ cells 
confirm that there are low numbers of CD34+ cells in the S, G2, and M phases of the cell 
cycle111,112.  Previous studies using PI FACS analysis demonstrated that the majority of CD34+ 
stem cells from the peripheral blood are in G0/ G1 and CD34+ cells were presumed to be 
quiescent113.  The caveat to this conclusion is that PI analysis does not discriminate between G0 
and G1.  Later DNA analysis revealed that the majority, but not all, of the peripheral blood 
CD34+ cells are in G1112.  When combined with previous studies mentioned above, it can be 
assumed that it is the adherent CD34+ cell fraction that is arrested in G0, while the majority of 
the non-adherent CD34+ cells are in G1.   
 
These data were confirmed by immunofluorescent staining for Ki-67 which demonstrated that 
the majority of adherent CD34+ cells were Ki-67- and the majority of non-adherent CD34+ cells 
were Ki-67+.  The Ki-67 protein is present in the nuclei of cells in the G1, S, G2 and mitotic 
phases of the cell cycle.  Quiescent cells or cells arrested in G0 lack Ki-67 antigen, thus 
indicating that adherent CD34+ cells are arrested in G0.  The majority of non-adherent CD34+ 
cells are Ki-67 positive and are thus in the cell cycle, probably in G1.  Overall the data suggest 
that mitotic quiescence is a property of plastic adherent CD34+ cells. 
 
3.3.4 Genetic attributes of adherent CD34+ cells which make them desirable for use in 
regenerative medicine  
The gene arrays conducted in this study revealed that adherent CD34+ cells highly upregulate 
genes which are involved in cell adhesion and transendothelial migration.  These two properties 
are important for stem cell mobilization to sites of tissue injury if the bone marrow serves as a 
reservoir for stem cells which maybe released to aid tissue repair and regeneration94.  Quiescent 
stem cells adhere to osteoblasts in the bone marrow niche28.  Quiescent stem cells in the bone 
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marrow express the receptor tyrosine kinase Tie2, which interacts with its ligand Angiopoietin-1 
(Ang1) expressed by osteoblasts28,94.  Tie2 is an important adhesion molecule since it is involved 
in retaining CD34+ cells in the stem cell niche in the bone marrow and is implicated in the 
maintenance of HSC quiescence93,94.  According to the transcriptional data, adherent CD34+ 
cells highly express Tie2, but non-adherent CD34+ cells do not significantly express this 
quiescence-related adhesion molecule.   
 
Gene analysis revealed that adherent CD34+ cells more highly express genes related to cell 
migration and transendothelial migration.  Regulated migration and proper localization is critical 
for stem cell function in aiding tissue repair and maintaining homeostasis114.  Migration through 
endothelial tight junctions is necessary for proper stem cell homing.  
 
Adherent CD34+ cells also express genes involved in the migration and recruitment of other 
effector cells.  These genes include MMP9 which is important for T cell migration through 
basement membrane115.  MMP9 is also important for recruiting other CD34+ progenitors116, and 
blocking MMP9 reduces T cell trafficking to injury115.  Adherent CD34+ cells also highly 
express genes related to the synthesis of 10 chemokines including anti-microbial CXCL8/IL-8.  
This implies that adherent CD34+ cells are involved in chemotactic recruitment of immune and 
tissue specific cells.  Given all the above evidence, it is reasonable to speculate that adherent 
CD34+ cells are those stem cells which home in immediate response to injury.   
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Table 2. Subset of genes highly up-regulated by adherent CD34
+
 cells. 
Functional Catergory   
 
  
Cell cycle  MTSS1 MIM, MIMA, MIMB metastasis suppressor 1 
 GAS7 MLL/GAS7 growth arrest-specific 7 
 p57 
BWCR, BWS, KIP2, 
WBS, p57 cyclin-dependent kinase inhibitor 1c (p57, kip2) 
 WWOX 
FOR, FRA16D, 
HHCMA56, PRO0128, 
WOX1, WWOX v8 putative oxidoreductase 
 EXT1 EXT, LGCR, LGS, ttv exostoses (multiple) 1 
 GAS2L1 GAR22 growth arrest-specific 2 like 1 
 HEXIM1 
CLP1, EDG1, 
FLJ13562, HIS1, MAQ1 hexamethylene bis-acetamide inducible 1 
 NIPBL 
CDLS, CDLS1, 
DELANGIN, IDN3, 
IDN3-B 
nipped-b homolog (drosophila) 
 IGF1R CD221, IGFIR, JTK13 insulin-like growth factor 1 receptor 
 PDGFa PDGF1 platelet-derived growth factor alpha polypeptide 
 RAD21 
HR21, MCD1, NXP1, 
SCC1, hHR21 
rad21 homolog (s. pombe) 
 CDC2L5 
CDC2L, CHED cell division cycle 2-like 5 (cholinesterase-related 
cell division controller) 
 PHB PHB1 prohibitin 
 PRMT5 IBP72, JBP1, SKB1 protein arginine methyltransferase 5 
 PDGFb 
PDGF2, SIS, SSV, c-sis platelet-derived growth factor beta polypeptide 
(simian sarcoma viral (v-sis) oncogene homolog) 
    
 CHES1 FOXN3 checkpoint suppressor 1 
 MAPK13 
PRKM13, SAPK4, 
p38delta mitogen-activated protein kinase 13 
 HECA HDC, HDCL, HHDC headcase homolog (drosophila) 
 PIK3CB 
PI3K, PI3KCB, 
PI3Kbeta, PIK3C1, 
p110-BETA 
phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
 CDK9 
C-2k, CDC2L4, CTK1, 
PITALRE, TAK cyclin-dependent kinase 9 (cdc2-related kinase) 
 CXCL7 
PPBP, B-TG1, Beta-TG, 
CTAP-III, CTAP3, 
CTAPIII, CXCL7, LA-
PF4, LDGF, MDGF, 
NAP-2, PBP, SCYB7, 
TC1, TC2, TGB, TGB1, 
pro-platelet basic protein (chemokine (c-x-c 
motif) ligand 7) 
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THBGB, THBGB1 
 HIPK2  homeodomain interacting protein kinase 2 
 MAPK1 
ERK, ERK2, ERT1, 
MAPK2, P42MAPK, 
PRKM1, PRKM2, p38, 
p40, p41, p41mapk mitogen-activated protein kinase 1 
 DUSP6 MKP3, PYST1 dual specificity phosphatase 6 
 NHP2L1 
NHPX, OTK27, SNU13 nhp2 non-histone chromosome protein 2-like 1 
(s. cerevisiae) 
 ESCO1 
EFO1, ESO1 establishment of cohesion 1 homolog 1 (s. 
cerevisiae) 
     
Cell adhesion CTNND1 p120, CAS, CTNND catenin (cadherin-associated protein), delta 1 
 CCR1 
CD191, CKR-1, 
CMKBR1, HM145, 
MIP1aR, SCYAR1 chemokine (c-c motif) receptor 1 
 CCL2 
GDCF-2, HC11, 
HSMCR30, MCAF, 
MCP-1, MCP1, 
MGC9434, SCYA2, 
SMC-CF chemokine (c-c motif) ligand 2 
 FN1 
CIG, ED-B, FINC, FN, 
FNZ, GFND2, LETS, 
MSF fibronectin 1 
 ADAMDEC1  adam-like, decysin 1 
 CSPG2 
CSPG2, 
DKFZp686K06110, 
ERVR, PG-M, WGN, 
WGN1, VCAN chondroitin sulfate proteoglycan 2 (versican) 
 DSC3 
CDHF3, DSC, DSC1, 
DSC2, DSC4, HT-CP desmocollin 3 
 SLAMF7 
19A, CD319, CRACC, 
CS1 
slam family member 7 
 CD61 
ITGB3, GP3A, GPIIIa integrin, beta 3 (platelet glycoprotein iiia, antigen 
cd61) 
 TEK Tie2 TEK tyrosine kinase, endothelial 
 BMPR2 
BMPR-II, BMPR3, 
BMR2, BRK-3, PPH1, 
T-ALK bone morphogenic protein receptor 2 
 PCDH9  protocadherin 9 
 CD62 
SELP, CD62P, 
FLJ45155, GMP140, 
GRMP, LECAM3, 
PADGEM, PSEL 
selectin p (granule membrane protein 140kda, 
antigen cd62) 
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 ITGA7  integrin, alpha 7 
 TAOK2 
MAP3K17, PSK, PSK1, 
TAO1, TAO2 
tao kinase 2 
 ITFG2 
 uncharacterized hematopoietic stem/progenitor 
cells protein mds028 
 THBS1 
THBS, TSP, TSP1, 
thrombospondin-1p180 thrombospondin 1 
 CD41 
ITGA2B, CD41B, 
GP2B, GPIIb, GTA, 
HPA3 
integrin, alpha 2b (platelet glycoprotein iib of 
iib/iiia complex, antigen cd41) 
 GP5 CD42d glycoprotein v (platelet) 
 PGM5  phosphoglucomutase 5 
 CTNNA1 
alpha-E-catenin; alpha-
catenin 
catenin (cadherin-associated protein), alpha 1, 
102kda 
    
Chemokine activity CXCL4 
SCYB4, PF4 platelet factor 4 (chemokine (c-x-c motif) ligand 
4) 
 CCL2 
GDCF-2, HC11, 
HSMCR30, MCAF, 
MCP-1, MCP1, 
MGC9434, SCYA2, 
SMC-CF chemokine (c-c motif) ligand 2 
 CXCL16 
CXCLG16, SR-PSOX, 
SRPSOX 
chemokine (c-x-c motif) ligand 16 
 CXCL5 ENA-78, SCYB5 chemokine (c-x-c motif) ligand 5 
 CCL3 MIP-1-alpha, MIP1A chemokine (c-c motif) ligand 3 
 CCL8 
HC14, MCP-2, MCP2, 
SCYA10, SCYA8 chemokine (c-c motif) ligand 8 
 CXCL7 
B-TG1, Beta-TG, 
CTAP-III, CTAP3, 
CTAPIII, CXCL7, LA-
PF4, LDGF, MDGF, 
NAP-2, PBP, SCYB7, 
TC1, TC2, TGB, TGB1, 
THBGB, THBGB1 
pro-platelet basic protein (chemokine (c-x-c 
motif) ligand 7) 
 CCL3L1  chemokine (c-c motif) ligand 3-like 1 
 IL8 
3-10C, AMCF-I, CXCL8, 
GCP-1, GCP1, K60, 
LECT, LUCT, LYNAP, 
MDNCF, MONAP, NAF, 
NAP-1, NAP1, SCYB8, 
TSG-1, b-ENAP interleukin 8 (CXCL8) 
 CXCL3 
CINC-2b, GRO3, 
GROg, MIP-2b, MIP2B, chemokine (c-x-c motif) ligand 3 
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SCYB3 
    
Leukocyte 
transendothelial 
migration 
CTNND1 
p120, CAS, CTNND 
catenin (cadherin-associated protein), delta 1 
 CXCL4 
PF4, SCYB4 platelet factor 4 (chemokine (c-x-c motif) ligand 
4) 
 PIK3CB 
PI3K, PI3KCB, 
PI3Kbeta, PIK3C1, 
p110-BETA 
phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
 PIK3R5 
FOAP-2, P101-PI3K, 
p101 
phosphoinositide-3-kinase, regulatory subunit 5, 
p101 
 CXCL7 
B-TG1, Beta-TG, 
CTAP-III, CTAP3, 
CTAPIII, CXCL7, LA-
PF4, LDGF, MDGF, 
NAP-2, PBP, SCYB7, 
TC1, TC2, TGB, TGB1, 
THBGB, THBGB1 
pro-platelet basic protein (chemokine (c-x-c 
motif) ligand 7) 
 PRKCB1 
PKC-beta, PKCB, 
PRKCB, PRKCB2 protein kinase c, beta 1 
 MSN  moesin 
 NCF2 
NCF-2, NOXA2, P67-
PHOX, P67PHOX 
neutrophil cytosolic factor 2 (65kda, chronic 
granulomatous disease, autosomal 2) 
 CYBB 
CGD, gp91-1, gp91-
Phox, NOX2, p91-Phox 
cytochrome b-245, beta polypeptide (chronic 
granulomatous disease) 
 CCR1 
CD191, CKR-1, 
CMKBR1, HM145, 
MIP1αR, ScyaR1 
RANTES receptor; Chemokine receptor 1 
 ACTN4 
ACTININ-4, FSGS, 
FSGS1 actinin, alpha 4 
 CXCL16 CXCLG16, SR-PSOX, chemokine (c-x-c motif) ligand 16 
 MMP9 
CLG4B, GELB matrix metallopeptidase 9 (gelatinase b, 92kda 
gelatinase, 92kda type iv collagenase) 
 MAPK13 
SAPK4, p38 delta, 
PRKM13 
mitogen-activated protein kinase 13 
 CTNNA1 
CAP102 catenin (cadherin-associated protein), alpha 1, 
102kda 
 CCRL2 
CKRX, CRAM-A, 
CRAM-B, HCR Chemokine receptor like 2 
Apoptosis IFG1R CD64, CD64A, FCRI insulin-like growth factor 1 receptor 
 CASP10 ALPS2, FLICE2, MCH4 caspase 10 
 CCL2 
GDCF-2, 
HC11, HSMCR30, chemokine (c-c motif) ligand 2 
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MCAF, MCP-1, SCYA2, 
SMC-CF 
 SERPINB2 
PAI, PAI-2, PLANH2 serpin peptidase inhibitor, clade b (ovalbumin), 
member 2 
 DIDO1 
BYE1, DATF1, 
DIDO2, DIDO3, DIO-1 
death inducer obliterator 1 
 DNAJA3 TID1 dnaj (hsp40) homolog, subfamily a, member 3 
 IER3 
DIF2, GLY96, IEX-1, 
IEX-1L, PRG1 
immediate early response 3 
 SERPINB9 
CAP3, p19 serpin peptidase inhibitor, clade b (ovalbumin), 
member 9 
 BIRC4 
AP13, ILP1, 
MIHA, XLP2 baculoviral iap repeat-containing 4 
 STK17A DRAK1 serine/threonine kinase 17a (apoptosis-inducing) 
 ALK7  activin A receptor type 1c 
 DAPK1  death-associated protein kinase 1 
 CTSB APPS, CPSB cathepsin b 
 SLAMF7 
19A, CD319, CRACC, 
CS1 slam family member 7 
 HIPK2  homeodomain interacting protein kinase 2 
 CARD9  caspase recruitment domain family, member 9 
 MAPK1 
ERK, ERK2, ERT1, 
MAPK2, P42MAPK, 
PRKM1, PRKM2, p38, 
p40, p41, p41mapk mitogen-activated protein kinase 1 
 PHB  prohibitin 
 HSPA1A 
HSP70-1, HSP70-1A, 
HSP72, HSPA1, 
HSPA1B 
heat shock 70kda protein 1a 
 MTCH1 PIG60, PSAP mitochondrial carrier homolog 1 (c. elegans) 
 DPF2 REQ, UBID4 d4, zinc and double phd fingers family 2 
 PRKCE  protein kinase c, epsilon 
 CASP2 
ICH-1L, ICH-1L/1S, 
ICH1, NEDD2 Caspase 2, apoptosis-related cysteine peptidase 
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Table 3. Subset of genes highly up-regulated by non-adherent CD34
+ 
cells. 
Functional Catergory   
 
  
M Phase and cell 
cycle TOP3A 
 
topoisomerase (dna) iii alpha 
 ANAPC5  APC5, PDL-108 anaphase promoting complex subunit 5 
 PAPD5 TRF4-2 pap associated domain containing 5 
 EML4 
C2orf2, , ELP120, 
ROPP120 
echinoderm microtubule associated protein 
like 4 
 NUSAP1 
ANKT, BM037, LNP, 
SAPL 
nucleolar and spindle associated protein 1 
 RAD54L 
HR54, RAD54A, 
hHR54, hRAD54 rad54-like (s. cerevisiae) 
 CIT 
CRIK, STK21 citron (rho-interacting, serine/threonine 
kinase 21) 
 TPX2 
DIL2, HCA519, 
HCTP4, REPP86, p100 
tpx2, microtubule-associated, homolog 
(xenopus laevis) 
 CDC25a CDC25A2 cell division cycle 25a 
 CDC25c CDC25 cell division cycle 25c 
 CCNA1  cyclin a1 
 NEK4 
NRK2, STK2 nima (never in mitosis gene a)-related 
kinase 4 
 APBB2 
FE65L, FE65L1 amyloid beta (a4) precursor protein-binding, 
family b, member 2 (fe65-like) 
 GTSE1 B99 g-2 and s-phase expressed 1 
 CHAF1B 
CAF-1, CAF-IP60, 
CAF1, CAF1A, MPP7 chromatin assembly factor 1, subunit b (p60) 
 SEPT9 
MSF, MSF1, NAPB, 
PNUTL4, SINT1, 
SeptD1 septin 9 
 MCM2 
BM28, CCNL1, 
CDCL1, MITOTIN, 
cdc19 
mcm2 minichromosome maintenance 
deficient 2, mitotin (s. cerevisiae) 
 UHRF1 
Np95, RNF106, hNP95 ubiquitin-like, containing phd and ring finger 
domains, 1 
 MYC c-Myc v-myc ptoto-oncogene80 
    
DNA replication PRIM1 P49 primase, polypeptide 1, 49kda 
 RRM2 R2, RR2M ribonucleotide reductase m2 polypeptide 
 CHAF1B 
CAF-1, CAF-IP60, 
CAF1, CAF1A, 
CAF1P60, MPP7 chromatin assembly factor 1, subunit b (p60) 
 POLG  polymerase (dna directed), gamma 
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 POLE  polymerase (dna directed), epsilon 
    
Leukocyte 
transendothelial 
migration 
RASSF5 
 ras association (ralgds/af-6) domain family 5 
                                                     ITGAL             LFA-1, LFA1A integrin, alpha l (antigen cd11a (p180) 
 CXCL13 
ANGIE, ANGIE2, BCA-
1, BCA1, BLC, BLR1L, 
SCYB13 
chemokine (c-x-c motif) ligand 13 (b-cell 
chemoattractant) 
 PTK2B 
CADTK, CAKB, 
FADK2, FAK2, FRNK, 
PKB, PTK, PYK2, 
RAFTK ptk2b protein tyrosine kinase 2 beta 
 PIK3R2 
P85B, p85, p85-BETA phosphoinositide-3-kinase, regulatory 
subunit 1 (p85 alpha) 
 PXN  paxillin 
  
 
 
Apoptosis FOXO3A 
FOXO3 
forkhead box o3a 
 ZNF346 
JAZ 
zinc finger protein 346 
 FAS 
ALPS1A, APO-1, APT1, 
CD95, FAS1, FASTM, 
TNFRSF6 fas (tnf receptor superfamily, member 6) 
 MPO 
 
myeloperoxidase 
 RNASE3 
 
ribonuclease, rnase a family 3 
 DOCK1 
DOCK180, ced5 
dedicator of cytokinesis 1 
 CD38 
T10 
cd38 antigen (p45) 
 NALP1 
CARD7, CLR17.1, 
DEFCAP, DEFCAP-L/S, 
DKFZp586O1822, 
KIAA0926, NAC, NALP1, 
PP1044, SLEV1, 
VAMAS1 
nacht, leucine rich repeat and pyd (pyrin domain) 
containing 1 
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Chapter 4 Neural differentiation of bone marrow derived stem cells 
 
Chapter summary 
 
Various laboratories have published data which suggest that bone marrow derived cells are 
capable of differentiating into neural lineage cells12, 13, 15, 75-77.  Based on these data along with 
data that suggests adherent CD34+ cells are primitive stem cells, it was reasonable to 
hypothesize that adherent CD34+ cells might be capable of neurogenic differentiation in vitro.  
Published neural differentiation protocols of bone marrow derived cells were first used to 
determine if they were capable of inducing adherent CD34+ cells to differentiate into neural 
cells.  This chapter outlines in vitro neural differentiation experiments of bone marrow derives 
stem cells and uses neural stem cells as positive differentiation controls.  No neural 
differentiation was observed, thus retrospective DNA replication timing analysis was conducted 
to determine if bone marrow derived cells are epigenetically primed for neural differentiation.  
The collective results revealed that bone marrow derived stem cells including adherent CD34+ 
cells do not differentiate into neural cells in vitro.  This chapter describes the following: 
• Neural differentiation patterns of human neural stem cells 
• Bone marrow derived stem cells do not differentiate into neural cells 
• DNA replication timing of neurogenicity associated genes by bone marrow derived stem 
cells  
 
 
 
 
 
4.1 Bone marrow-derived cells in the brain 
 
It is known that bone marrow and peripheral blood derived cells migrate through the blood brain 
barrier during CNS injury.  Results of experiments using radiation bone marrow chimeras have 
indicated that 0.5% to 2% of astrocytes are derived from the bone marrow117.  The caveat of this 
study is that radiation may affect the permeability of the blood brain barrier.  Several groups 
have independently identified stem/progenitor cells which show neural characteristics; however, 
these instances are highly controversial as the sources for such cells are non-neural 
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tissues68,118,119.  In addition, bone marrow derived cells have been induced in vitro to express 
mature neuron phenotypes75,77,120,121.  There remains a need for scrutiny as to the reproducibility 
and functionality of the cells used for these types of experiments.  This appreciation has forced 
more rigorous and thorough investigation of stem/progenitor cells in the bone marrow, umbilical 
cord, and peripheral blood.  It is possible that discrepancies in the results are due to a lack of 
uniformity in bone marrow cell isolation.  For example, Priller et al60 used bone-marrow from 5-
fluoruracil treated mice stimulated with IL-3 and IL-6.  The cells isolated by D’Ippolito and 
colleagues (MIAMI)13 cells are isolated by adherence to fibronectin and colony isolation.   
 
The administration of non-neural cells in animal models of cerebral ischaemia has lead to 
explorations of non-neural cells providing neuroprotection and stimulating endogenous 
neurogenesis. There is a school of thought which believes that most if not all organs in the body 
have a reservoir of stem and progenitor cells which are mobilized after insult, thus expediting 
tissue repair and regeneration.  Moreover, it is known that haematopoietic stem and progenitor 
cells circulate in the peripheral blood.  Ratajczak and colleagues16,25,68 hypothesized that 
CXCR4+/CD45- tissue-specific stem cells also circulate in the peripheral blood, maintaining a 
pool of cells which are easily distributed to areas of the body distant from the bone marrow.  
Fluorescence activated cell sorting and mRNA analysis have shown that a small population of 
neural-tissue committed stem cells which express neural markers (GFAP, nestin, β-III tubulin, 
and NeuN) is found in the mononuclear fraction of peripheral blood.  Furthermore, blood from 
G-CSF-mobilized patients contains a higher number of tissue-specific stem cells than steady-
state blood.  Of particular interest, after cerebral ischaemia, there is a marked increase in neural 
tissue-specific stem cells in the circulation15.  In vitro analyses of these cells show that after a 
stroke, neural-tissue committed stem cells respond to chemoattractants SDF-1, HGF, and LIF15.  
This leads to the hypothesis that the bone marrow contains a population of non-haematopoietic 
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stem/precursor cells that express early neural specific markers, and are mobilized into the 
peripheral blood after CNS injury15.  These findings suggest a quiescent reservoir of neural 
lineage cells in the bone marrow, which may be triggered after CNS damage.  Alternatively, 
there exists a population of cells which has a high potential for differentiating into neural cells 
and responding to chemoattractants released after cerebral ischaemia.   
 
4.1.1 DNA replication timing  
During development neural specification occurs early in embryogenesis.  Once specified, 
progenitors generate distinct neural cell types.  This process requires establishing patterns of 
neural-specific gene expression and a concerted restriction of alternative cell fates122.  Although 
regulators of neural commitment have been identified, only recently have chromatin based 
studies of neural commitment been studied and little is known about the epigenetics of neural 
lineage restriction46,48.  One contributing factor is the availability of neural cells and difficulties 
in acquiring a homogenous population of neural tissue.  The terminally differentiated nature of 
neural cells which are out of cycle creates a problem in DNA replication timing studies, as cells 
are required to be in the cell cycle in order for BrdU incorporation.   
 
The previous chapter validated that adherent CD34+ cells are primitive stem cells and previously 
published data demonstrated that adherent CD34+ cells express transcriptional message for 
neural associated markers NeuroD, Pax6, and Nkx2.211, thus it was reasonable to hypothesize 
that adherent CD34+ cells might have neural differentiation potential.  Here the primary aim was 
to evaluate the ability of bone marrow-derived cell populations to differentiate into neural 
lineages, using neural stem cells (NSC) as a model for differentiation.  The DNA replication 
timing kinetics of human neural stem cells was defined and compared with the kinetics of 
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adherent CD34+ cells and fhMSCs to determine whether they have potential neurogenic 
capabilities at the chromatin level.   
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4.2 Results 
 
4.2.1 Neuronal differentiation of neural stem cells 
Neural stem cells or primary neural cells were used to provide a reference for comparison in 
neuronal differentiation experiments using various types of stem cells.  To investigate antigenic 
expression of neural markers during NSC differentiation, R197 NSCs were cultured in an 
established neuronal induction medium.  Briefly, NSCs were grown in neural basal media 
supplemented with N2, EGF, and bFGF.  At days 0, 10, and 21, differentiating cells were stained 
for neuronal marker βIII-tubulin, astrocytic marker GFAP, oligodendrocyte marker olig2, and 
neural stem cell marker nestin.  Antigenic expression was compared between NSCs in standard 
culture conditions and NSCs treated in neuronal differentiation conditions (Figure 16).  
Untreated NSCs had an increase in nestin expression and a sustained expression of GFAP 
indicating astrocytic differentiation.  In neuronal differentiation conditions, Nestin expression 
was strongest after 10 days, but decreased after 21 days in differentiation conditions.  This 
downregulation of nestin, a stem cell marker, validates differentiation of NSCs.   
 
NSCs in neuronal differentiation conditions upregulated βIII tubulin at 10 days, and began 
growing in an observable pattern as seen in Figure 10b.  β-III tubulin positive cells grow in large 
clusters and extend processes towards adjacent, evenly spaced clusters of similar size and shape.  
A typical cell will keep its cell body close to adjacent cell bodies, and extend long axons towards 
dendrites of another cell.  The growth patterns mimic those seen in human neural stem cell 
differentiation into neurons (Figure 16).    
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Figure 16.  Neural lineage differentiation of NSC.  Antigenic expression of neural stem cell marker nestin 
and early oligodendrocyte marker olig2 were followed at three time points during neuronal differentiation 
of human neural stem cells (A).  In standard culture conditions, nestin expression increased over time at 
day 10 and day 21. In neuronal differentiation conditions, nestin expression increased at day 10, but was 
dim at day 21.  Olig2 expression was absent in both treated and untreated conditions by day 10.  
Antigenic expression of astrocyte marker GFAP and  immature neuronal marker β-III tubulin were also 
followed during neuronal differentiation (B). In standard culture conditions, NSCs upregulate GFAP and 
express little or no β-III tubulin at both day 10 and 21.  Under neuronal differentiation conditions, a 
proportion of cells retain GFAP expression. β-III tubulin is expressed by day 10 and retained at day 21. At 
day 21, cells that express β-III tubulin begin to exhibit growth patterns whereby large clumps of β-III 
tubulin positive cells cluster and extend processes towards adjacent clusters of similar cells. These 
immunofluorescent investigations help give an idea of an appropriate pattern of antigenic expression to 
be expected during differentiation experiments with various stem cell types.  Results are representative of 
three replicates.   
102 
 
4.2.2 Non-neural stem cell differentiation into neural lineage cells 
4.2.2.1 Adherent CD34+ cells  
To determine if plastic adherent CD34+ cells differentiate into neural lineage cells in vitro, 
previously described neuronal differentiation methods were first used12,75-77.  These published 
protocols were used for bone marrow-derived cells, the details of which are described in chapter 
2 materials and methods, neural induction protocols 1-412,75-77.  Woodbury and colleagues 
previously observed neuronal differentiation capabilities of bone marrow-derived cells by 
treating them with DMSO, followed by bFGF for 24 hours (neural induction protocol 1)75.  Tao 
et al76 induced neural differentiation of bone marrow derived cells with cytokines known to be  
present in the brain microenvironment, bFGF, EGF, and PDGF (neural induction protocol 2).  
Munoz-Elias and colleagues77 employed a serum free method to differentiate plastic adherent 
mesenchymal stem cells (MSC), using a pre-induction step with BHA, followed with cytokines 
bFGF, EGF, and PDGF (neural induction protocol 3).  Jiang and colleagues12 induced bone 
marrow derived cells into neuro-ectodermal cells by using DMEM/F12 with N2 supplement, and 
additional growth factors basicFGF, sonic hedgehog, FGF8, and retinoic acid (neural induction 
protocol 4).  When cultured using these protocols, adherent CD34+ cells died within 24-72 
hours.   Variations of these protocols were then used in attempts to induce neural differentiation 
of adherent CD34+ cells.  These protocols are described in chapter 2, neural induction protocols 
5-9.  Neural differentiation was not observed under any of these conditions (Figure 17).  Positive 
controls were used to ensure that the antibodies used for immunofluorescent microscopy were 
functioning properly.   
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Figure 17.  Neural differentiation of bone marrow-derived cells.  The stem cell marker nestin is expressed 
by NSC, fhMSC, and adherent CD34+ cells (A).  Neural induction of adherent CD34+ cells and fhMSC 
revealed that these bone marrow derived stem cells do not differentiate into oligodendrocytes (B), 
astrocytes (C), nor neurons (D), in vitro.  Human or rat neural cells were used as positive staining controls 
for neural antibodies.  Results are representative of three replicate experiments.  
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4.2.2.2 Foetal mesenchymal stem cells 
A similar experimental protocol was used to induce neural differentiation of foetal human 
mesenchymal stem cells (fhMSC).  The cells were plated onto poly-D-lysine/fibronectin coated 
plastic 96 well plates.  As a positive control for differentiation, NSCs were plated and treated in 
parallel.  Human fibroblasts (hFibs) were used as a negative control, treated in parallel to 
fhMSCs.  The hFibs were not expected to differentiate into neural cells nor to express neural 
antigens.  After 10 days in culture, fhMSCs expressed low levels of nestin.  After 21 days, both 
treated and untreated fMSCs express nestin.  Treated cells also exhibited morphological changes, 
assuming a bipolar morphology under neural differentiation conditions rather than the fibroblast-
like morphology of the untreated fhMSCs.  At 21 days, untreated and treated fhMSCs expressed 
β-III-tubulin at low levels, with no significant difference in expression (Figure 18).  At 10 and 21 
days of treatment, fhMSCs did not express oligodendrocyte specific antigens (A2B5, O4, Olig2, 
GalC) nor astrocyte specific antigens (GFAP) (Figure 18).   
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Figure 18. Foetal human mesenchymal stem cells express low levels of β-III-tubulin in culture.  Under 
neural differentiation treatment conditions, fhMSCs have higher expression of β-III-tubulin after 10 and 21 
days.  Neural stem cell controls cultured and treated in parallel to fhMSCs express little or no β-III-tubulin 
under standard conditions, but are positive for the neuronal marker after 10 and 21 days in treatment.  
Untreated, NSCs express astrocytic GFAP, but GFAP expression seems to be downregulated under 
neuronal differentiation treatment.  The fhMSCs do not express GFAP with or without treatment 
conditions in neither 10 nor 21 days.  Results are representative of three replicate experiments.   
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4.2.3 Chromatin state of bone marrow derived cells  
The results described above suggest that adherent CD34+ cells and fMSCs do not differentiate 
into neural lineage cells in vitro.  To substantiate this view, DNA replication timing experiments 
were conducted to determine if genes associated with neural cell differentiation are replicated 
early by CD34+ cells, adherent CD34+ cells, non-adherent CD34+ cells and  fhMSC.  As 
controls for the replication timing of neurogenic genes, NSCs and ES cells were also analysed.  
Early replication of genes during S phase of the cell cycle is considered to be a feature of 
transcriptionally active regions of the genome, indicating chromatin accessibility, whereas late 
replication is characteristic of inactive gene regions and constitutive heterochromatin46. 
 
These experiments examined whether total CD34+ cells, adherent CD34+ cells, non-adherent 
CD34+ cells and fMSCs have epigenetic features which associate them with neural lineage 
restricted NSCs.  The timing of DNA replication was assessed as before (section 3.2.3).  The 
relative abundance of chosen sequences within newly synthesized DNA then determined using 
real-time qPCR (Figure 12) and replication timing colour coded as described above (Figure 12).  
 
4.2.3.1 Adherent CD34+ cells and fhMSCs do not replicate neurogenicity genes early 
To determine when genes involved in neural cell fate determination are replicated in NSC, DNA 
replication timing for loci of SOX1, SOX2, SOX3, NESTIN, and PAX6 in NSC was conducted 
(Figure 19).  SOX1, SOX2, SOX3 and, PAX6 were replicated late in the cell cycle.  NESTIN was 
replicated at G1/S1 early stages of the cell cycle.  SOX3 was not replicated until S2-S3.  To 
ensure that early replication was specific to neural related genes, we also probed for 
haemopoietic genes Ebf and Ikaros expression in NSCs.  Both haemopoietic genes were 
replicated middle (S2-S3) to middle-late (S3) in NSCs, as predicted.   
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Ensuring that neurogenic genes replicate early in NSCs, the study continued by determining if 
bone marrow derived cells have the propensity to express neurogenic genes.  The replication 
timing of SOX1, SOX2, SOX3, NESTIN, and PAX6 in total CD34+ cells, adherent CD34+ cells, 
non-adherent CD34+ cells, and fhMSCs relative to known neurogenic NSC.  Genes involved in 
neural specification during development replicated late in the cell cycle of the bone marrow 
derived populations (Figure 19).  SOX1, SOX2, and SOX3 replicated during S2-S4/G2, middle to 
late during the cell cycle.  The stem cell marker NESTIN replicated early in G1 in all cell 
populations, indicating the propensity of NESTIN expression.  Nestin is a broadly expressed gene 
and protein, thus its early replication and expression is not unexpected.  All bone marrow derived 
cells have a similar pattern of DNA replication timing of neurogenic genes.  This suggests that 
the chromatin structure of the loci for neurogenic genes in total CD34+, adherent CD34+, non-
adherent CD34+, and fhMSC makes neural expression unlikely.   
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Adherent 
CD34+ 
Non-
adherent 
CD34+ 
Total 
CD34+ fhMSC NCS ES*       
α-globin                   
β-amylase                   
Sox 1                   
Sox 2                   
Sox 3               Early    
Nestin                Middle Early  
Pax 6                Middle  
Ebf                Middle Late 
Ikaros                Late    
             
Adherent CD34+: Adherent CD34+ cells which are thought to be primitive quiescent stem cells 
Non-Adherent CD34+ : Non-adherent CD34+ cells (to compare to the asherent CD34+ cells) 
Total CD34+ : CD34+ cells from peripheral blood 
  
fhMSC: Foetal human mesenchymal stem cells 
  
NSC: Human neural stem cells 
      
ES: Human embryonic stem cells *Replication timing prepared by Sandra Pinho 
 
Figure 19.  DNA replication timing of nerogenicity-associated genes by different stem cell populations.  
Cells were fractionated by cell cycle phase and probed for the loci in question.  Relative abundance of 
genes in each fraction was analysed using real-time qPCR (A).  The fraction with the highest gene 
expression is said to be the time in the cell cycle when the gene is replicated.  Genes replicated early 
in the cell cycle are more accessible and its transcription likely.  BrdU purified templates from cell 
cycle fractions of adherent CD34+ cells, non-adherent CD34+ cells, total CD34+ cells, fhMSCs, and 
NSC were probed for neurogenicity genes Sox1, Sox2, Sox3, Nestin, and Pax6.  The peak relative 
abundance of Sox1, Sox2, Sox3, and Pax6 genes were late in the cell cycle suggesting that these 
cells are not likely to be neurogenic.  The histogram for the replication timing of each gene is 
represented as a coulor code (B).   
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To validate replication timing data, real-time qPCR was conducted to determine relative 
expression of SOX1, SOX2, SOX3, PAX6, EBF, REX1, NANOG, and OCT4  in adherent 
CD34+, non-adherent CD34+, fetal mesenchymal stem cells (24XY fMSC), and neural stem 
cells (R197) (Figure 20).  This epigenetic evidence validates the previous findings that 
adherent CD34+ cells and fhMSCs do not differentiate into neural cells.   
 
Figure 20.  Real-time qPCR of pluripotency and neurogenicity-associated genes expressed by bone 
marrow-derived stem cells.  This histogram shows relative expression of pluripotent and neurogenic 
genes expressed in adherent CD34+ cells, non-adherent CD34+ cells, fhMSC and NSC.  The low 
expression of neural genes supports previous replication timing data.  Relative expression was 
normalized to the expression of housekeeping genes GAPDH and HPRT.   Results are an average of 
two replicate experiments, thus any statistical significance in expression among populations cannot 
be determined.   
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4.3 Discussion 
 
Investigations have shown an increase in neural cell proliferation and neurogenesis after 
insult66,67, and a mounting number of studies attempt to stimulate post-natal neurogenesis as 
an alternative therapy to transplantation.  It has been demonstrated that in response to acute 
ischaemia in the forebrain, endogenous neural stem cells proliferate, are recruited to the 
penumbra region, and give rise to hippocampal pyramidal neurons.  Infusion of exogenous 
growth factors FGF2 and EGF led to 40% recovery of the neurons lost due to ischaemia.  
Newly generated neurons show functional synapse formation as well as recovery of brain 
function66.  This points to the possibility of stimulating neurogenesis of endogenous neural 
stem cells using pharmaceuticals as an alternative to transplantation.   
 
There are two main lines of investigation which address neural lineage differentiation of cells 
from non-neural tissue.  First, several groups have independently identified stem and 
progenitor cells in peripheral blood and bone marrow which express neural lineage 
markers15,68,118,119,123.  Second, cells derived from non-neural tissue such as umbilical cord, 
peripheral blood and bone marrow have been induced to express a neural phenotype12,75,77,121.  
This leaves the question: are there pre-determined neural committed precursor cells outside 
the CNS/PNS, or are there adult derived stem cells which are truly plastic? 
 
Here previously defined protocols12,75-77 were employed for neural differentiation of bone 
marrow derived cells in order to differentiate adherent CD34+ cells and fMSCs into neural 
cells.  To ensure protocols used were appropriate for neuronal or glial differentiation, NSCs 
were cultured in the differentiation media to ensure that the culture conditions induced 
lineage specified differentiation.  This study found that adherent CD34+ cells do not 
differentiate into neurons or oligodendrocytes under the conditions used.  Adherent CD34+ 
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cells did not reproducibly differentiate into astrocyte-like cells.  In three of five experiments, 
adherent CD34+ cells upregulated markers S100β and GFAP, and demonstrated 
morphological changes (data not shown).  The reproducibility of these observations was 
questionable, and it is not possible to conclude that neural differentiation occurred.  The 
literature reveals that bone marrow-derived cells have been observed to spontaneously 
differentiate into astrocyte like cells12,75,77,121.  The observed differentiation of adherent 
CD34+ cells may be spontaneous and an artefact of culture.  It is possible that the neural 
differentiation medium provided an appropriate inductive microenvironment, inducing the 
differentiation of adherent CD34+ cells into astrocyte-like cells.  Inconsistencies may also be 
due to variations in donors.   
 
Similar results were observed when fhMSCs were cultured in neural induction medium.  
There was no morphological or antigenic evidence of glial differentiation.  In a single 
instance, in neuronal differentiation conditions, fhMSC upregulated the neuronal markers 
PSA-NCAM and MAP2.  This result was irreproducible and observed only once in five 
replicate experiements.  It is noteworthy that both adherent CD34+ cells and fhMSC 
upregulated neural markers in single instances indicating that it might be a rare event.  The 
cellular mechanisms which govern the spontaneous differentiation of bone marrow-derived 
cells may be the key to in vitro differentiation across germ lineages.  With this in mind, 
previous irreproducible results from other studies may have been artefacts or random 
spontaneous events.   
 
As cells replicate their DNA, some sequences replicate early in S phase (G1-S1), while others 
replicate late in S phase (S3-S4).  Early replication is associated with chromatin accessibility 
and the active transcription of the gene.  In this study the replication kinetics of genes which 
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encode transcription factors important during neural development, SOX1, SOX2, SOX3,PAX6, 
and NESTIN were examined.  Non-neural adherent CD34+ cells and fhMSCs were compared 
to neurogenic NSCs.  The genes which control developmental neurogenesis are replicated 
early in NSCs, but late in adherent CD34+ cells and fhMSCs.  The replication timing findings 
validate the above in vitro neural differentiation experiments.  Replication timing revealed 
that the chromatin structure of bone marrow-derived cells may decrease the propensity of 
these cells to actively transcribe neural genes.  As the chromatin structure does not allow 
genes involved in neurogenesis to be easily transcribed, neural differentiation of adherent 
CD34+ cells and fhMSCs is unlikely.   
 
It was proposed that adherent CD34+ cells are multilineage primed stem cells which express 
lineage specific genes associated with liver, pancreas, and neural tissues.  It was hypothesized 
that the genetic expression of neural markers enables adherent CD34+ cells to differentiate 
into neural lineage cells when placed in a neural inductive microenvironment.  However, the 
results of the differentiation and replication timing experiments suggest that adherent CD34+ 
cells and fhMSCs do not have neurogenic potential in vitro.  Although real-time qPCR shows 
that adherent CD34+ cells and fhMSCs express low levels of neurogenic genes, and 
spontaneously upregulate neural associated proteins, the DNA replication timing data 
suggests that these cells may not have a definitive potential for neural differentiation.  Studies 
have revealed that bone marrow-derived cells affected during CNS injury, such as 
recruitment during ischaemia, immunosuppressive properties, promote/inhibit 
angiogenesis124,125.  Perhaps direct differentiation of bone marrow and peripheral blood 
derived adherent CD34+ cells are not an appropriate means for cell therapy; instead it may be 
possible to exploit the indirect effects of adherent CD34+ cells.   
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Chapter 5 Microglial differentiation of adherent CD34+ cells 
 
Chapter summary 
It is known that the immune cells of the CNS, called microglia, are of haematopoietic 
developmental origin57, 61, 62, 117, 130.  Davoust and colleagues130 demonstrated that a proportion 
of bone marrow derived cells differentiated into microglia when exposed to astrocyte 
conditioned medium.  As peripheral blood and bone marrow derived CD34+ cells are of 
haematopoietic origin, it was hypothesized that adherent CD34+ cells are capable of 
differentiating into microglia.  Astrocyte conditioned medium was used to induce microglial 
differentiation of adherent CD34+ cells.  Adherent CD34+ cells exposed to astrocyte 
conditioned medium upregulated antigens associated with microglia.  Adherent CD34+ cells 
derived microglia also released TNFα and IL-6 in response to LPS, which is a functional 
property of microglia.  This chapter describes the following: 
• Adherent CD34+ cells upregulate morphological features and antigenic expression of 
microglia 
• Adherent CD34+ cell derived microglia respond to LPS 
• Adherent CD34+ cell derived microglia secrete TNFα and IL-6 in response to LPS 
 
 
5.1 Role of microglia 
Glial cells provide physiological support for neurons and maintain homeostasis by aiding in 
neuronal repair during injury or disease.  Glial cells are classified as macroglia, which are the 
astrocytes and oligodendrocytes, and microglia, which are the immune effector cells of the 
central nervous system (CNS).  Macroglia are derived from neuroectoderm, but the 
developmental origin of microglia remains debatable.  Although traditional concepts state 
that microglia are derived from neuroepithelial cells, current studies suggest that microglia 
residing in the CNS are of mesodermal origin62,117,126.  In the adult brain, microglia are 
recruited from peripheral blood monocytes, originating from the bone marrow62,126,127.   
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Several studies have demonstrated that, in irradiated chimeric mice, neural injury induced an 
increase in microglial recruitment and engraftment of GFP+ bone marrow-derived cells in the 
brain60,62,117,128,129.  Furthermore, models of neural injury include those characterized by an 
influx of leukocytes from the blood as a result of an altered blood-brain barrier; those 
characterized by region-specific neurodegeneration such as Parkinson’s disease, Alzheimer’s 
disease, and amyotrophic lateral sclerosis; and models of focal or acute neural degeneration 
such as facial nerve axotomy129,130.  Under specific conditions, bone marrow-derived cells are 
able to cross the blood brain barrier and differentiate into microglial cells129,131.  This 
observation implies that the adult bone marrow contains a subpopulation of cells with 
microglial differentiation potential.   
 
As microglia are suggested to be of haemopoietic developmental origin, the aim of this part 
of the study was to determine if adherent and/or non-adherent CD34+ cells can differentiate 
into microglia.  Several factors suggest that adherent CD34+ cells might be microglial 
precursors including (i) adherent CD34+ cells are more primitive than non-adherent CD34+ 
cells, in terms of their potential for differentiation, (ii) the previously described microarray 
study revealed that adherent CD34+ cells highly express genes which encode for 
transendothelial migration, indicating that they are more likely to respond to injury than their 
non-adherent CD34+ counterparts, and (iii) adherent CD34+ cells more highly express 
CCL2, the ligand thought to be responsible for adhesion to, and migration through the blood 
brain barrier130.  Here, different subpopulations of bone marrow-derived cells were placed 
under microglial differentiation conditions previously described by Davoust et al130.  This 
study revealed that mesenchymal stem cells die when placed in microglia differentiation 
conditions, and that non-adherent CD34+ cells do not demonstrate any characteristic of 
microglia-like cells.  Adherent CD34+ cells demonstrate morphological and antigenic 
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evidence of microglial differentiation.  Functionality of these adherent CD34+ cell derived 
microglia-like cells (CD34MG) was assessed by examining baseline cytokine secretion, 
cytokine secterion in response to LPS activation, and antigen presentation capabilities.   
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5.2 Results 
5.2.1 Adherent CD34+ cells differentiate into cells with microglia-like morphology 
Adherent CD34+ cells or non-adherent CD34+ cells were cultured in astrocyte conditioned 
medium (ACM) for 7, 10, or 21 days.  No significant morphological changes were observed 
in the adherent CD34+ cells cultured for 7 days, but after 10 days, approximately 40% of 
them assumed the morphology of microglia, including a ramified appearance and small 
neurite spines (Figure 21).  After 21 days, approximately 80% of the adherent CD34+ cell-
derived microglia-like cells (henceforth referred to as CD34MG) had multiple cellular 
processes (Figure 1).  In contrast, no morphological changes were observed in non-adherent 
CD34+ cells cultured in ACM after 7, 10 and 21 days.   
 
Day 7 Day 10 Day 21 
Figure 21.  Adherent CD34+ cells upregulate morphological changes in response to astrocyte 
conditioned medium.  To induce microglial differentiation, adherent CD34+ cells were treated cultured 
in ACM 24hrs after isolation.  After 7 days in ACM, no morphological changes were observed, but after 
10 days, cells had similar morphology to the bipolar microglia in a resting state.  Twenty one days in 
ACM treatment induced a ramified resting microglial morphology with multipolar processes.    
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5.2.2 CD34MG upregulate microglial markers  
Expression of antigens associated with microglia, Ox42, Iba1, and HLA-DR was investigated 
by immunofluorescence microscopy (Figure 22).    Newly isolated adherent CD34+ cells 
expressed low levels of microglial markers.  About 9 ± 4.2% expressed Ox42, 5 ± 2.7% 
expressed Iba1, 1 ± 0.7% expressed TLR4, about 9 ± 2.8% expressed HLA-DR, and none 
expressed B7.1.  Since morphological changes were not observed until after 10 days of 
culture in ACM, immunofluorescence microscopy was conducted at this time. A significantly 
higher frequency of CD34MG cells than adherent CD34+ cells expressed these microglial 
markers; 81 ± 10.4% of adherent CD34+ cells which expressed Ox42, 71 ± 9.6% expressed 
Iba1, 16 ± 7.3% expressed TLR4, 35 ± 8.1% expressed HLA-DR, and 16 ± 6.4% upregulated 
the co-stimulatory molecule B7.1.  Non-adherent CD34+ cells expressed very low levels of 
Ox42, Iba1, and TLR4.  Interestingly, 38 ± 6.2% of non-adherent CD34+ cells expressed 
HLA-DR and 21 ± 12.6% expressed co-stimulatory molecule B7.1.  Exposure to ACM for 10 
days caused a decrease in HLA-DR and B7.1 expression by non-adherent CD34+ cells 
(Figure 22)  
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*p-value determined using the Wilcoxon Signed Rank  nonparametric test on SPSS software  
§ p-value determined using paired student’s t-test on SPSS software 
Antigen 
Adherent  
CD34
+
 cells 
CD34MG 
Non-adherent  
CD34
+
 cells 
ACM treated  
non-adherent CD34
+
 
cells 
n= 
Ox42 9 ± 1.3 81 ± 2.9 3 ± 2.9 7 ± 4.3 5 
p= (compared to adherent CD34+ 
cells)*   0.0001 0.25 0.29   
Iba1 5 ± 2.8 72 ± 7.9 7 ± 1.7 13 ± 5.6 5 
p= (compared to adherent CD34+ 
cells)*   0.0012 0.55 0.003   
TLR4 1 ± 1.8 16 ± 3.5 7 ± 0.33 3 ± 2.4 4 
p= (compared to adherent CD34+ 
cells)§   0.02 0.004 0.014   
HLA-DR 9 ± 4.2 35 ± 3.6 38 ± 3.2 27 ± 5.2 5 
p= (compared to adherent CD34+ 
cells)*   0.002 0.0014 0.02   
B7.1 2 ± .9 16 ± 0.6 21 ± 4.4 8 ± 2.4 3 
p= (compared to adherent CD34+ 
cells) §   0.001 0.037 0.31   
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5.2.3 Cytokine secretion by adherent CD34+ cells and CD34MG 
To determine if adherent CD34+ cells and CD34MG secrete cytokines, a semi-quantitative 
human cytokine array was used to measure relative amounts of release of 36 cytokines which 
were pre-determined by the manufacturer.  Supernatant from adherent CD34+ cells (5 days 
after medium change) and supernatant from CD34MG (5 days after medium change), as well 
as fresh standard culture medium and ACM was collected and analyzed.  Adherent CD34+ 
cells secrete CXCL1, IL1ra, IL8, IL16, MCP1, MIP1α, MIP1β, and SerpinE1.  After 
treatment in ACM for 10 days, there was a downregulation of all cytokines, except for an 
increase in SerpinE1 release.  CD34MG secrete relatively lower levels of IL1ra, IL8, MIF, 
MIP1α, MIP1β, and SerpinE1 (Figure 23).  This downregulation of cytokine secretion may 
suggest that as adherent CD34+ cells differentiate into CD34MG, they downregulate Th1 
cytokine secretion.  This is consistent with the literature which reports that microglia are less 
immunocompetent than peripheral blood macrophages and other immune cells found in the 
circulation.   
 
 
 
 
 
 
Figure 22.  CD34MG cells upregulate microglia-associated markers.  Adherent CD34+ cells and 
non-adherent CD34+ cells were treated with ACM for 10 days and microglial antigen expression of 
Ox42, Iba1, TLR4, HLA-DR and B7.1 was assessed with immunofluorescence microscopy.  
Upregulation of microglia associated markers by CD34MG was statistically more significant than 
untreated adherent CD34+ cells.  ACM treated non-adherent CD34+ cells did not significantly 
upregulate the panel of markers used to identify microglia.  
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Figure 23. Cytokine released by adherent CD34+ cells and CD34MG.  Supernatants were collected 
from cultures of adherent CD34+ cells and CD34MG cells, and analyzed for cytokine content using a 
semi-quantitative cytokine array (A).  The array measured presence of cytokine and its relative 
abundance between samples which was captured on X-ray film.  Locations of spots on the array 
corresponded with specific cytokines pre-defined by the manufacturer.  Densitometry measurements 
are represented in histogram form (B).  Densitometry of relative cytokine abundance between 
samples was measured and recorded as mean pixel density of each spot on the array.  Adherent 
CD34+ cells secrete more pro-inflammatory cytokines CXCL1, IL-1ra, IL-8, IL-16, MCP-1, MIF, 
MIP1α, and SerpinE1.  CD34MG secrete relatively lower levels of IL-1ra, IL-8, MIF, MIP1α, MIP1β, 
and SerpinE1.  These results represent an average of two experiments. 
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5.2.4 LPS activation 
Previous immunofluorescence analysis revealed that a low frequency of adherent CD34+ 
cells and CD34MG express TLR4, the receptor through which gram negative bacteria 
activate an immune response in certain cells including microglia.  To determine if adherent 
CD34+ cells and CD34MG become activated in response to LPS, 1µg of LPS was added to 
cell cultures for two hours and the supernatants were collected and analyzed as before.  The 
results revealed that adherent CD34+ cells released greater amounts of CXCL1, CCL1, IL6, 
IL8, MCP1, MIF, MIP1α, SerpinE1, RANTES, and TNFα in response to LPS (Figure 24a).  
There was downregulation of IL1ra, IL16, and MIP1β.  This upregulation of pro-
inflammatory cytokines indicates activation via TLR4.  When exposed to LPS for 2 hours, 
CD34MG released more amounts of G-CSF, CXCL1, IL1ra, IL6, IL8, IL27, MIF, MIP1α, 
and MIP1β when exposed to LPS for 2 hours relative to CD34MG without LPS activation 
(Figure 24b).  This indicates pro-inflammatory activation of CD34MG via TLR4.  LPS 
activation induced an increase in SerpinE1 release, but the opposite pattern was observed in 
the CD34MG cells where LPS induced a decrease in SerpinE1 secretion (Figure24a and b).  
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Figure 24.  Exposure to LPS alters cytokine secretion by adherent CD34+ cells and CD34MG. 
Exposure of adherent CD34+ cells and CD34MG to LPS caused a pro-inflammatory activation in both 
populations.  Adherent CD34+ cells secreted relatively more amounts of cytokine after activation with 
LPS, as well as a greater number of pro-inflammatory cytokines (A).  CD34MG cells secreted 
significantly greater amounts of pro-inflammatory cytokines as well as a greater number of cytokines 
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relative to their non-activated counterparts (B).  These results represent an average of two 
experiments. 
 
 
 
Release of TNFα and IL-6 is a hallmark of microglial LPS activation.  Neither adherent 
CD34+ cells nor CD34MG cells released TNFα nor IL-6 in their resting states.  The semi-
quantitative cytokine array revealed that LPS activation induced TNFα and IL-6 release by 
adherent CD34+ cells, and IL-6 release by CD34MG.   
 
A quantitative analysis of TNFα and IL6 secretion by adherent CD34+ cells and CD34MG 
cells with and without LPS activation was then performed.  Both adherent CD34+ cells and 
CD34MG were exposed to LPS for 2, 4, 8, 16, 32, and 48 hours, and supernatant and cell 
lysates were collected.  This procedure was repeated 7, 10, and 21 days after the beginning of 
ACM treatment.   
 
5.2.5 TNFα 
The quantitative assay revealed that without LPS activation, adherent CD34+ cells do not 
constitutively secrete TNFα at 7, 10, or 21 days of culture (Figure 25).  After LPS activation, 
day 7 adherent CD34+ cells secrete peak levels of 1887.4pg/ml TNFα after 32 hours.  LPS 
activation of day 10 adherent CD34+ cells induced peak TNFα release only 4 hours after 
activation, releasing 1262.56pg/ml.  Day 21 cells peak secretion of TNFα was also after 4 
hours of LPS activation, secreting 1082pg/ml (Figure 25).  
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CD34MG cells in an unactivated resting state constitutively release low amounts of TNFα.  
Analysis of ACM medium alone confirmed that it did not contain any TNFα.  Day 7 
CD34MG supernatants were found to contain 31.2pg/ml TNFα; day 10 and 21 CD34MG 
secreted lower amounts of 3.09- 8.3pg/ml TNFα (Figure 25). 
 
LPS activated day 7 CD34MG cells secreted 2pg/ml after 2 hours to 244pg/ml after 16 hours 
of LPS exposure.  Day 10 and 21 CD34MG demonstrated a release of TNFα after 2 hours of 
LPS exposure with peak cytokine levels of 4385pg/ml and 4319pg/ml respectively.  After 
peak cytokine release at 2 hours, TNFα levels decline. This may reflect an initial response of 
TNFα release and its subsequent degradation or metabolism by the cells (Figure 25).  The 
limitation of this assay is that cytokine secretion is not measured until 2 hours of exposure to 
LPS.  A measurement of immediate cytokine secretion over shorter periods of time may be 
necessary in the future to confirm cytokine secretion.   
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Figure 25.  TNFα secretion by adherent CD34+ cells and CD34MG.  (A) LPS exposure commenced 
on the 7
th
 day of culture and continued for 72 hours.  Untreated adherent CD34+ cells were used as 
controls.  (B) LPS exposure commenced on the 10
th
 day and (C) 21
st
 day of culture.  Unstimulated 
resting adherent CD34+ cells did not constitutively secrete TNFα in culture, but secreted cytokine 
after LPS activation.  CD34MG cells did not constitutively secrete TNFα in culture.  LPS activation of 
CD34MG cells in the 10
th
 (B) and 21
st
 (C) day of culture induced peak TNFα secretion after 2 hours of 
exposure.  Results represent five replicate experiments.   
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5.2.6 IL-6 
Adherent CD34+ cells cultured for 7 days in standard culture conditions secrete constitutive 
amounts of IL6, between 4389 to 5503pg/ml (Figure 26a).  After 10 days in culture, IL6 
levels decreased to levels
 
from 72 to 300pg/ml (Figure 26b).  At day 21, IL6 release was as 
low as 16 to 194pg/ml (Figure 26c).   
 
When activated with LPS, day 7 adherent CD34+ cells secreted up to 9055pg/ml IL-6 after 
16 hours to exposure to LPS, but levels returned to constitutive levels after 48 hours in 
culture (Figure 26a).  LPS-activated day 10 adherent CD34+ cells had maximum IL-6 
secretion at 16 hours of LPS exposure, secreting 7310pg/ml IL-6 (Figure 26b).  By day 21 of 
culture, adherent CD34+ cells only secreted a maximum of 6259pg/ml IL-6 after 8 hours of 
LPS exposure (Figure 26c). 
 
CD34MG cells secreted very low amounts of IL-6 in the resting state.  CD34MG cells after 7, 
10 and 21 days of culture secreted constitutively low levels of IL-6 between 16 and 52pg/ml 
at all three time points (Figure 26a-c).  LPS-activated day 7 CD34MG cells secreted up to 
1087pg/ml IL-6 32 hours after commencement of LPS exposure.  Day 10 CD34MG secreted 
1265pg/ml IL-6 after 32 hours of LPS exposure (Figure 26b), and day 21 CD34MG cells 
secreted 1349pg/ml after 32 hours of exposure (Figure 26c).  The time course shows that IL-6 
secretion of LPS activated CD34MG cells increases slightly over time, which is the inverse 
of the pattern seen in TNFα secretion which showed a decrease in TNFα with time.   
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Figure 26.  IL-6 secretion by adherent CD34+ cells and CD34MG.  Adherent CD34+ cells 
constitutively secreted IL-6 at 7 days in culture, but levels of IL-6 decreased by 10 and 21 days in 
standard culture.  LPS activation of adherent CD34+ cells caused massive spikes in IL-6 secretion at 
8 hours after LPS exposure.  Although levels decreased by 24 hours, a constitutive amount of IL-6 
remained in culture up to 48 hours.  ACM treated CD34MG cells did not secrete constitutive amounts 
of IL-6, but LPS activation caused relatively mild IL-6 secretion after 2 hours exposure to LPS.  This 
level of activation decreased as the age of cell cultures increased.  This observed IL-6 release is 
similar to documented patterns seen in microglia.  Results represent five replicate experiments.   
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5.2.7 Antigen presentation by CD34MG  
Antigen presentation experiments were conducted with the help of Stefania Lymperi (Prof 
Francesco Dazzi’s lab).  To determine if CD34MG are antigen presenting cells, mixed 
lymphocyte reactions were conducted using autologous leukocytes.  CD34MG (from donor 
A) was loaded with EBV peptide by pulsing overnight.  Loaded CD34MG was then cultured 
in a round bottom 96-well plate with PBMC (also from donor A).  PBMC proliferation was 
then measured by thymidine uptake.  CD34MG loaded with EBV peptide caused a moderate 
proliferation of PBMCs, indicating antigen presenting cell function.  Peptide alone did not 
cause PBMC proliferation.  CD34MG alone caused a minimal PBMC proliferation.  
Adherent CD34 loaded with EBV peptide did not cause a significant proliferation of PBMCs, 
indicating that adherent CD34 are not antigen presenting cells.  Although proliferation caused 
by peptide loaded CD34MG was not as much as that caused by an HLA mismatched reaction, 
it was considerably greater than that caused by peptide pulsed adherent CD34+ cells or 
CD34MG cells that were not pulsed with peptide.  This corroborates the immunofluorescence 
data (Figure 22) which showed that although some (9%) adherent CD34+ cells express HLA-
DR, they do not express the costimulatory molecule B7.1 (Figure 27).   
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Figure 27.  Mixed lymphocyte reactions determine if CD34MG cells are capable of antigen 
presentation.  To determine if CD34MG cells are capable of presenting antigen, CD34MG cells were 
loaded with EBV peptide overnight, washed and the cells irradiated.  PBMC from the same donor 
from which CD34MG cells were produced were introduced to the EBV loaded CD34MG cells.  An 
immune response was determined by measuring proliferation of PMBC with 
3
H tritiated thymidine 
uptake.  The graph shows that CD34MG induced more proliferation than adherent CD34+ cells in an 
autologous reaction, indicating that CD34MG was able to present EBV peptide to peripheral immune 
cells.  Results represent three replicate experiments.   
 
 
Stimulators added to responders 
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5.3 Discussion 
Although it has been well documented that microglia are of haematopoietic origin, and are 
recruited from the bone marrow during neural injury, the precise identity of the microglial 
precursors has not yet been determined62,131,132.  Here it was proposed that adherent CD34+ 
cells differentiate into microglial cells in vitro.  Four subpopulations of bone marrow cells 
were exposed to ACM in order to induce microglial differentiation.  It was observed that 
fhMSC and adult MSC died relatively quickly under these conditions. 
 
Non-adherent CD34+ cells did not show morphological evidence of differentiation or 
upregulate microglial markers in ACM.  It was previously described that known that adherent 
CD34+ cells and non-adherent CD34+ cells are genetically and morphologically different.  
As migrating immune cells of the nervous system, bone marrow-derived microglia must 
tether to and adhere to the endothelium of the blood brain barrier.  Adherent CD34+ cells also 
upregulate the gene which encodes for CCL2, the ligand that allows migration through the 
tight junctions of the blood brain barrier.   
 
Adherent CD34+ cells secrete pro-inflammatory cytokines, and increase cytokine levels in 
response to LPS, as an in vitro model of immune response.  There was an inverse relationship 
between the age of the cells and the amount of cytokine secretion.  As time in culture 
increased, the amount of cytokine release decreased.  Differences in cytokine levels through 
the culture period may indicate that the adherent CD34+ cells may either be regulating 
cytokine secretion with time in culture, metabolising the cytokines, or that the secretion is 
temporarily released by the cells as an acute response.   
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The lower levels of cytokines secreted by CD34MG may reflect the immunosuppressive 
effects of the astrocyte conditioned medium on the adherent CD34+ cells or reflect 
differentiation.  It is widely known that astrocytes secrete factors that cause 
immunosuppression10-12 and that infiltrating peripheral monocytes are immunosuppressed in 
the brain13,14.   Based on morphological, antigenic, and functional evidence, it is assumed that 
CD34MG cells are microglia like cells.  The modes of microglia reaction to various 
pathological stimuli include pro-inflammatory cytokine release including TNFα and IL-6.  
LPS activation of CD34MG revealed large amounts of TNFα and IL-6 secretion, similar to 
patterns of cytokine release by microglia133.  The release of these pro-inflammatory cytokines 
further validates microglial characteristics of CD34MG cells. 
 
Interestingly, LPS activation of adherent CD34+ cells and CD34MG cells induced different 
patterns of cytokine secretion.  Figure 8 illustrates that adherent CD34+ cells (Figure 29a) 
rapidly release increasing amounts of IL-6 up to 8 and 16 hours of LPS exposure, and 
relatively higher levels of IL-6 secretion are sustained in the presence of LPS.  In contrast, 
CD34MG secreted 7 times less IL-6 than adherent CD34+ cells in response to LPS activation 
and relatively low amounts of IL-6 in culture in the presence of LPS.   
 
Although LPS activation of adherent CD34+ cells caused a spike in IL-6 secretion, the 
amount of TNFα secretion was relatively low and remained at constitutive levels in the 
presence of LPS (Figure 28a).  LPS activation had the opposite effect on CD34MG cells 
which showed an immediate and relatively high release of TNFα within 2 hours of LPS 
exposure.  After an initial spike of cytokine release, levels decreased and were down to 
negligible levels within 24 hours.    
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In both cell populations, inverse patterns of cytokine secretion were observed in response to 
LPS.  Adherent CD34+ cells secreted relatively large amounts of IL-6, but low amounts of 
TNFα (Figure 28a).  In contrast, CD34MG released high amounts of TNFα immediately in 
response to LPS and relatively low levels of IL-6 (Figure 28b). 
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Figure 28.  Cytokine release in response to LPS activation.  LPS activation was used to determine if 
either adherent CD34+ cells (A) or CD34MG cells (B) released cytokine in response to pathogens, in 
this case LPS.  Adherent CD34+ cells and CD34MG in 10 days of culture were exposed to LPS for 2 
to 72 hours and TNFα and IL-6 levels were measured.  Patterns of cytokine secretion by adherent 
CD34+ cells are the opposite of those for CD34MG cells.  In response to LPS, adherent CD34+ cells 
(A) secreted almost 7 times more IL-6 within 8 to 16 hours than CD34MG, but adherent CD34+ cells 
secreted 6 times less TNFα than CD34MG in response to LPS.  In both cell populations, when one 
cytokine was released in relatively high amounts, the other cytokine was released in relatively low 
amounts.   
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The results of experiments investigating antigen presentation revealed that CD34MG have 
moderate antigen presenting activity relative to adherent CD34+ cells in vitro, suggesting that 
they may be functional immune effecter cells.  The results described above suggest that 
CD34MG cells upregulate microglial characteristics and functionality.  It is widely known 
that microglia are of haematopoietic developmental origin, thus it is reasonable to expect that 
primitive bone marrow-derived adherent CD34+ cells are capable of differentiating into 
microglia-like cells.  The next part of this study examines the potential use of adherent 
CD34+ cells and CD34MG in therapy.   
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Chapter 6 Stem cell therapy of glioblastomas 
 
Chapter summary 
 
The previous chapter described the ability of adherent CD34+ cells to differentiation into 
microglia like cells called CD34MG cells.  In this chapter, the therapeutic potential of 
CD34MG cells were explored for use in brain tumors, particularly glioblastoma multiforme 
(GBM).  Experiments revealed that adherent CD34+ cells and CD34MG cells have tropism 
towards glioblastoma cell lines.  CD34MG cells also demonstrated possible effector function, 
and cause apoptosis of glioblastoma cell lines in vitro.  This chapter describes the following 
in detail: 
• Adherent CD34+ cells and CD34MG cells have tropism towards glioblastoma cell 
lines 
• CD34MG cells are antigen presenting cells 
• CD34MG cells are capable of presenting glioblastoma cell antigen  
• CD34MG cells cause apoptosis of glioblastoma cell lines in a dose dependent manner 
 
 
 
6.1 Brain tumors  
During the later stages of glioblastoma multiforme (GBM), single cell infiltrates begin to 
diffuse into the peritumoral region134-138.  Although the bulk of the tumor can be surgically 
removed, the diffuse infiltrates remain embedded within healthy brain tissue.  These cells are 
inaccessible to current therapeutic strategies, thus leading to tumor recurrence138.  Viral 
vectors have not been proven to deliver apoptotic agents to tumor-specific regions, and have 
lead to damage of healthy brain tissue74,136.  The lack of known glioma-specific antigens has 
lead to poor outcomes of antibody mediated drug and gene delivery74.  Other experimental 
strategies include immunotherapy with autologous dendritic cells whereby the patient’s 
dendritic cells are isolated and pulsed with peptide derived from their own tumor74,135,139,140.  
The peptide-loaded dendritic cells are then re-infused into the patient.  Although the results 
from animal models have lead to the prevention of tumor growth, patients in clinical trials 
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have developed autoimmunity135,139,140.  In the previous chapter, it was described that 
CD34MG cells are capable of acting as antigen presenting cells, presenting viral peptide and 
causing PBMC proliferation in an autologous reaction.  Experiments were then conducted to 
determine if CD34MG was able to present glioblastoma specific antigen in an autologous 
reaction.  Induction of PBMC proliferation would suggest that CD34MG cells might have 
potential use in immunotherapy by a similar way as dendritic cells.   
 
6.1.1 Uses of stem/progenitor cells in GBM 
Cell-based gene delivery is emerging as a strategy for brain tumor therapy.  Current 
chemotherapeutic treatments for brain tumors are not tumor specific and cause large scale 
toxicity including damage to non-tumorigenic brain tissue, leading to further brain damage 
136,137
.  The major advantage of using stem cells as vehicles for gene or drug delivery is their 
potential for therapeutic specificity136,137.  Embryonic stem cells, NSCs and MSCs have 
demonstrated tumor trophic properties in animal models and they infiltrate solid tumors134,136-
138,141
.  Stem and progenitor cell-mediated drug and gene delivery is being studied to improve 
the efficacy of the delivery of therapeutic agents.    
 
6.1.2 Immune evasion  
Endogenous microglia and peripheral leukocytes have been observed within human 
gliomas74,142.  Regardless of leukocyte migration and tumor infiltration, gliomas are able to 
evade innate immune surveillance74,142,143.  Gliomas express HLA class I and II molecules, 
but do not express the costimulatory molecule B7-1 (CD80) and express low amounts of B7-
2 (CD86)74,142-144.  The lack of costimulation leads to failure of antigen presentation and 
subsequent T cell activation74,143.  Gliomas also secrete immunosuppressive cytokines TGF-
β, VEGF, and interleukin 10145,146, and recruit T regulatory cells which play a role in tumor 
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tolerance74.  Vaccines created to augment tumor-specific cellular immunity have been found 
to partially overcome glioma immunosuppression by boosting low level immunity and 
stimulating the proliferation of higher avidity T cells74,139,140,147.  Recent investigations 
showed that dendritic cell (DC) and peptide antigens are capable of inducing an antitumor 
response within the CNS, emphasizing that the brain is accessible to systemic 
immunotherapy74,135,139,148-150.  This opens the door for immunotherapeutic approaches for 
glioma.   
 
The aim of the experiments described herein was to explore the potential of adherent CD34+ 
cells and CD34MG for therapeutic purposes in glioblastoma.  This study sought to determine 
if adherent CD34+ cells and CD34MG had tumor trophic properties, invasive properties or 
immune properties which might be exploited for therapy.   The studies described in previous 
chapters revealed that CD34MG cells have antigen-presentating capabilities, inducing 
proliferation of immune cells in vitro in an autologous lymphocyte reaction.  The following 
experiments were conducted to determine if CD34MG cells might be potentially useful for 
future immunotherapy in gliomas.  As antigen-presenting cells, the ability of CD34MG cells 
to present glioma-specific antigen was observed which might be exploited in the future to 
mimic dendritic cell therapy and boost low level immune responses.     
6.2 Results 
6.2.1 Migration 
Stem cells and microglia are tumor-tropic.  A transwell migration assay was used to 
determine if adherent CD34+ cells and CD34MG have tropism towards glioblastoma cells in 
vitro.  Approximately 5 x 103 GFP transfected U251, U118, or U87 glioblastoma cells (GFP 
transfection was performed by Dr. Faisal Altaf) were plated in the bottom wells of a 24 well 
plate transwell system (as described in materials and methods) and 2 x 104 either adherent 
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CD34+ cells or CD34MG cells were placed into the 6µm nylon mesh transwell insert for 5 
hours.    After 5 hours, the transwell was removed and the remaining cells within the 
transwell insert were trypsinized and scraped, collected, centrifuged, and counted.  Five 
replicate experiments were performed.  The adherent CD34+ cells and CD34MG cells were 
obtained from the same donor samples for each replicate.   
The results indicated that 83 ± 4.8% of adherent CD34+ cells migrated through the transwell 
membrane in response to trophic factors released by U87glioma cells, 81 ± 7.13% in response 
to U118, and 84.4 ± 8.02% in response to  U251.  Similar patterns of migration were 
observed with CD34MG cells where 80.8 ± 8.35% of cells migrated in response to U87 
glioma cells, 83 ± 9.03% migrated in response to U118 cells, and 75 ± 5.48% migrated in 
response to U251 cells (Figure 29).  There was no observed difference in migration in 
response to the different glioma cell lines. As shown in Figure 30, 5 ± 3.16% of adherent 
CD34+ cells and 7.4 ± 2.97% of CD34MG cells migrated in response to primary fibroblasts.  
This was significantly less migration than in response to the glioma cell lines (p=0.009).  This 
result indicated that the adherent CD34+ cells and CD34MG cells migrate in response to 
soluble trophic factors secreted by glioma cells in vitro.   
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Figure 29.  Migration assays demonstrate tropism of adherent CD34+ cells and CD34MG towards 
glioma cells.  Transwell migration assays were conducted to determine if adherent CD34+ cells and 
CD34MG cells have tropism towards glioma cell lines U87, U118, or U251 (A).  The majority of both 
adherent CD34+ cells and CD34MG cells migrated through the transwell membrane in response to 
trophic factors released by glioma cells.  There was no significant difference in the percent of 
adherent CD34+ cells and CD34MG cells which migrated in response to glioma cells.  Comparing the 
migration potential between the two cell populations, the p values were calculated using the Wilcoxon 
Signed Rank nonparametric test (n=5 biological replicates) on SPSS software (migration to U87 
p=0.223, U118 p= 0.686, U251 p=0.08) (B).  The migration levels of adherent CD34+ cells and 
CD34MG cells in response to the glioma cells were compared to the percent of cells which migrated 
in response to primary fibroblasts using the Mann-Whitney nonparametric test.  There were 
A 
B 
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significantly more adherent CD34+ cells and CD34MG cells which migrated in response to glioma 
cells than in response to normal primary fibroblasts.   
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6.2.2 Invasion 
Experiments similar to the migration assay were conducted to determine if either adherent 
CD34+ cells or CD34MG cells can digest and migrate through a Matrigel extracellular 
matrix.  Active digestion of extra cellular matrix would suggest that these cells could be 
invasive in vivo.  A 24 well plate transwell system for invasion assays was used where the 
transwell inserts were coated with Matrigel extra cellular matrix.  5,000 glioma cells U87, 
U118, or U251 cells were plated in the bottom well of the system, and an equal number of 
either adherent CD34+ cells or CD34MG cells were placed in the transwell insert.  After 24 
hours (as per the manufacturer’s instructions), the number of adherent CD34+ cells or 
CD34MG cells which passed through the Matrigel were counted.  The cells were counted 
under a fluorescent microscope.  The GFP-transfected glioma cells showed as green; the non-
fluorescing cells were assumed to be the adherent CD34+ cells or CD34MG cells which had 
migrated through the transwell.  To ensure that the cell migration was in response to trophic 
factors released by the glioma cells, primary fibroblasts were plated instead of glioma cells as 
a control.   
 
Like the pattern observed in the migration assay, the invasion assay revealed that 70.8 ± 
9.47% of adherent CD34+ cells invaded in response to U87 glioma cells, 69.6 ± 7.83% 
invaded in response to U118 cells, and 65.8 ± 5.81 in response to U251 cells.  CD34MG cells 
were also invasive, with 72.4 ± 7.16% invading through the matrix in response to U87 cells, 
67.6 ± 5.37 in response to U118 cells, and 66.8 ± 4.21% in response to U251 cells.  There 
was no significant difference in invasion due to different glioma cell lines U87, U118, or 
U251 (Figure 30).  Only 9.2 ± 6.38% of adherent CD34+ cells and 7.6 ± 3.21% of CD34MG 
cells invaded in response to primary fibroblasts.   
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Approximately 7 times fewer adherent CD34+ cells and 10 times fewer CD34MG cells 
invaded in response to primary fibroblasts than in response to glioma cells.  The data suggest 
that both adherent CD34+ cells and CD34MG cells are invasive, and that this response can be 
mediated by tropic factors released by glioma cells.   
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Figure 30.  Invasion assays demonstrate tropism of adherent CD34+ cells and CD34MG towards 
glioma cells.  Invasion assays using Matrigel matrix coated transwell system were conducted to 
determine if adherent CD34+ cells and CD34MG cells are invasive.  The active digestion of extra 
cellular matrix suggests that cells would be invasive through tissue in vivo.  Patterns of invasion are 
similar to that seen in migration assays above.  The majority of both adherent CD34+ cells and 
CD34MG cells actively digested through the extra cellular matrix in response to either U87, U118, or 
U251 glioma cells.  Comparing the migration potential between the two cell populations, the p values 
were calculated using the Wilcoxon Signed Rank nonparametric test (n=5) using SPSS software 
(migration to U87 p=0.893, U118 p= 0.588, U251 p=0.786).  The invasion of adherent CD34+ cells 
A 
B 
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and CD34MG cells in response to the glioma cells was compared to the percent of cells which 
invaded in response to primary fibroblasts using the Mann-Whitney nonparametric test (B).  
Significantly more adherent CD34+ cells and CD34MG cells invaded through extra-cellular matrix in 
response to glioma cells than in response to normal primary fibroblasts.   
 
6.2.3 Potential of CD34MG cells to present glioma antigen 
Experiments reported in the previous chapter revealed that the microglia-like CD34MG cells 
are antigen presenting cells.  To determine if CD34MG cells are able to present tumor 
specific antigen in an autologous leukocyte reaction, CD34MG cells were cultured overnight 
with U251 lysate to “load” them with tumor specific antigen.  Antigen loaded CD34MG cells 
were then irradiated and incubated for 5 days with fresh PBMCs from the same donor.  
Leukocyte proliferative responses were determined with 3H (tritiated) thymidine 
incorporation during the last 18 hours of culture.  Cells were harvested for liquid scintillation 
counting and the results expressed as counts per minute.  The results are shown in Figure 31.  
To demonstrate professional antigen presentation, macrophages were isolated as stimulators 
and loaded with tumor antigen (macrophage isolation was performed by Allison Russell, Dr. 
N Dibb’s laboratory).  Macrophages were irradiated and cultured with PBMCs from the same 
donor.  Stimulators in the experiment consisted of lysate pulsed macrophages, lysate pulsed 
adherent CD34+ cells, CD34MG cells alone, and CD34MG cells pulsed with tumor lysate.  
Peripheral blood macrophages loaded with tumor lysate induced proliferation of PBMCs and 
served as a positive control for the purposes of these experiments.  This provided a control 
that the overnight pulsing of antigen presenting cells with U251 tumor lysate was sufficient to 
“load” the cells with tumor antigen and that proper antigen presenting cells are able to present 
the tumor antigen.  Lysate pulsed adherent CD34+ cells did not induce responder 
proliferation.  Lysate pulsed CD34MG cells induced proliferation of autologous PBMCs, but 
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responder proliferation was not as much as that induced by macrophages.  These reactions 
were conducted using samples from three normal donors.  As glioma cells theoretically do 
not upregulate MHC molecules, and tumor cell lysate did not induce proliferation, the 
observed proliferation is likely to result from antigen presentation by macrophages and 
CD34MG, and not from the glioma cells themselves (Figure 31). 
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Figure 31.  Determination of glioma-specific antigen presentation by CD34MG.  CD34MG cells were 
pulsed overnight with U251 lysate to load them with tumor specific antigen.  The cells were then 
cultured with PBMCs from the same donor, the proliferative response measured, and the results 
expressed as counts per minute (CPM).  Macrophages, which are professional antigen presenting 
cells and were used as a positive control, induced proliferation of immune cells, presumably T cells.  
Adherent CD34+ cells loaded with antigen did not induce proliferation, but CD34MG cells loaded with 
tumor specific antigen induced proliferation of leukocytes.  In this autologous reaction, there was no 
significant difference in responder proliferation due to exposure to tumor lysate alone versus naive 
macrophages (p=0.0841), but lysate pulsed macrophages induced a significant proliferation when 
compared to naive macrophages (p=0.0027), lysate pulsed adherent CD34+ cells (p=0.0029), and 
CD34MG cells alone (p=0.0025).  There was no significant difference in proliferation in responders 
exposed to lysate pulsed macrophages versus lysate pulsed CD34MG (p=0.0067).  The graph 
represents results from three replicate experiments.  Paired student’s t-test was conducted to 
determine significance.     
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6.2.4 Possible effector function of CD34MG 
To determine if either adherent CD34+ cells or CD34MG cells have effector functions, either 
cell population was co-cultured with U251-GFP glioma cells in effector:target ratios of 1:10, 
1:5, or 1:1.  After 10 hours, apoptosis of U251-GFP cells was detected by trypan blue 
exclusion.  All the cells in the co-culture were trypsinized and diluted with trypan blue, 
loaded onto a haemacytometer, and visualized under a fluorescence microscope.  Cells which 
fluoresced green and took up the trypan blue were assumed to be the apoptotic U251-GFP 
cells.  As a control, primary fibroblasts were also co-cultured with U251-GFP cells to ensure 
that cell death was due to effector function, not due to co-culture conditions.  The results 
demonstrated that adherent CD34+ cells did not cause significantly more apoptosis than the 
fibroblast control at any of the three cell ratios (Figure 32).  Comparisons of the means were 
conducted with t-tests on SPSS, and the details of the statistical results are seen in Figure 33b.  
CD34MG cells caused significantly more U251 cell death than the control fibroblasts at all 
three cell ratios.  At a 1:10 (CD34MG:U251) dilution, 6.08 ± 0.82% of U251 cells were 
apoptotic after 10 hours.  At a 1:5 dilution, 13.77 ± 2.4% of U251 cells were apoptotic, and in 
a 1:1 culture, up to 20.33 ± 4.5% of U251 cells were apoptotic.  When comparing levels of 
apoptosis caused by adherent CD34+ cells and CD34MG cells, there was no difference in 
U251 apoptosis at a 1:10 effector-target ratio.  At 1:5 and 1:1 co-cultures of CD34MG and 
U251 cells, there was significantly more U251 apoptosis than in the adherent CD34+ cell and 
U251 co-cultures with the same ratios.  These results are an average of four replicate 
experiments.  They indicate that adherent CD34+ cells do not cause apoptosis of U251 
glioma cells in co-culture.  CD34MG cells induced increasing amounts of U251 cell death as 
the effector-target ratio decreased.  This evidence indicates that CD34MG cells are cytotoxic 
to U251 cells in vitro, but their effects on gliomas in vivo remain unknown.   
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Figure 32.  Effector function of adherent CD34+ cells and CD34MG cells.  Adherent CD34+ cells, 
CD34MG or primary fibroblasts were co-cultured with U251-GFP glioma cells for 10 hours.  The cells 
were then trypsinized, collected, and apoptosis of U251-GFP cells was assessed by trypan blue dye 
exclusion under a fluorescence microscope.  Adherent CD34+ cells did not cause significantly more 
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apoptosis than the fibroblast control at any cell ratio.  CD34MG cells caused significantly more U251 
cell death than the control fibroblasts at all three cell ratios.  There was no difference in apoptosis 
caused by adherent CD34+ cells and CD34MG cells in co-cultures in a 1:10 ratio.  In 1:5 and 1:1 co-
cultures of CD34MG and U251 cells, there was significantly more U251 apoptosis than in the 
adherent CD34+ cell and U251 co-cultures with the same ratios. 
 
6.2.5 Possible mechanism of killing 
Previous experiments revealed that adherent CD34+ cells and CD34MG cells secrete pro-
inflammatory cytokines and increase the amounts of cytokine release in response to foreign 
pathogens.  One of these cytokines is TNFα which is a well documented inducer of apoptosis 
of glioblastoma cells151-153.  To determine if CD34MG-mediated apoptosis might be due to 
TNFα release, preliminary experiments were conducted where either adherent CD34+ cells or 
CD34MG cells were co-cultured with GFP transfected U251 glioma cells.  Cells were co-
cultured in a 1:1 ratio for 8 hours (similar to the above mentioned killing experiment) and the 
supernatant collected.  TNFα was measured quantitatively with a Luminex multiplex assay as 
in previous experiments (Figure 33).  From previous experiments, it was revealed that 
adherent CD34+ cells and CD34MG cells secrete low amounts of TNFα in standard cultures.  
In these experiments, adherent CD34+ cells secreted 32 ± 12pg/ml TNFα and CD34MG cells 
secreted 176 ±28pg/ml TNFα.  U251 cells in standard culture produced negligible amounts of 
TNFα, (8 ± 5pg/ml TNFα).  When either cell type was co-cultured with U251 cells, relatively 
higher levels of TNFα were measured in the supernatant.  In adherent CD34+ cell and U251 
co-culture supernatant, 359 ± 82pg/ml TNFα was present.  In CD34MG and U251 co-culture 
supernatant, 1487 ± 294pg/ml TNFα was measured.  As TNFα is cytotoxic to glioma cells, it 
is assumed that it is unlikely that U251 cells would upregulate the mechanisms to synthesize 
and secrete TNFα  in this co-culture condition.  Thus, the TNFα found in the co-culture 
supernatants is assumed to be released by the adherent CD34+ cells or the CD34MG cells.   
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Figure 33.  TNFα secretion by adherent CD34+ cells and CD34MG when co-cultured with glioma 
cells.  Adherent CD34+ cells in standard culture conditions secrete 38.3 ± 8.5pg/ml TNFα , and 
CD34MG cells secret 184 ± 29.91 pg/ml TNFα.  U251 cells in standard culture have negligible 
amounts of TNFα in the supernatant, 14.6 ± 6.5 pg/ml TNFα.  When either adherent CD34+ cells or 
CD34MG cells are co-cultured with U251 glioma cells, relatively larger amounts of TNFα is found in 
the supernatant.  Supernatant collected from co-cultures of adherent CD34+ cells and U251 cells 
contained 396.3 ± 21.03 pg/ml TNFα.  Co-cultures of CD34MG cells and U251 cells contained 
1771.33 ± 298.94 pg/ml TNFα.  This suggests that the levels of TNFα may contribute to observed 
U251 cell death.   
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6.3 Discussion  
One of the aims of the overall project was to explore the potential use of adherent CD34+ 
cells in neurodegenerative disease neurological malignancy.  Here it was observed that 
adherent CD34+ cells and CD34MG cells have tropism for glioma cells in vitro, and that 
CD34MG cells are able to present glioma antigen in a lymphocyte reaction.  These properties 
might be further studied and exploited for possible therapeutic use in glioblastoma.   
 
Evidence from the literature indicates that stem cells isolated from various tissues possess 
inherent tumor tropism, and that systemically administered stem and progenitor cells migrate 
to and infiltrate primary and metastatic solid tumors136.  This trophic property has been 
exploited by other workers to deliver multiple therapeutic genes including IL-4, IL-12, IL-23, 
TRAIL, and IFNβ136,137.  Tropism of stem cells to tumors is likely to be mediated by multiple 
cell-surface and secreted proteins.  Cytokine/receptor pairs include SDF-1/CXCR4154, SCF/c-
kit155 and MCP1/CCR2156.  Adherent CD34+ cells have been previously demonstrated to 
express CXCR426, while glioma cells express CXCL12/SDF1, the ligand for CXCR4, one  
possible factor contributing to the tumor tropism of adherent CD34+ cells.   The present 
study demonstrated that adherent CD34+ cells are potentially tumor-tropic as they migrated 
in response to U251 glioma cells in vitro.  The in vitro migration and invasion assays 
demonstrate that motility of adherent CD34+ cells and CD34MG cells can be mediated by 
gliomas, suggesting the potential use of these for cell-based therapy in gliomas. 
 
Preliminary experiments were conducted to determine if either adherent CD34+ cells or 
CD34MG cells were functional immune effector cells.  CD34MG cells co-cultured with 
U251 glioma cells and resulted in apoptosis of the glioma cells.  Previous experiments 
revealed that adherent CD34+ cells and CD34MG cells secrete TNFα in response to a model 
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of exposure to pathogen, namely LPS activation.  TNFα is known to cause apoptosis to 
glioma cells including U251 cells.  Analysis of TNFα in standard conditions and co-culture 
conditions revealed that TNFα release is induced by the direct co-culture of adherent CD34+ 
cells or CD34MG cells with U251 glioma cells.  As all cell types released relatively low 
amounts of TNFα when cultured alone, it cannot be definitively deduced which cell type is 
responsible for the cytokine synthesis and release.  One likely explanation is that CD34MG 
cells are activated by the presence of non-autologous cells, causing them to synthesize and 
release TNFα.  CD34MG cells activate TNFα receptors on U251 cells, causing apoptosis.  
The mechanisms of cell death are of considerable interest and should be pursued further.   
 
The observed cytokine release may explain the glioma cell apoptosis in co-culture conditions.  
Apoptosis was only observed in co-cultures with at 1:1 effector to target ratio.  This result 
suggests that apoptosis of U251 cells in co-culture with CD34MG cells may require either 
direct cell to cell contact or co-culture with the cells for a constant supply of cytokine.  Thus 
TNFα release could be induced when CD34MG reach a tumor in vivo, but it is noteworthy 
that TNFα is toxic to normal brain tissue157.  Further analysis of the apoptotic mechanisms 
would require apoptosis assays when cells are in direct contact cultures compared with 
apoptosis when cells are in transwell cultures.  This would determine if apoptosis was 
contact-mediated or due to secreted factors.   
 
Glioma cells downregulate the co-stimulatory molecules required to initiate activation of 
innate immunity139.   The goal of cancer immunotherapy is to boost immunity and stimulate T 
cell response of those which home to the tumor74,139.  Animal and human studies have 
demonstrated that immunotherapy with dendritic cells and peptide antigen is capable of 
inducing an anti-glioma response74,140,149.  This suggests that the systemic immune response 
can be altered to mediate intracranial anti-tumor responses.  The experiments described in 
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this chapter explored the possibility of exploiting the immune properties of adherent CD34+ 
cells and CD34MG cells for immunotherapy.  The work reported in previous chapters 
revealed immunological properties of CD34MG cells including the secretion of TNFα in 
response to pathogens, tumor-tropism, and antigen presenting capabilities.  Overall, these 
experiments suggest that CD34MG cells might have immunotherapeutic potential in gliomas.   
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Chapter 7 Discussion  
 
 
7.1 Adherent CD34+ cells  
Adherent mononuclear cells from bone marrow were first identified in a study by Gordon and 
colleagues98. which demonstrated that plastic adherent mononuclear cells were a 
heterogeneous population that includes stromal and hematopoietic progenitor cells which can 
be sustained in long term culture98.  The primitive nature of these cells was demonstrated by 
the ability of adherent cells to produce several granulocyte-macrophage colony-forming cells 
(CFU-GM) and erythroid burst-forming units (BFU-E)97,174.  The majority of adherent cells 
were identified as CD34+ and comprised of 5-10% of the total CD34+ cells174.  Further 
characterization of adherent CD34+ cells was conducted which revealed that these cells are 
quiescent and out of cell cycle175, and simultaneously express tissue specific genes26.  The 
combined data qualify adherent CD34+ cells as primitive stem cells derived from bone 
marrow and peripheral blood.   
 
In order to deliver effective stem cell based clinical therapy, it is important to understand the 
basic biological and molecular mechanisms which govern how and when lineage 
specification occurs.  The present study contributed to defining the stem cell biology of 
adherent CD34+ cells which are a bone marrow-derived population by (i) identifying genetic 
differences between adherent CD34+ cells and non-adherent CD34+ cells, (ii) validating the 
stem cell qualifications of adherent CD34+ cells by examining gene expression profiles, 
antigen expression, and DNA replication timing, (iii) determining if the adherent CD34+ 
cells have in vitro  neural differentiation potential, (iv) phenotypically and functionally 
characterizing adherent CD34+ cell-derived microglia-like cells CD34MG, and (v) exploring 
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the potential of adherent CD34+ cells and CD34MG cells for cellular therapy in 
glioblastoma.   
 
The comparison of gene expression between adherent CD34+ cells and non-adherent CD34+ 
cells revealed that adherent CD34+ cells more highly express genes which are involved in 
cell cycle control, adhesion to the bone marrow, and transendothelial migration.  These 
characteristics contribute to their quiescent stem cell qualifications.  Real-time qPCR and 
immunoflurescence microscopy validated the gene data and further revealed that adherent 
CD34+ cells express antigens associated with pluripotent ES cells.  Previously published data 
revealed that adherent CD34+ cells express tissue specific transcription factors26, indicating 
that this primitive stem cell population maybe multilineage primed.   
 
When cultured in an in vitro neural microenvironment of astrocyte conditioned medium, 
adherent CD34+ cells differentiated into microglia/brain macrophages, CD34MG cells.  It is 
documented that there is an increase of CD34+ cells in circulation after neural injury176,177.  If 
it is assumed that adherent CD34+ cells lie quiescent in the bone marrow and migrate during 
injury, it is a reasonable to speculate that during neural injury, a higher frequency of adherent 
CD34+ cells are mobilized from the bone marrow.  These cells might then migrate to the site 
of neural damage and differentiate into microglia, the immune cells of the CNS. 
 
Functional experiments revealed that CD34MG cells secrete pro-inflammatory cytokines 
TNFα and IL-6 in response to LPS, an in vitro model of pathogens.  These cells also 
demonstrated antigen presentation capabilities.  The potential of these cells for autologous 
cell based therapy in glioblastoma was then explored.  These cells are tumor-tropic and 
secrete TNFα which is known to cause apoptosis in glioblastoma cells.  Although in vitro 
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studies demonstrate the anti-glioblastoma potential of CD34MG, the molecular mechanisms 
of action remain unknown.  As cells which demonstrate immune capable functions, it is 
important to examine the immune responses triggered by the presence of these cells in an 
animal model before they are considered for stem cell therapy. 
 
Gordon and colleagues26 demonstrated through nested-PCR that adherent CD34+ cells 
express neural associated message including Nkx2.2, NeuroD, and Pax6 suggesting that 
adherent CD34+ cells might have neural differentiation potential.  The results revealed by 
this study demonstrated that adherent CD34+ cells are not capable of neural cell 
differentiation in vitro.  This lack of neurogenic potential was further validated by DNA 
replication timing which indicated that neurogenic genes are not likely to be expressed by 
bone marrow derive stem cells including adherent CD34+ cells.  Although nested-PCR 
results show expression of neural associated genes, their translation may not necessarily 
occur.  Although neural genes are expressed, other regulatory molecules might be present, 
preventing neural differentiation.    
 
 
7.2 Stem cell hierarchy 
 
The ‘stemness’ continuum is anchored at one end by plastic totipotent stem cells, and at the 
other end by terminally differentiated cells.  Within the stem cell developmental hierarchy, 
adherent CD34+ cells are believed to be more similar to pluripotent stem cells than to germ 
lineage committed multipotent stem cells.  The original data on adherent CD34+ cells 
revealed that these cells can give rise to cells of the haematopoietic lineage, but further 
analysis demonstrated that adherent CD34+ cells express mRNA for multiple tissue specific 
transcription factors.  Adherent CD34+ cells also express genes and antigens closely 
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associated with ES cells, strengthening their relatively primitive status.  Within the bone 
marrow stem cell compartment, a hierarchy can be extracted from current literature available.  
Mesenchymal stem cells are multipotent stem cells which give rise to cells of the mesodermal 
germ layer.  Haematopoietic stem cells are lineage restricted unipotent stem cells which give 
rise to the various cells of the circulatory and immune systems.  Within the bone marrow 
there are other stem cells whose lineage differentiation restrictions are uncertain.  Stem cells 
that resemble mesenchymal stem cells which have been identified recently are the MAPC and 
MIAMI cells12,13,178.  The MAPCs do not appear until several passages in an artificial culture, 
raising uncertainty about their place in the natural bone marrow12,179.  They differentiate into 
cells of mesoderm, but have not been proven to reproducibly differentiate into cells of a 
different germ layer.  MIAMI cells express antigens associated with pluripotent stem cells, 
Oct4, Rex1, SSEA4 and have been demonstrated to differentiate into cells of mesodermal, 
ectodermal, and endodermal lineage13,178. These cells are also only characterized and 
identified after several artificial passages and expansion for over 50 cell doublings13,178.  
Although MAPC and MIAMI cells express pluripotency markers, the fact that they are only 
identifiable after artificial culture suggests that these populations may result from prolonged 
culture rather than being natural populations which are identifiable in the bone marrow.  
VSEL cells are small embryonic like cells that are proposed to have been deposited in the 
bone marrow during ontogeny14,25.   They are identifiable in peripheral blood, bone marrow, 
and umbilical cord blood, and express pluripotency markers as well as tissue-specific 
markers14,16,25,33,180.  These cells share similar properties with adherent CD34+ cells and could 
be the same population of stem cells.   
 
Within the bone marrow stem cell continuum, VSEL cells and adherent CD34+ cells are 
likely to be the most primitive cells thought to have been deposited during development.  
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Ratajczak et al31,32 hypothesized that during development, pluripotent stem cells are deposited 
in the bone marrow for future use.  This phenomenon that has been termed ‘developmental 
migration’ whereby stem cells are chemoattracted during ontogeny, to the bone marrow 
which provides a microenvironment appropriate for a stem cell niche14,25,33.  The 
developmental origins of adherent CD34+ cells are evidenced by fetal cell microchimerism 
dwhich is the presence of fetal cells in maternal tissue27.  Fetal cells persist for many years 
after pregnancy and have been identified in multiple organs.  In a study of maternal blood, 
cells from male offspring were detected among maternal adherent CD34+ cells27.  In 
addition, studies using murine models have demonstrated that fetal microchimeric cells are 
recruited in response to injury.  This provides evidence that adherent CD34+ cells are 
residual of developmental cells and supports their primitive status. 
 
Enver and colleagues revealed that hematopoietic stem cells are ‘multilineage primed’, 
expressing low levels of mRNA of various hematopoietic lineages11,41,42.  This implies that a 
single stem cell is capable of transcribing genes of multiple lineage specifications when 
placed in the appropriate inductive microenvironment11,41,42.  Adherent CD34+ cells express 
genetic messages for multiple tissue lineages including haematopoietic, hepatic, pancreatic, 
cardiac, and neural cells11,26.  Applying the theory of multilineage priming, the corresponding 
genes should be available for transcription by adherent CD34+ cells, thus enabling these cells 
to contribute to the regeneration and repair of injured tissue.  Since the cells are innately 
primed for multiple lineage specification, they lack the need for de-differentiation, 
transdifferentiation, or cell fusion11.   
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7.3 Potential use of adherent CD34+ cells in neurological deficits 
 
Although the timely limitations of this study restrict the exploration of the potential 
therapeutic use of adherent CD34+ cells in glioblastoma multiforme, further studies may 
reveal their use for other neurological disease.  Two neurological diseases often explored by 
other laboratories for stem cell therapy are Parkinson’s disease and cerebral ischaemia.  It is 
speculated that stem cells migrate in response to injury in order to aid in tissue repair and 
regeneration11, 15, 16,19, including during cerebral ischaemia15, 177.  Studies have reported 
increases in stem cell frequency in the peripheral blood after cerebral ischemia15, 177, based on 
these observations, it is a reasonable assumption that microenvironmental cues within the site 
of injury either induces stem cells to mobilize into the peripheral blood, or quiescent stem 
cells into the cell cycle, or induces the rapid proliferation of transitamplifying cells to give 
rise to as many cells as possible to aide repair8.  Diseases in which this rapid proliferation of 
cells is desirable are those associated with tissue death.  In the CNS, diseases involving focal 
cell death are cerebral ischemia and Parkinson’s Disease.  Parkinson’s Disease requires a 
specific neuronal regeneration and re-circuitry, thus far stem cell therapy has not proven to 
either replace degenerated dopaminergic neurons nor restore innervations to the site of injury.  
It is a reasonable suggestion that stem cells which are capable of differentiating into 
endothelial cells are most suitable for therapy in cerebral ischemia.  Previous data from this 
group demonstrated that adherent CD34+ cells are capable of differentiating into endothelial 
cells201.  The endothelial potential of adherent CD34+ cells suggests that they might be able 
of contributing to angiogenesis, further suggesting they might be useful in cerebral ischaemia.  
This section discusses the potential additional uses of adherent CD34+ cells in the two 
neurological diseases where these cells would likely be most beneficial.  Although this study 
focused only on glioblastoma multiforme, the potential use of adherent CD34+ cells in 
cerebral ischemia is also discussed for future studies.   
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7.3.1 Cellular requirements for cell therapy in cerebral ischemia 
In three types of animal models of cerebral ischemia, global forebrain ischemia, focal 
ischemia, and middle cerebral artery occlusion, endogenous neurogenesis is induced in the 
two neurogenic regions of the brain67,160.  BrdU labeling experiments revealed that middle 
cerebral artery occlusion of an animal model is followed by a marked increase in neural cell 
proliferation in the subventricular zone and neuroblast migration to the site of injury67,158.  
This observation suggests that the brain has the capacity to regenerate neural cells after 
damage.  Despite this regeneration, there is limited permanent replacement of lost neurons.  
About 80% of new neurons die within 6 weeks of the ischemic event, and only about 0.2% of 
lost neural cells are replaced67,158.  Although new neural cells are regenerated, the lack of 
blood supply to the area leads to death of the new cells.  In order for stem cell replacement 
therapy to be effective, there must be (i) revascularization of the damaged area and 
reestablishment of the blood supply, (ii) migration of transplanted stem cells through site of 
injury, (iii) concerted regeneration and differentiation of stem cells into multiple types of 
neural cells, and (iv) establishment of saltatory conductivity with existing circuitry67,125,158-160.   
 
The angiogenic properties of bone marrow derived stem cells including adherent CD34+ 
cells, MSC, MAPC and HSC would contribute to neovascularization of the ischemic 
penumbra.  After ischemia, the blood brain barrier is compromised, allowing extra-cranial 
delivery of stem cells injected into the carotid artery.  Stem cell replacement therapy using 
bone marrow derived stem cells would be ideal for cerebral ischemia to aid revascularization 
and prevention of further neural cell damage.  Using adherent CD34+ cells would allow for 
an autologous transplant of stem cells.  Although this study has demonstrated that adherent 
CD34+ cells might not differentiate into functional neurons, if they aide angiogenesis, this 
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would allow the regeneration and establishment of endogenous neurogenesis.  A Phase I 
clinical trial using CD34+ cells in patients with acute cerebral ischemia has begun.  To date, 
one patient with focal ischaemia was infused with autologous adherent CD34+ cells.  This 
patient has demonstrated recovery of motor and cognitive function, not typically associated 
with acute ischaemia. The results are promising in this one patient, but further patients must 
be recruited.  Retrospective studies of the possible mechanisms of recovery must be derived 
in an appropriate animal model.  One speculated mechanism is by adherent CD34+ cell 
contributions to intracranial angiogenesis, possibly restoring partial blood supply to the 
ischaemic area. 
 
7.3.2 Potential use of stem cells in brain tumors 
Bone marrow derived stem cells are tumor trophic and can contribute to existing vasculature 
and home to sites of neovascularization181.  Although this property is extremely useful in 
ischaemic injuries such as myocardial infarct, cerebral ischaemia, or ischaemic limbs179,182-
186
, increasing vasculature in malignant settings contributes to tumor growth and 
development187.  Both MSC and MAPCs contribute to tumor angiogenesis and 
neovascularization of solid tumors181,187,188.  In the case of brain tumors, MSCs are recruited 
to the peritumoral region by glioma cells which release angiogenic factors.  These MSCs then 
contribute to angiogenesis and tumor vasculature138,188.  HSCs are also known to contribute to 
the vasculature in brain tumors189,190.   
 
The specificity of stem cell migration to solid tumors is either taken as a negative indication 
as they contribute to angiogenesis and vascularization of the tumor, or as an indication that 
they can be exploited for therapeutic purposes such as the delivery of anti-tumor genes and 
apoptotic molecules.  Adherent CD34+ cells may be seen in the same light.  Work by 
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previous members of the group demonstrated that adherent CD34+ cells are capable of 
differentiating into vascular endothelial cells, upregulating von Willebrand factor, EGFR and 
VEGF.  In an animal model of myocardial infarction, adherent CD34+ cells administered to 
the site of injury induced functional recovery.  Based on the in vitro expression of pro-
angiogenic factors, the functional recovery in the animal might be due to revascularization of 
the ischemic tissue by mechanisms induced by adherent CD34+ cells.  The pro-angiogenic 
effect of adherent CD34+ cells may be valuable in treatment of ischemic injuries, but likely 
detrimental in tumor therapy.  In contact co-cultures of adherent CD34+ cells with 
glioblastoma cell line U251 in this study, the U251 cells persisted.  Thus adherent CD34+ 
cells do not prevent the survival of glioma cells in vitro, and this has also been observed with 
other cancer cell lines by other members of the group.  However when adherent CD34+ cells 
were differentiated into CD34MG cells, cell dose dependent apoptosis of U251 cells was 
observed in contact co-cultures with CD34MG.  This result demonstrated that naïve adherent 
CD34+ cells do not cause apoptosis of glioblastoma cells, but their differentiated derivatives 
do.  The pro-apoptotic effect might be due to TNFα release by CD34MG cells which was 
observed in the presence of pathogens.  Whether similar results will be seen in brain tumor 
bearing animal models will give a more accurate view of the potential therapeutic value of 
CD34MG cells in gliomas. 
 
7.3.3 Potential use of adherent CD34+ cells in glioblastoma therapy 
Conventional therapies for glioblastomas are non-specific and often lead to incapacitating 
damage to surrounding normal tissue73,190.  There is a need for the development of tumor 
specific therapeutic strategies.  The tumor specificity of stem cells including NSC, MSC, and 
umbilical cord derived MSC, has been exploited to deliver pro-apoptotic genes, such as IFNβ 
and TNFα, and anti-tumor drugs, to glioblastomas in animal models136,141,191.  These studies 
167 
 
have found tumor regression in murine models of glioblastoma.  Having demonstrated 
tropism towards glioma cells in vitro, adherent CD34+ or CD34MG cells might be a useful 
tool for drug or gene delivery for glioblastoma and should be further explored in future 
studies.  Evidence from the literature concludes that naïve stem cells, especially those which 
are capable of long term culture and expansion, should not be used as therapy for cancer as 
they are more likely to contribute to malignancy187,188,190.  Conversely, genetically 
manipulated stem cells with tumor tropic features can be exploited to deliver anti-tumor 
genes and drugs136.  Adherent CD34+ cells are likely to contribute to tumor vascularization 
and growth, but perhaps either their manipulation into CD34MG cells, or transfecting them 
with anti-tumor molecules might prove therapeutic.   
 
One caveat of stem cell therapy is the risk of teratoma formation by the stem cells 
themselves164,181,187,188,190.  Adherent CD34+ cells are not likely to form tumors themselves.  
Adherent CD34+ cells are a slowly cycling or quiescent cell population.  The genetic 
characterization of adherent CD34+ cells and non-adherent CD34+ cells revealed that 
adherent CD34+ cells more highly express genes involved in cell cycle checkpoints and 
suppression, while non-adherent CD34+ cells highly express proliferation genes including c-
Myc.  Although it is speculated they are not tumor forming, adherent CD34+ cells might 
contribute to tumor angiogenesis.   
 
7.3.4 The potential usefulness of CD34MG 
This work demonstrated that adherent CD34+ cells differentiate into microglia-like cells, 
CD34MG.  After insult or injury, endogenous microglia, the immune cells in the nervous 
system, are the first cells to migrate and respond to the site of injury.  Microglia become 
activated, proliferate, and secrete pro-inflammatory cytokines such as TNFα, IL6, and IL8.   
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It was previously thought that the blood brain barrier was impermeable, but recent evidence 
shows that the blood brain barrier is compromised during neural injury192,193.  Murine models 
of cerebral ischemia demonstrated that after ischemia, CD34+ cells from the bone marrow are 
recruited and differentiate into microglia and astrocytes176,177.  Brain tumors recruit peripheral 
blood derived monocytes which infiltrate the solid tumor73,194.  These infiltrates include 
immune cells such as T cells, dendritic cells, and macrophages, but these cells are 
immunosuppressed within the glioma environment.  This immunosuppression is part of the 
immune evasion strategy of gliomas.  Although glioblastoma cells express HLA Class I and 
II, they lack co-stimulatory molecules B7.1 and B7.2143, thus CD4+ T cells which infiltrate 
solid tumors are not activated and no anti-tumor immune response is induced.  Glioblastoma 
associated T cells can be activated by the addition of exogenous B7 stimulatory molecules, 
anti-CD28 antibody143.    
 
Tumor surveillance is a function of the immune system mediated by natural killer T cells 
(NKT) which mount an antitumor immune response by activating natural killer cells and 
cytotoxic T lymphocytes (CTL)143.  Either the level of activation is insufficient in the 
prevention of malignancy, or the immune escape mechanisms of the tumor are effective 
enough to overcome innate anti-tumor immunity.  Tumor-specific antibodies and CTLs have 
been isolated from the peripheral blood of glioblastoma patients73.  Antigens drain from the 
CNS to the cervical lymph nodes where they can be presented by antigen presenting cells to 
naïve T cells.  Although naïve T cells cannot cross the blood brain barrier, activated T cells 
migrate to sites of inflammation in the CNS73.  Professional antigen-presenting cells have not 
been documented in the CNS and it is thought that the microglia are the antigen presenting 
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cells in the brain195,196.  Microglia are bone marrow derived and can present antigen to T cells 
in a mixed lymphocyte reaction197.   
 
 
There was demonstrable evidence in this study that CD34MG cells are functional microglia 
that are capable of presenting antigen and tumor specific antigen.  There may be value in 
exploring the potential of CD34MG for use in active immunotherapy.  The caveat with 
dendritic cell therapy is that it induces such a strong anti-tumor response that autoimmunity is 
a great risk.  In vitro lymphocyte reactions in this study demonstrated that although capable 
of glioma tumor antigen presentation, CD34MG cells do not induce as robust a responder 
proliferation as professional antigen presenting cell, peripheral macrophages.  This result 
suggests that CD34MG in vivo activation of anti-tumor immunity may not be as strong as that 
induced by professional antigen presenting cells.  It will be important to determine whether 
the immune response will be sufficient to induce CD8+ cytotoxic T cell activation and tumor 
clearance.   
 
7.4 Future studies  
 
Gordon and colleagues11 have previously successfully demonstrated the clinical safety of 
adherent CD34+ cells and have begun their use in a neurodegenerative disease.  This project 
was explore the potential use of adherent CD34+ cells for cell therapy in an in vitro setting.  
Future studies should next focus on creating pre-clinical models of neurological diseases in 
murine models.  Possible studies are discussed below.    
 
Neural differentiation experiments determined that these cells o not have neurogenic potential 
in vitro.  Given time and resources, this finding should have been confirmed in vivo.  A 
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possible experiment would be to induce neural cell death in an immunodeficient mouse 
model, such as acute stroke.  The adherent CD34+ cells should then the transplanted, and cell 
migration and localization tracked.  After assessment of possible functional recovery in the 
animal model, histology should be conducted to determine the final fate of the transplanted 
adherent CD34+ cells.  These results might then reveal a possible mechanism of functional 
regenerative capacity in the animal, regardless of neuronal differentiation of the cells.   
 
Adherent CD34+ cells were capable of differentiating into microglia like cells CD34MG, and 
their potential for use in therapy in glioblastoma muliforme explored.  Here it was 
demonstrated that the cells migrate and invade in specific response to glioma cells, and that 
CD34MG cells are antigen presenting cells, capable of presenting glioma specific antigen in 
an autologous reaction.  It was further demonstrated that CD34MG secrete TNFα, a cytokine 
known to induce apoptosis in glioma cells152-153.  This may be the mechanism by which 
CD34MG cells caused apoptosis to glioma cell line U251 cells in a dose dependent manner.  
Given time and resources, this study should continue in an intracranial tumor bearing 
immunodeficient murine model.  Two main studies can be conducted, the first would be to 
examine if transfusion of CD34MG cells causes tumor regression or prevents tumor growth.  
The second possible study would be based on immunotherapy.  CD34MG have demonstrated 
their antigen presenting capabilities.  In vitro, CD34MG cells can be pulsed with glioma 
lysate to load them with glioma specific antigen.  The loaded cells would then be infused into 
tumor bearing murine models, and possible tumor regression measured.  Monitoring for 
tumor specific immune cells (such as cytotoxic CD8+ cells) would also be analysed.   
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7.5 Overview 
Adherent CD34+ cells are a primitive stem cell-enriched population which is distinct from 
the non-adherent CD34+ population.  This study contributed to their genetic, antigenic, and 
functional characterization, and further supported their status as a primitive quiescent stem 
cell population.  Adherent CD34+ cells are capable of differentiating into microglia like cells, 
upregulating antigenic markers and functional characteristics of microglia.  As the ultimate 
aim of this project was to exploit adherent CD34+ cells for use in neurological deficits, in 
vitro investigations were conducted to determine if the adherent CD34+ cell derived 
microglia-like cells had properties which might be useful for therapy against glioblastomas.  
Tumor trophic characteristics, TNFα secretion and antigen presentation are properties that 
were observed by this study and may prove useful for translational use.  Adherent CD34+ 
cells have been proven safe for clinical use, and although their potential for use in stem cell 
based therapy in neurodegenerative disease has only been explored in vitro, they demonstrate 
potential for autologous cell transplant in glioblastoma cell therapy.   
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